Folding and aggregation of IgGs-influence of mutations and expression systems by Schaefer, Jonas
Zurich Open Repository and
Archive
University of Zurich
Main Library
Strickhofstrasse 39
CH-8057 Zurich
www.zora.uzh.ch
Year: 2012
Folding and aggregation of IgGs-influence of mutations and expression
systems
Schaefer, Jonas
Posted at the Zurich Open Repository and Archive, University of Zurich
ZORA URL: https://doi.org/10.5167/uzh-68828
Dissertation
Published Version
Originally published at:
Schaefer, Jonas. Folding and aggregation of IgGs-influence of mutations and expression systems. 2012,
University of Zurich, Faculty of Science.
Folding and Aggregation of IgGs -  
Influence of Mutations and Expression Systems 
 
Dissertation 
zur 
Erlangung der naturwissenschaftlichen Doktorwürde 
(Dr. sc. nat.) 
 
vorgelegt der 
Mathematisch-naturwissenschaftlichen Fakultät 
der 
Universität Zürich 
 
 
von 
Jonas V. Schaefer 
aus 
Deutschland 
 
 
Promotionskomitee 
Prof. Dr. Andreas Plückthun (Vorsitz) 
Prof. Dr. Inger Sandlie 
Prof. Dr. Peter Sonderegger 
Prof. Dr. Ari Helenius 
 
 
Zürich, 2012 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Die vorliegende Arbeit wurde von der Mathematisch-naturwissenschaftlichen Fakultät der 
Universität Zürich im Sommersemester 2012 als Dissertation angenommen. 
Promotionskomitee: Prof. Dr. Andreas Plückthun (Vorsitz und Leitung der Dissertation), Prof. Dr. 
Inger Sandlie, Prof. Dr. Peter Sonderegger, Prof. Dr. Ari Helenius 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
To my family 
 
 
ʺThe most exciting phrase to hear in science, the one that heralds the most  
discoveries, is not 'Eureka!' (I found it!) but 'That's funny...' ʺ  ~ Isaac Asimov 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 Erklärung 
 
Diese Dissertation wurde selbstständig, ohne unerlaubte Hilfe im Sinne von §3 und §5 der 
Promotionsverordnung vom 08. Juli 2002 angefertigt. Bei der Abfassung der Dissertation wurden 
keine anderen als die darin angegebenen Hilfsmittel benützt. 
 
 
Zürich, Januar 2012 
 
 
Jonas V. Schaefer 
 
 
Acknowledgments 
 
 
Acknowledgments 
This thesis and my research at the University of Zurich would not have been possible without the kind 
assistance, practical contributions and great support of the following individuals and organizations: 
My foremost thanks go to my supervisor, Prof. Dr. Andreas Plückthun, for his encouragement, 
guidance and continuous support during my PhD studies as well as the freedom to pursue my own 
ideas and thoughts. Our discussions and his valuable feedback enabled me to accomplish hypothesis-
driven research and I am thankful for the ability to gain insight into many different aspects of antibody 
engineering and various lab techniques. I also want to extend my gratitude to the members of my 
thesis committee, Prof. Dr. Inger Sandlie (Centre for Immune Regulation, University of Oslo, Norway), 
Prof. Dr. Ari Helenius (Institute of Biochemistry, ETH Zurich, Switzerland) and Prof. Dr. Peter 
Sonderegger (Department of Biochemistry, University of Zurich, Switzerland), for their helpful 
comments and valuable advice during the entire course of this study. 
I would also like to gratefully acknowledge the support of my colleagues in the Plückthun laboratory 
who helped me in my research through many fruitful discussions and inspiring suggestions. Especially, 
many thanks to the M74 crew at various stages (Fabio, Patricia and Matthias) for such a friendly and 
relaxed working atmosphere and all the fun we had in our office. I owe special thanks to Dr. Peter 
Lindner, who - next to being a great lab manager - aided me in numerous aspects of my research 
through his thoughtful assistance and by critically reading various manuscripts. I further thank Dr. 
Ykelien Boersma for also critically reading some of my manuscripts, for valuable suggestions and for 
her friendship including all the yummy deserts. I am also grateful to the following individual of the 
Plückthun laboratory: Anja, Petra, Annemarie, Christian, Birgit, Erik, Niki, Myriam, Patricia, Gabriela 
and all the others not explicitly mentioned current and past colleagues of the Plückthun laboratory, in 
particular all those who have provided any advice or technical assistance during my thesis. Next to 
leading to a motivating and enjoyable atmosphere, many of them were part of various social lab 
activities from city trips, weekend hikings, BBQs and movie nights. I especially appreciate your help 
and amazing support in the months after my sledging accident – thanks guys! 
In addition I´d like to thank several people from academic and industrial partners that were involved at 
various stages of this project. For their help with DSC, DSF and MALS analyses I am thankful to Dr. 
Ilian Jelezarov, Dr. Paolo Cinelli and Dr. Birgit Dreier from the University of Zurich. I want to further 
thank Dr. Peter Gimeson (GE Healthcare, Sweden), Dr. Thomas Müller-Späth (ChromaCon, 
Switzerland) and Dr. Daniel Weinfurtner (MorphoSys, Germany) for their generous willingness to 
support me in the DSC, CIEX and Capillary electrophoresis experiments. I would like to acknowledge 
Dr. Manfred Heller (University of Bern, Switzerland) for his active help in MS analyses. I am further 
grateful to the personnel of the Functional Genomics Center at University of Zurich for their help with 
MS analyses, protein sequencing and RP-HPLC. My thanks are also due to Dr. Stefan Duhr 
(NanoTemper, Germany) for the chance to determine affinities by microscale thermophoresis. 
Moreover I am indebted to the P-CUBE program and the Welcome Trust Center (Oxford, UK), 
especially Dr. Yuguang Zhao and Margaret Jones, for their help and support during my stay in Oxford. 
Acknowledgments 
 
 
 
I highly appreciate the great help of all the people who supported my work in terms of administration, 
infrastructure and materials. Thanks to the entire staff of the Department of Biochemistry, especially 
Petra Vogt, the IT-Team (Steve Rast and Dr. Stephan Klauser) and the workshop crew (Adrian 
Schmid und Sascha Weidner). Finally, I´d like to thank the Molecular Life Science PhD Program of the 
Life Science Zurich Graduate School for giving me the opportunity to be part of the PhD program, 
allowing me to get to know many other PhD students from various fields and to exchange our ideas 
and thoughts at various retreats and events. 
Furthermore, I am very grateful for the financial support of a Kekulé-Scholarship from the 'German 
Chemical Industry Association' during the first two years of my PhD studies. I also want to thank the 
University of Zurich, the Life Science Zurich Graduate School, the Hartmann Müller Foundation as well 
as the Swiss Society of Biochemistry for providing several travel grants for the attendance of various 
conferences in Europe and in the United States. 
Most importantly, I would like to thank my family for the support they provided throughout my entire life 
and, in particular, my stays abroad. They have always been there for me when I needed them and 
encouraged me continuously through all these years. I am further extremely thankful for the love and 
support of my girlfriend Alexandra who helped me to stay balanced and motivated once labwork was 
getting tough. Thanks for accepting the numerous times I left you behind going to the next conference 
or meeting and sorry for regularly messing up our vacation plans. 
   Table of Content 
 
 
 
Table of Content 
 
1. Summary 1 
 
 Zusammenfassung 4 
 
 
2. Introduction 7 
 
 
3. Results 23 
 
 3.1 Validation of antibody engineering: transferability of improved biophysical properties from 
scFv to IgG and from prokaryotes to eukaryotic expression systems 23 
Supplementary Material for Chapter 3.1 59 
 3.2 Engineering aggregation resistance in IgG by two independent mechanisms: lessons from 
comparison of Pichia pastoris and mammalian cell expression 65 
Supplementary Material for Chapter 3.2 103 
 3.3 Construction of scFv Fragments from Hybridoma or Spleen Cells by PCR Assembly 109 
 3.4 Miniantibodies  135   
 3.5 Improving Expression of scFv Fragments by Co-expression of Periplasmic Chaperones 151 
 
 
4. General Discussion and Outlook  169 
 
 
5. Appendix 175 
 
 5.1 Abbreviations  175 
 5.2 Plasmid / Vector overviews  177 
 5.3 Protein Sequences  180 
 5.4 Conferences, Posters and Oral presentations  187 
 5.5 Curriculum Vitae  188 
 
 
 
 
 
 
1. Summary 
1 
1. Summary 
 
Recombinant antibodies and their derivatives are widely used molecules in a broad range of 
applications, from basic research to medical therapy. Although immunoglobulins (IgGs) generally 
belong to the more stable natural proteins, by far not all of them show the characteristics required for 
these tasks. Their biophysical properties can differ greatly from very stable to highly aggregation- 
prone. Aggregation is a serious concern for therapeutic antibodies, since it can lead to reduced 
bioactivity, cause severe side effects and increase the risk of immunogenicity.  Therefore, the 
understanding and the engineering of antibody degradation and aggregation mechanisms is crucial for 
the development of potent pharmaceutical products. In addition, developing methods to improve the 
expression level and overall stability of IgG molecules is of great importance, as the high cost of their 
production is still a major drawback of these molecules. 
Previous work from our laboratory consolidates the combination of structure-based analysis with 
family-consensus alignments as a powerful method for improving the properties of immunoglobulin 
variable domains. Particular germline residues in the framework of these domains were shown to be 
responsible for poor biophysical properties of some of the IgG subclasses. The exchange of these 
amino acids in the VH domain greatly influenced both the stability as well as the expression level of 
scFv fragments produced in Escherichia coli. However, nowadays almost all approved therapeutic 
antibodies are still in the IgG format produced in mammalian cells. Therefore, the main focus of this 
thesis was to investigate whether these effects were unique to the scFv format and the prokaryotic 
expression system or whether they were applicable to other antibody formats as well. Therefore, 
antibody-formats with more than the variable domain (Fab fragment and full-length IgGs) were 
designed and different expression hosts (E. coli, Pichia pastoris and mammalian cells) selected as 
production systems. As so far very little is known about the extent to which results derived from one 
antibody format (like scFv) can be applied to other formats (like the full -length IgG), this project 
showed great promise for gaining further insights into the influence of intrinsic domain interactions. In 
addition, it was intended to elucidate to which extent the choice of the expression system with its 
respective protein folding and quality control machineries influence the expressed proteins.  
In the first part of this thesis, the transferability of beneficial mutations to other antibody formats came 
to the fore. Analyses clearly indicated that - although increased expression levels were only detectable 
for periplasmatic expression in the prokaryotic system - advanced stabilities both with respect to 
thermal and denaturant-induced unfolding could be found in formats other than the scFv, independent 
of the expression system. Interestingly, the mutations also influenced the structural integrity of the 
engineered full-length IgG. An increased homogeneity was not restricted to the VH domain but even 
affected the structural integrity of the adjacent CH1 domain with its intrachain disulfide bond. These 
results confirm the potential of structure-based protein engineering for applications involving full-length 
IgGs and the transferability of improvements implemented in smaller antibody fragments.  
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The comparison of the different expression hosts led to an additional important finding. The analysis of 
IgGs of identical amino acid sequence that were produced either in mammalian cells (HEK293) or in 
the yeast P. pastoris detected dramatic differences in some of their biophysical characteristics. While 
the thermodynamic stabilities of the constructs were quite similar, they unexpectedly revealed very 
different aggregation susceptibilities: Antibodies expressed in mammalian cells aggregated at ~75°C 
whereas the analogous constructs from P. pastoris did not show any detectable aggregation. This 
phenomenon was found to be mainly caused by two factors. As a first cause, differences in the 
glycosylation pattern attached to the CH2 domain of the IgGs were identified. While the mannose-rich 
glycan found in the Pichia IgGs slightly destabilized the molecules with respect to thermal and 
denaturant-induced unfolding, it strongly inhibited their aggregation propensity compared to the 
complex mammalian glycan.  
Secondly, the increased tolerance towards aggregation of the Pichia-derived antibodies was found to 
be caused by residues left behind from the α-factor pre-pro sequence at the N-termini of both the 
heavy and light chain due to imperfect processing. This additional EAEA-tetrapeptide proved to 
increase the temperature of the onset of aggregation considerably and reduced aggregate formation 
after extended incubation at elevated temperatures. The experimental attachment of these residues to 
IgGs produced in the mammalian cell culture confirmed their beneficial effect on aggregation 
resistance. While the extension with control tetrapeptides even increased the aggregation propensity 
of mammalian IgGs, the addition of EAEA to the light chain - but not to the heavy chain - resulted in an 
apparent increase in the onset temperature of aggregation by approximately 10°C. Data derived from 
analyses performed at various pH support the hypothesis that the positive impact of the EAEA-
tetrapeptide most likely is based on its contribution towards the local charge distribution of the 
antibody molecule.  
To warrant an extensive comparison of IgG molecules, great efforts were made to enable secretion of 
IgGs with native N-termini in the yeast system. Systematic engineering of the precursor proteins and 
the processing site was performed and showed that the heavy chain did not require the pro-region for 
efficient transport and folding in Pichia. These results led to the definition of optimal sequence 
composition for either aggregation-resistant or correctly processed IgGs, respectively.  
Taken together, the second part of this thesis investigated the impact of certain sequences on the 
aggregation properties of IgGs and showed that their aggregation susceptibilities could be engineered 
by modifying their charge distributions at certain locations.  These results will hopefully improve the 
engineering of aggregation-resistant IgGs and further be useful for the efficient production of full-
length IgGs in P. pastoris. In addition, the data shed new light on potential biophysical effects of tag 
sequences in general. As could be shown, the addition of only a few amino acids to the N-terminus of 
the IgG, a protein of several hundred residues, had dramatic effects on the molecule's biophysical 
properties in vitro. In a broader view, these findings have important implications for the common 
practice of adding different tags to proteins of interest, assuming that few additional amino acids will 
not have major impacts on these molecules. 
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As a last part of this thesis, various practical aspects of antibody production were addressed. 
Developing and enhancing previous techniques and methods, improved instructions could be 
established allowing the direct application of this part to practical challenges. By  designing a new set 
of primer sequences for the amplification of VH and VL genes, the faithful cloning of the variable region 
genes could be promoted, preserving as much sequence identity as possible while avoiding the 
generation of non-natural residue combinations which could result in sequences problematic for 
folding and stability. In an additional approach, methods to create multivalent molecules were 
elucidated. These designed ʺminiantibodiesʺ mimic the geometry of IgG molecules and thus increase 
their functional affinity (avidity) to a corresponding multimeric antigen structure. At the same time, the 
used components can conveniently be produced in bacterial systems. Since, furthermore, two different 
specificities can be combined within the same miniantibody, these molecules allow numerous 
applications in biotechnology, diagnostics and potentially therapy. Allowing the crosslinking of two 
targets, this approach is of special interest as bispecific binders have already proven to be of great 
therapeutical benefit. Finally, aspects of antibody fragment production in E. coli were addressed. Due 
to their conserved intradomain disulfide bonds, antibody fragments need to be secreted to the 
oxidizing compartment of the periplasm for correct folding. As the periplasmic folding, however, is the 
yield-limiting step, co-expression of periplasmic factors is thought to improve the yield of correctly 
folded antibodies. This problem of soluble expression of scFvs was tackled by creating a modular 
system that allows a flexible co-expression of many factors with virtually any antibody expression 
vector. 
 
Summarized, this thesis deals with various aspects of antibodies and challenges of their application, 
highlighting ways how to engineer and improve their properties for the next generation of IgGs. 
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Zusammenfassung 
 
Rekombinant-hergestellte Antikörper und ihre Derivate sind für viele Aufgabengebiete - angefangen 
von der Grundlagenforschung bis hin zu klinischen Anwendungen - von besonderem Interesse. 
Immunglobuline (IgGs) gehören zu den eher stabilen natürlichen Proteinen, dennoch weisen nur 
wenige dieser Moleküle die für ihre zahlreichen Anwendungen benötigten Merkmale auf. Besonders 
ihre biophysikalischen Eigenschaften können hierbei deutlich variieren, angefangen von extrem stabil 
bis hin zu höchst aggregationsanfällig. Aggregation ist für therapeutische Antikörper von großer 
Bedeutung, da es sowohl zu einer reduzierten Bioaktivität führen als auch das Risiko der 
Immunogenität deutlich erhöhen kann. Daher ist es für die Entwicklung von erfolgreichen 
pharmazeutischen Produkten entscheidend, die Abbau- und Aggregationsmechanismen von 
Antikörpern besser zu verstehen und zu beeinflussen. Zusätzlich sollten Methoden zur Verbesserung 
der Expressionsmengen sowie der generellen Stabilität von IgG Antikörpern entwickelt werden, da 
deren hohe Produktionskosten immer noch einen bedeutenden Nachteil darstellen.  
Frühere Arbeiten unserer Arbeitsgruppe haben gezeigt, dass die Kombination von strukturbasierten 
Analysen mit Vergleichen der Konsensus-Sequenzen der IgG Familien eine leistungsfähige Methode 
zur Eigenschaftsverbesserung der variablen Immunglobulin-Domänen darstellt. Hierbei konnte 
nachgewiesen werden, dass spezielle Positionen innerhalb der in der Keimbahn codierten konstanten 
Strukturen für die mangelhaften Eigenschaften mancher IgG Familien verantwortlich sind. Der 
Austausch dieser Aminosäuren innerhalb der VH Domäne verbesserte tatsächlich sowohl die 
Expressionsmenge als auch die Stabilität von scFv-Fragmenten, welche im Bakterium Escherichia coli 
hergestellt wurden. Da heutzutage jedoch fast alle therapeutisch zugelassenen Antikörper noch immer 
als ganze Antikörper in eukaryotischen Zellen hergestellt werden, steht im Mittelpunkt dieser 
Doktorarbeit die Frage, ob die eben erwähnten Effekte einzig und allein für das scFv-Format und 
prokaryotische Expressionssysteme gelten oder ob sie auch auf andere Antikörperformen übertragen 
werden können. Um dies zu untersuchen, wurden verschiedene Antikörperformate (Fab-Fragmente 
und ganze IgGs) ausgewählt und in verschiedenen Expressionssystemen (E. coli, Pichia pastoris 
sowie Säugerzellen) hergestellt. Da bislang wenig darüber bekannt ist, in welchem Ausmaß die von 
einem Antikörperformat (z.B. scFv-Fragmente) gewonnenen Ergebnisse auf ein anderes Format (z.B. 
ganze IgGs) übertragen werden können, sollte dieses Projekt weitere Erkenntnisse über den Einfluss 
der Wechselbeziehungen der intrinsischen Domänen liefern. Darüber hinaus galt es zu analysieren, 
inwiefern die verschiedenen Expressionssysteme mit den dazugehörigen Proteinfaltungs- und 
Qualitätskontroll-Mechanismen die Eigenschaften der hergestellten Proteine beeinflussen.  
Im ersten Teil dieser Doktorarbeit stand die Frage nach der Übertragbarkeit der vorteilhaften 
Mutationen auf andere Antikörperformate im Vordergrund. Diese konnte positiv beantwortet werden. 
Verbesserte Expressionsmengen wurden zwar nur für die periplasmatische Expression im 
prokaryontischen System erzielt - jedoch konnte klar gezeigt werden, dass eine erhöhte Stabilität 
bezüglich der thermischen sowie der durch Denaturierungsmittel ausgelösten Entfaltung auch in sich 
von scFv unterscheidenden Formaten erreicht wird. Dies scheint unabhängig vom verwendeten 
Expressionssystem der Fall zu sein. Interessanterweise veränderten die Mutationen auch die 
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strukturelle Integrität und die Homogenität der veränderten IgG Antikörper. Diese verbesserte 
Homogenität betraf nicht nur die VH Domäne, sondern beeinflusste zusätzlich auch die strukturelle 
Integrität der benachbarten CH1 Domäne mit ihrer Disulfidbrücke zwischen leichter und schwerer 
Kette. Zusammengenommen bestätigen diese Ergebnisse das große Potenzial des strukturbasierten 
Antikörper-Engineerings und die Übertragbarkeit von Erkenntnissen, welche im Zusammenhang mit 
kleineren Antikörper-Fragmenten gewonnen wurden. 
 
Der Vergleich der verschiedenen Expressionssysteme führte zu einer weiteren wichtigen Erkenntnis. 
Bei der Analyse von IgG Molekülen - welche zwar die identische Aminosäuren-Sequenz besaßen, 
jedoch entweder in Säugerzellen (HEK293) oder von der Hefe P. pastoris produziert wurden – zeigten 
sich erstaunliche Unterschiede in einigen biophysikalischen Eigenschaften. Während die 
thermodynamische Stabilität aller Konstrukte recht ähnlich war, konnten überraschenderweise doch 
sehr unterschiedliche Aggregationsanfälligkeiten nachgewiesen werden. Antikörper, welche in 
Säugerzellen hergestellt wurden, aggregierten bei ~75°C, während die entsprechenden Konstrukte 
aus dem Hefesystem keinerlei nachweisbare Aggregation aufwiesen. Bei den durchgeführten 
Untersuchungen stellte sich heraus, dass dieses Phänomen auf zwei unterschiedlic hen Ursachen 
basiert. Als erste konnten Unterschiede bei der Glykosylierung der CH2 Domänen identifiziert werden. 
Während die Zuckerstrukturen der Hefe-Antikörper zahlreiche Mannose-Einheiten aufwiesen und das 
Molekül geringfügig destabilisierten, verminderten sie dennoch die Aggregationsanfälligkeiten deutlich 
im Vergleich zu den entsprechenden Säugerzuckern.  
Als zweite Ursache der vergrößerten Aggregationstoleranz der Hefe-Antikörper konnten Aminosäuren 
ausgemacht werden, welche von der verwendeten α-factor Pre-Pro-Sequenz herrührten und durch ein 
unvollständiges Prozessieren der schweren und leichten Kette jeweils an deren N-Termini 
zurückblieben. Dieses zusätzliche Tetrapeptid mit der Sequenz ʺEAEAʺ war für die erhöhte 
Starttemperatur der Aggregation verantwortlich und reduzierte darüber hinaus auch die Menge und 
Größe von Aggregaten nach längerer Lagerung bei erhöhten Temperaturen. Das Anhängen dieser 
Reste an in Säugerzellen produzierte IgG Antikörper bestätigte deren positiven Beitrag zur 
Verminderung der Aggregationsanfälligkeit. Während Kontrollpeptide die Resistenz in Säuger-IgGs 
sogar noch reduzierten, erhöhte das zusätzliche EAEA-Peptid die messbare Starttemperatur der 
Aggregation um rund 10°C - jedoch nur dann, wenn es an die leichte, nicht aber an die schwere Kette 
gehängt wurde. Aggregationsanalysen bei verschiedenen pH Werten deuten darauf hin, dass der 
Vorteil des EAEA-Peptids auf dessen Beitrag zur lokalen Ladungsverteilung innerhalb des 
Antikörpermoleküls zurückzuführen ist.  
Um die Antikörper aus den verschiedenen Expressionssystemen direkt miteinander vergleichen zu 
können, wurden auf mehrfache Weise versucht, die Herstellung von IgG Molekülen mit ursprünglichen 
N-Termini im Hefesystem zu ermöglichen. Systematisches Engineering der Vorläufer-Moleküle und 
der benötigten Schnittstellen der beteiligten Enzyme ergab, dass die schwere Kette die verwendete 
Pro-Region nicht zum effizienten Transport und zur erfolgreichen Faltung benötigt. Diese Ergebnisse 
erlaubten die Festlegung von optimalen Sequenzzusammensetzungen für aggregationsresistente 
oder alternativ korrekt-prozessierte IgG Antikörper. 
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Durch die Untersuchung des Einflusses bestimmter Sequenzen auf das Aggregationsverhalten von 
IgG Antikörpern konnte gezeigt werden, dass die Aggregationsanfälligkeit durch das Verändern der 
Ladungsverteilungen innerhalb des Moleküls reduziert werden konnte. Diese Erkenntnisse werden, so 
ist zu hoffen, sowohl das Engineering von aggregations-resistenten IgGs ermöglichen als auch die 
effiziente Herstellung von ganzer IgGs in P. pastoris weiter vorantreiben. Gleichzeitig zeigen diese 
Resultate potenzielle Auswirkungen verschiedener Protein-Tags auf deren biophysikalische 
Eigenschaften. Denn schon wenige zusätzliche Aminosäuren am N-Terminus von IgG Molekülen - 
welche immerhin aus mehreren hundert Resten bestehen - haben einen dramatischen Einfluss auf 
deren in vitro Eigenschaften. Übergreifend weist dies auf eine bisher unterschätze Problematik hin, 
wenn heutzutage generell die verschiedensten Tags an Proteine gehängt werden – immer in der 
Annahme, dass die zusätzlichen Aminosäuren keinen großen Einfluss auf das zu untersuchende 
Protein haben. 
 
Schließlich befasst sich diese Doktorarbeit noch mit verschiedenen praktischen Aspekten der 
Antikörperherstellung. Vorhandene Techniken und Methoden wurden weiterentwickelt, um verbesserte 
Anleitungen zur Verfügung stellen zu können. So konnte durch das Generieren eines neuen Primer-
Sets für die Vervielfältigung der VH und VL Gene das Klonieren dieser variablen Domänen 
verlässlicher gestaltet werden. Hierbei wurde eine größtmögliche Sequenzidentität erhalten und nicht-
natürliche Aminosäure-Kombinationen verhindert, welche zu Sequenzen mit problematischen 
Faltungs- und Stabilitätseigenschaften führen könnten. In einem weiteren Ansatz wurden Methoden 
zur Herstellung multivalenter Moleküle entworfen und verfeinert. Die in Kapitel 3.4 vorgestellten 
ʺMiniantikörperʺ ahmen den Aufbau von IgG Molekülen nach und erlauben daher eine verbesserte 
funktionelle Affinität (Avidität) zu multimeren Antigenen. Als großer Vorteil erweist es sich, dass die 
verschiedenen Komponenten bequem in prokaryotischen Systemen hergestellt werden können. Da 
hierbei auch zwei verschiedene Spezifitäten innerhalb desselben Miniantikörpers vereint werden 
können, ergeben sich für sie verschiedene technologische, diagnostische und sogar therapeutische 
Anwendungen. Durch die Möglichkeit, durch Miniantikörper zwei Ziele wie z.B. Zellen zu verlinken, ist 
dieser Ansatz von besonderem Interesse - angesichts des nachgewiesenen therapeutischen Nutzens 
von bispezifischen Bindern. Abschließend wurden Aspekte der Produktion von Antikörper-Fragmenten 
in E. coli behandelt. Wegen der Disulfidbrücken innerhalb ihrer Domänen müssen Antikörper-
Fragmente in das oxidierende Milieu des Periplasma sekretiert werden. Da das dort stattfindende 
Falten jedoch in der Regel der (mengen-) limitierende Schritt ist, könnte die Koexpression von 
periplasmatischen Faktoren die Anzahl an korrekt gefalteten Antikörper erhöhen. Um diese 
Herausforderung anzugehen, wurde ein modulares System entwickelt, welches die flexible 
Koexpression zahlreicher Faktoren mit fast allen erdenklichen Expressionsvektoren für die 
Antikörperherstellung ermöglicht. 
 
Zusammengefasst beschäftigt sich diese Dissertation sowohl mit verschiedenen Aspekten von 
Antikörpern als auch mit einigen  Herausforderungen ihrer Anwendung und zeigt Wege auf, die 
Eigenschaften der nächsten IgG Generation weiterzuentwickeln und zu verbessern. 
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2. Introduction 
Antibodies, also called immunoglobulins (Ig), are an important component of the vertebrate immune 
system. As part of the humoral immune response, these molecules recognize many pathogens and 
thereby protect vertebrates against infections of e.g. viral and bacterial origin. In addition, antibodies 
and their derivatives are used in an increasing number of applications from basic research to 
biomedical therapy and thus represent one of the most important classes of molecules in the 
biotechnological and pharmaceutical industry. The main reason for this wide range of applications is 
the ability of antibodies to selectively recognize even small quantities of many kinds of substances, 
from small organic components to large surface structures of microbes or mammalian cells. Moreover, 
antibodies can bind their targets with both extraordinary specificity as well as high affinity, making 
them ideal tools for a broad variety of applications. Currently, 30 therapeutic monoclonal antibodies 
(mAbs) have been approved for therapeutic use by the US Food and Drug Administration (FDA) and 
several hundred antibody-derivatives are in clinical development, making up over a third of the 
proteins currently undergoing clinical testing in the USA.
1; 2
 Most of the therapeutic antibodies are used 
in the areas of oncology or the treatment of arthritis and immuno-inflammatory disorders. In cancer 
therapy, for example, mAbs successfully support the standard treatments of surgery and radiation.
3
 In 
addition to their pharmaceutical relevance, antibodies are also employed in a wide range of analytical 
techniques like immunoblotting, flow cytometry, immunohistochemistry or enzyme-linked immune-
sorbent assays (ELISA), just to name a few examples. Furthermore, antibodies are employed in 
specific protein purification by affinity chromatography.  
 
Structure and function of antibodies 
Immunoglobulin G (IgG), the immunoglobulin most frequently found in human serum, is a 
heterotetramer composed of two identical light (L) chains and two identical heavy (H) chains, having a 
molecular weight of ~25 kDa and ~50 kDa per chain, respectively. There are two variants of human 
light chains present in human IgGs, the more frequent kappa-(κ-)chain and the less frequent lambda-       
(λ-)chain. The two heavy chains of the IgG molecule are held together by noncovalent forces such as 
hydrophobic interactions or van-der-Waals forces and additionally linked by two interchain disulfide 
bonds (in the case of IgG1) within the hinge region (Fig. 2.1). Each of these heavy chains is further 
connected with one light chain by hydrophobic interactions and an additional disulfide bridge. This 
composition leads to the well-known Y-shaped structure of IgGs with two identical antigen-binding 
sites, one in each of its arms (Fab fragments). These binding sites are formed by the complementarity 
determining regions (CDRs) - loops which are highly diverse in length and sequence. These six 
hypervariable regions - three each within the N-terminal variable (V) regions of both the light and 
heavy chain, respectively - generate the unique surface that specifically recognizes and binds the 
corresponding antigen.
4; 5
 The CDRs themselves are flanked by four framework regions that guarantee 
the stability of the variable domains and the orientation of the CDRs, all together forming the so-called 
paratope which specifically binds to the epitope on the antigen. The remaining IgG framework is highly 
conserved both in its sequence as well as in the structure of its constant regions that mediate the 
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biological activities characteristic for antibodies. These include the ability to initiate host immune 
responses such as antibody-dependent cellular cytotoxicity (ADCC) or complement-dependent 
cytotoxicity (CDC).
6
 All these effects are mediated by the crystallizable fragment of the IgG (Fc part) 
consisting of the second and third constant domains of the heavy chain (CH2 and CH3). In addition, a 
complex N-linked glycosylation present at Asn297 within the CH2 domain is required for the interaction 
of the IgG with some of the activating Fcγ receptors. These receptors , and among them especially 
FcγRIIIa, are responsible for triggering ADCC by recruiting immune cells that lead to phagocytosis or 
lysis of the targeted cells. In CDC, antibodies activate the complement cascade at the cell surface, 
eventually killing the targeted cells. 
 
 
 
Fig. 2.1: Schematic representation of immunoglobulin G. The IgG molecule is comprised of four 
polypeptides, two identical heavy (H) and two identical light chains (L), each with variable (V) and constant 
(C) domains. The antigen binding sites are situated in the arms of the molecule and are comprised of the 
CDR loops of the variable VH and VL domains. Framework regions are located between these CDRs. The 
hinge and the interchain disulfide bonds connecting the heavy chains or the heavy and light chain at CL 
and CH1, respectively, are indicated in green. Green lines also represent intrachain disulfide bonds. The 
conserved glycosylation at Asn297 of the CH2 domain is shown in red. Papain digest generates the two 
antigen binding Fab and one Fc fragment indicated in this scheme adapted from Beck and colleagues.
7
 
Abbreviations: CL: constant domain of the light chain; CH1-CH3: constant domains of the heavy chain; VL: 
variable domain of the light chain; VH: variable domain of the heavy chain. 
 
As depicted in Fig. 2.1, each of the IgG chains consist of multiple domains (two or four for the light and 
heavy chain, respectively), all possessing the so-called ʺimmunoglobulin foldʺ. This characteristic 
structural unit has a molecular weight of ~12.5 kDa (corresponding to about 110 amino acids) and 
consists of two antiparallel β-sheets forming a β-sandwich (Fig. 2.2a).
8; 9
 In constant domains, this β-
sandwich is composed of seven β-strands while two additional strands are present in the variable 
domains. A hallmark of this immunoglobulin fold is the intradomain disulfide bond that covalently links 
the two β-sheets and is deeply buried in the interior of the IgG domain (Fig. 2.2b). 
 
 
 
2. Introduction 
9 
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Fig. 2.2: Topological structure of the immunoglobulin fold and the 6B3 Fv fragment . (a) The model 
structure of VH6 was used to illustrate the nine-stranded antiparallel β-barrel of a variable domain. The 
three complementarity determining regions (CDR-H1 to 3, indicated in yellow) protrude as loops from the 
variable domain core structure and form half of the antigen binding site. (b) Model of the 6B3 Fv fragment 
(PDB entry VL3_VH6_FV). The VH domain is shown in blue with yellow CDR loops while the VL domain is 
depicted in green with orange CDRs. Yellow spheres represent both intrachain disulfide bonds. Residues 
modified within this study (see below) are highlighted as red sticks. 
 
The immune system of vertebrates relies on antibodies to protect the organism against infections by 
various pathogens. Based on the different structures of the heavy chains, human immunoglobulins 
can be grouped into the five main classes, also termed isotypes, IgA, IgD, IgE, IgG and IgM with their 
corresponding heavy chains α, δ, ε, γ and μ. These classes differ in their b iological properties, their 
functional locations and the ability to deal with different antigens. In the early stages of B-cell mediated 
immunity, IgM molecules are produced to eliminate pathogens. Secreted members of this isotype are 
polymeric proteins with a starlike structure composed of five single Ig subunits , thereby revealing a 
rather high avidity to their targets. IgA (with human subclasses IgA1 and IgA2) is present in mucosal 
areas preventing their colonization by pathogens and has both a monomeric variant present in the 
serum and a dimeric secreted form. All other isotypes - IgD, IgE and IgG (with its four human 
subclasses IgG1-IgG4, see below) - are only to be found in the serum as monomers. Of these 
immunoglobulins, IgG provides the majority of antibody-based immunity against invading pathogens 
and is the only type of antibody that can cross the placenta during pregnancy due to its binding to 
placental trophoblasts. Importantly, while antibodies of all other isotypes have a relatively short half-life 
of only a couple of days, IgGs have a much longer half-life of up to three weeks, making them a very 
important component of the human immune system. 
The human IgG family itself consists of four distinct subclasses (IgG1, IgG2, IgG3 and IgG4, 
respectively) which are known to possess differences in certain antigenic, structural and biologic 
properties.
10
 Having a sequence homology of more than 95%, the subclasses show their most 
conspicuous differences in the amino acid composition and structure of their hinge regions with their 
interchain disulfide bonds.
11
 Thus, the length and the flexibility of the hinge regions vary considerably 
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among the different subclasses. While e.g. the hinge of IgG1 can move rather freely, its flexibility is 
restricted for IgG2 and IgG4 due to its shorter length.
12
 IgG3, on the contrary, has a peculiar extended 
hinge region and exhibits eleven interchain disulfide bonds – substantially more than the two or four 
disulfide bonds found in IgG1 and IgG4 or IgG 2, respectively. Irrespective of these differences, the Fc 
regions of each IgG subclass still are structurally very similar with distinct affinities for the Fc 
receptors. However, IgG1 and IgG3 show a more effective binding than IgG2 and IgG4.
10
 
 
Diversity of antibodies 
To fulfill its task, the human immune system requires a large repertoire of immunoglobulin molecules, 
differing in the sequence and the structure of their variable regions. This diversity is achieved through 
a combination of various rearrangements and combinatorial assemblies of different genetic 
segments.
13
 The variable domains of the heavy chain are generated by the combination of variable 
(V), diversity (D) and joining (J) gene segments while those of the light chain only consist of V - and J-
regions. The variable VH domain is an assembly of a segment of the approximately 50 functional V-
segments, 30 D-segments and 6 J-segments each, all located on chromosome 14.
14
 For the κ-light 
chains, around 40 functional V-segments and 5 J-segments are located on chromosome 2
15
 whereas 
31 V-segments as well as 6 J-segments on chromosome 22 are used to create the variable domain of 
the λ counterpart.
16
 The arrangement of these gene segments, termed V(D)J recombination, takes 
place during the development of B-lymphocytes.
17-19
 The diversity arising from these combination 
events is even further increased through nucleotide deletions or insertions at the junction sites of the 
V, D and J fragments
17
 as well as through the random combination of a certain heavy with any other 
light chain.  
The last diversification mechanism occurs after B-cell maturation is completed. When first contacts 
with the antigen have been made, stimulated B-lymphocytes start a process termed somatic 
hypermutation
20
 in which several point mutations are introduced into the variable regions of the 
rearranged genes. This last process, also called affinity maturation, increases the potential and 
effective diversity by many orders of magnitude. All of the mentioned mechanisms finally lead to a 
theoretical diversity of up to 10
12 
different immunoglobulins, which are subsequently expressed on the 
surface of B-cells and secreted as soluble antibodies into the serum.
21
  
 
Selection of recombinant antibodies and different immunoglobulin formats 
Next to the isolation of polyclonal antibodies from immunized animals and the hybridoma technology 
developed by Köhler and Milstein,
22
 the recombinant construction of antibodies is the most popular 
method for obtaining immunoglobulins nowadays. The knowledge of the IgG structure in molecular 
details and the development of advanced methods in gene technology over the last decades 
significantly contributed to the success of this technology. Today, numerous libraries have been 
described
23
 and antibodies can be obtained from naive repertoires
24; 25
 or libraries of fully synthetic 
genes
26
 - allowing the selection of recombinant antibodies of completely human nature with regard to 
their sequence and characteristics.  
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A requirement for the selection of antibodies from man-made libraries was the development and 
establishment of the phage display technology.
27; 28
 Thus, it became possible to select specific binders 
from large recombinant in vitro libraries. Nowadays, there are also alternative display technologies that 
couple the genotype to the phenotype of the selected binders such as yeast display,
29
 bacterial 
display
30
 and further in vitro display technologies including ribosome display.
31
 In most of these 
techniques, antibodies are not selected as full-length IgGs but rather are used in a variety of smaller 
formats. In the past, several antibody fragments have been created of which some are applicable for 
these selection methods. Generally, the Fv-fragment
32
 (VL/VH; shown on top of Fig. 2.3) is the minimal 
setup which still contains the complete antigen binding site. However, due to the non-covalent 
connection of both variable domains, this fragment is generally rather instable and not well suited for 
selection purposes. This problem was solved by the development of the scFv (single chain Fv; 
depicted on the left side of Fig. 2.3) fragments,
33; 34
 single polypeptides containing an additional 15 to 
20 amino acids long flexible peptide linker connecting the VH with the VL domain (or vice versa). As an 
alternative, Fv fragments could be stabilized by the introduction of a disulfide bond between the C-
terminal regions of the variable domains – leading to so-called dsFvs fragments which, however, 
shows lower expression levels than scFvs.
35
 Next to scFvs, also Fab-fragments (ʺfragment antigen 
bindingʺ; illustrated on the right side of Fig. 2.3) are frequently used in selection setups. These 
fragments are heterodimers and consist of the complete light chain (VL/CL) and the Fd-fragment 
(VH/CH1) of the heavy chain.  
 
 
 
Fig. 2.3: Model structures of various antibody fragments. Derivatives of the full-length IgG molecule, 
indicated in the centre. The scFv fragment is depicted on the left side, consisting of VL and VH connected 
by a flexible peptide linker. Shown is only the VH-VL orientation although the other orientation also exists. 
The Fab-fragment, displayed on the right side, is composed of the whole light chain and the Fd fragment of 
the heavy chain (VH and CH1 domain) connected by a disulfide bond between CL and CH1. Above the IgG, 
the unlinked Fv fragment is shown. 
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Due to their small size of ~30 kDa and the relative ease with which these single polypeptide chains 
can be expressed in bacteria, scFv fragments are a very popular, if not the most popular antibody 
format.
36
 Compared to full-length IgGs, they possess some clinical advantages such as better tumor 
penetration
37
 and faster clearance from the organism.
38
 However, neither scFv nor Fab fragments 
contain any effector function part which could activate compounds of the immune system, as 
described above. Although there are some applications which do not depend on or even want to 
prevent any immune response,
39; 40
 most marketed antibodies still comprise full-length human IgG 
molecules, mainly since long half-lives have been considered desirable for most applications.  
 
Production of full-length IgGs and antibody fragments 
During the mid-1980's, developments in molecular biology and recombinant DNA techniques allowed 
the first expression of functional full-length antibodies in yeast
41
 and cells of higher eukaryotes.
42; 43
 
Since the yields were rather low and the cultivation of these cells quite elaborate, antibody expression 
systems were also developed for the bacterium Escherichia coli.
44; 45
 However, it was not until the 
genes for the heavy and light chain, respectively, were fused to N-terminal signal sequences that 
functional antibody fragments were successfully expressed in E. coli.
32; 46
 These signal sequences 
allowed the secretion of the antibody fragments into the periplasm, whose oxidative environment and 
various chaperones allowed the proper folding and formation of disulfide bonds which are important for 
the structure of the immunoglobulin domains.
47
 Ever since, bacterial hosts have been commonly used 
for the production of antibody fragments, mainly due to the ease of genetic manipulation of this well 
established and relatively inexpensive expression system. However, while the expression of small 
antibody fragments (like scFv or Fab fragments) in E. coli nowadays can be performed at large scale 
in fermenter cultures,
48; 49
 often only a minor fraction of product can be recovered in functional form 
due to limitations of the antibody assembly in the periplasmic space. Even though meanwhile the 
expression of full-length IgG has been achieved in E. coli,
50-52
 their levels are still very low and 
incompletely assembled molecules also occur. Therefore, therapeutic antibodies generally are 
produced in mammalian cells, since in addition only this expression system can carry out the proper 
posttranslational modifications necessary for the functional activities of IgGs. 
To date, different expression systems have been developed for the recombinant production of various 
antibody formats. In addition to other prokaryotic systems such as Bacillus subtillis,
53
 Streptomyces 
lividans
54
 or Proteus mirabilis,
55
 several eukaryotic systems were successfully employed, such as 
yeasts and filamentous fungi,
56; 57
 insect cells,
58
 algae,
59
 plants
60
 and transgenetic animals.
61
 However, 
currently all approved therapeutic antibodies of the IgG format are produced in mammalian cells,
62
 
since only this system introduces the complex glycosylation which is necessary for the interaction of 
the antibodies with Fcγ receptors.
63
 In addition, mammalian cells can be cultured in large-scale 
fermenters, offer high expression yields and can be optimized due to recent improvements in cell 
engineering.
64; 65
 Furthermore, nowadays the establishment of stable cell lines, expressing the 
antibodies permanently at high levels from constitutively active promoters, can be easily achieved.
64; 66
 
Of additional importance are the sophisticated folding machinery and quality control mechanisms, 
located in the endoplasmatic reticulum of mammalian cells.
67; 68
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In some cases, however, the FcγR interaction is neither needed nor wanted, thus widening the range 
of potential production hosts to e.g. Pichia pastoris. In the past, this methylotrophic yeast has been 
widely used for the expression of both secreted and intracellular eukaryotic proteins.
69
 P. pastoris was 
initially developed as a biological tool in the 1970's to exploit methanol, the byproduct of the oil 
industry, to generate yeast biomass or single cell protein which could be used as livestock feed. Being 
a microbial eukaryote, Pichia combines several advantages of eukaryotic expression systems, like its 
capacity of performing posttranslational modifications, with the easy handling and simplicity of 
techniques needed for the genetic manipulation of microbes like E. coli. In addition, P. pastoris has a 
shorter generation cycle and is cheaper to use than mammalian expression systems. While it is able to 
carry out efficient disulfide bond formation and isomerization using the eukaryotic secretion quality 
control machinery,
69-71
 Pichia expression generates mannose-rich glycosylation of IgG.
72
 The attached 
glycan moieties differ markedly from the product of mammalian cells, resulting in antibodies that lack 
FcγR binding capacity. However, recently, P. pastoris has been engineered to introduce complex, 
human-like glycosylation.
73-76
 
Due to its respiratory growth, P. pastoris can grow to very high cell densities,
77
 and therefore express 
high levels of recombinant protein
78
 through efficient and tightly regulated promoters, accounting for 
up to 30% of the total cell protein.
79
 Moreover, comparatively few endogenous proteins are secreted 
by this yeast system, which offers further advantages for efficient subsequent protein purification and 
downstream processing.
80
 Since Ridder and colleagues reported the first successful production of 
functional antibody fragments in Pichia,
81
 more than 50 reports have been published describing 
antibody expression in this system.
82
 While most of these molecules were scFv fragments and fusions 
thereof, several Fab fragments have been produced in Pichia as well.
83-85
 Interestingly, until today P. 
pastoris has only been used as an expression host for a handful of full-length IgGs.
75; 76; 86
  
 
Antibody Engineering 
The availability of a number of crystal structures and their modular composition make immunoglobulins 
quite suitable for protein engineering attempts. In recent years, two principal methods have proven to 
be successful for improving antibody sequences, being classifiable as either ʺrationalʺ approaches or 
ʺdirected evolutionʺ ones. 
Rational or structure-based engineering relies on the detailed analysis of three-dimensional (3D) 
structures of the protein of interest (POI) and usually results in the exchange of certain amino acids by 
site-directed mutagenesis.
87
 To optimize key residue interactions, at first those suboptimal amino acids 
in the original sequences leading to decreased stability have to be determined, followed by the careful 
decision with which amino acid they should be replaced. Therefore, the rational approach partly is 
based on alignments of particular antibody sequences to well-expressing stable and non-aggregating 
fragments,
88-92
 an analysis of exposed hydrophobic residues
93
 or the grafting of CDRs onto a stable 
and well folding framework.
94-96
 Thereby, several aspects such as the packing of the hydrophobic core, 
hydrogen bonding or electrostatic interactions among many others must be taken into account.
97
 To 
avoid unfavorable strain in the resulting mutants, high-resolution structures are a fundamental 
prerequisite to allow the estimation of possible conformational as well as energetic and steric 
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influences upon the replacements. With the present efforts in the field of structural genomics, these 
rational approaches are likely to become more and more important in the future.  
On the other hand, different evolutionary strategies have been designed, all of them mimicking 
principles of Darwinian evolution.
97
 In this approach, the POI is subjected to an evolutionary pressure 
which often rewards stability and expression.
97-99
 After creating a randomized genetic library of 
mutants derived from the wild-type sequence of the POI, sequence diversity can be increased by 
several methods. Using for example either error-prone PCR,
100
 bacterial mutator strains
101
 or DNA 
shuffling,
102
 random mutations are introduced into the sequence and the resulting proteins 
subsequently screened and selected under defined conditions for the desired features. For selection, 
the phenotype must be linked to its genotype in order to use the positive-selected members for the 
next round of evolution. As mentioned above, phage and ribosome display have proven to be powerful 
evolutionary technologies which can be used for the optimization of protein structure and 
interactions.
28; 31
 
Combining these two approaches, several different methods for antibody engineering have proven to 
be successful
97
 and have gained more and more importance over the last few years. Recent advances 
in the engineering of protein stability have shown that even minor changes in a given sequence can 
have profound effects on the biochemical and biophysical properties of the respective protein. Thus, 
for many proteins, some specific mutations may be sufficient enough to considerably increase these 
characteristic features. Hence, the challenge of protein engineering is to identify these positions in a 
given sequence among the vast number of possible changes and to advantageously exchange them.  
 
Context and aim of this study 
Due to their high degree of specificity and broad target range, recombinant antibodies are used in an 
ever increasing number of applications. These make great demands on the molecules concerning their 
obtainable production yield, a low aggregation-tendency and their stability against high denaturant 
concentrations, proteases and elevated temperatures. However, only a subset of antibodies actually 
has the biophysical properties required for these applications. The resulting inability to reach the 
disease-relevant target in sufficient concentrations is one of the biggest problems limiting the clinical 
usage of recombinant antibodies.
103
 Therefore, engineering approaches nowadays are particularly 
aiming at the improvement of the expression levels and overall stabilities of IgG molecules. This is of 
great importance, as the high costs of production are a further major drawback of these molecules. 
More stable antibodies would result in longer half-lives in vivo and thereby decrease both the dosage 
as well as the frequency at which antibody drugs have to be administered. In addition, the best binders 
are useless if they cannot be produced in sufficient amounts or if they are not stable enough to fulfill 
their tasks.  
Previously, our laboratory as well as others analyzed sequence modifications in the variable domain 
for their impact on aggregation propensity and conformational stability.
90; 93; 104-106
 By analyzing the 
human antibody repertoire in terms of structure, amino acid sequence diversity and germline usage, 
our laboratory showed that seven VH (VH1a, VH1b, VH2, VH3, VH4, VH5, VH6) and seven VL (Vκ1, Vκ2, 
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Vκ3 Vκ4 and Vλ1, Vλ2, Vλ3) germline families cover more than 95% of the human antibody diversity.
26
 
Based on these data, consensus framework sequences could be derived for each of these families, 
eventually resulting in the design of the fully synthetic Human Combinatorial Antibody Library 
(HuCAL).
26
 These subfamily-specific consensus sequences cover 98% of all VH, 99% of all Vκ and 
93% of all Vλ sequences. The biophysical properties of these VH and VL consensus domains were 
subsequently evaluated alone and in different VH/VL combinations in the scFv context for their 
expression behavior and denaturant-induced unfolding equilibria under non-reducing conditions.
107
 
This study revealed that antibody fragments containing VH domains of the even-numbered human 
germline families 2, 4 and 6 had comparatively lower expression yields as well as lower midpoints and 
low cooperativity in equilibrium unfolding compared to those of the odd-numbered families 1a, 1b, 3 
and 5. 
In subsequent studies,
91
 members of our laboratory performed sequence comparisons of the seven VH 
consensus domains (see Fig. 2.4), detecting residues potentially responsible for the unsatisfactory 
features of the families with less favorable biophysical properties (VH2, VH4, VH6). These sequence 
analyses revealed differences in the packing of the hydrophobic core, the completeness of charge 
clusters, the occurrence of unsatisfied hydrogen bonds and residues with low β-sheet propensities, 
positive Φ angles as well as exposed hydrophobic side chains. Interestingly, most of these amino acid 
residues were present in all members of the even-numbered families (VH1a, VH1b, VH3, VH5), but did 
not occur in the odd-numbered ones. Based on this sequence comparison in conjunction with 
analyses of structural models, six distinct residues of the framework regions were chosen which were 
characteristic for their respective family and which were hypothesized to be acting independently and 
to be individually exchangeable. Among the performed mutations was the replacement of non-glycine 
loop residues with positive φ angles to glycines (positions 16 and 76, numbering scheme according to 
Honegger and Plückthun
5
), as well as the exchange of non-optimal β-strand residues with amino acids 
possessing higher β-sheet propensity (residues 5 and 90). In addition, at position 72, a solvent -
exposed hydrophobic residue was mutated into a hydrophilic one and residue 58 having an unsatisfied 
H-bond was replaced. All the selected mutations (Q5V, S16G, T58I, V72D, S76G and S90Y, 
highlighted in Fig. 2.4 by red bold letters in the columns with the blue background) were located only in 
the VH framework and not in the CDR regions, since these mutations were intended to be as generally 
applicable as possible and unlikely to affect antigen binding. The exact location of these mutations 
within the Fv fragment can be seen in Fig. 2.3b with the mutated residues highlighted in red. 
Indeed, the introduction of the six mutated residues turned out to dramatically increase both the 
expression yield as well as the thermodynamic stability of engineered scFv fragments produced in the 
prokaryotic system of E. coli without affecting their binding properties. These data were recorded for 
two model antibody scFv named 2C2 and 6B3 that had originally been selected from the HuCAL 
library by panning against the peptide M18 coupled to transferrin or myoglobin from horse skeletal 
muscle, respectively. These molecules were chosen as both belonged to the human VH6 framework 
family whose members are known to have a rather aggregation prone behavior and the lowest 
thermodynamic stability of all human VH domains.
107
 Originating from the same framework family, their 
VH6 sequences were identical except for different CDR-H3 loops, causing the 2C2 and 6B3 constructs 
to recognize different antigens. In addition, the two antibodies differed in the nature of their respective 
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light chain, the 2C2 having a Vκ3 and 6B3 containing a Vλ3 light chain. Importantly, the improvements 
found for the engineered scFv fragments were independent of both, the VL domain and the sequence 
and length of the CDR-H3, as both constructs gave similar results concerning increased scFv yields 
and stabilities.  
In this project and in most studies of other laboratories, the vast majority of antibody engineering 
attempts are performed for antibody formats smaller than the full-length IgG. This was done in order to 
obtain interpretable results, as the occurrence of multiple domains in the IgG make the analysis of 
unfolding curves extremely difficult. A further complication arises from the interaction of the domains.
36
 
In particular, scFv fragments expressed in E. coli have been the focus of most studies concerning 
biochemical and biophysical properties so far. However, so far very little is known about the extent 
with which results derived from studies using a certain antibody format (like scFv) can be applied to 
other antibody formats (like full-length IgGs). Keeping in mind that most approved therapeutic 
antibodies are in the IgG format and produced in mammalian cells, the engineering of full-length 
antibodies will become more and more important in the years to come. Unfortunately, almost nothing 
is known about the biochemical and biophysical effects of mutations in the context of the IgG molecule 
made in mammalian cells. Therefore, the main focus of this thesis was to analyze whether the 
previously found beneficial mutations in scFvs still stayed true in the context of ʺ less-truncatedʺ 
antibody-formats (Fab fragment and full-length IgGs) and to investigate the influence of the expression 
system. 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 2.4: Aligned HuCAL VH sequences. The amino acids are color-coded according to residue type: 
aromatic residues  (Tyr, Phe, Trp) are orange, hydrophobic residues (Leu, Ile, Val, Met, Cys, Pro, Ala) 
yellow, uncharged hydrophilic residues (Ser, Thr, Gln, Asn, Gly) green, acidic residues (Asp , Glu) red and 
basic residues (Arg, Lys, His) blue. Residues that show correlated sequence differe nces among the 
groups of VH domains with favorable properties (VH1a, VH1b, VH3, and VH5) and VH domains with less 
favorable properties (VH2, VH4, and VH6) are indicated by red bold letters in the columns with the dark blue 
background. The numbering scheme is according to Honegger and Plückthun
5
 and the figure adapted from 
Ewert and collegues.
91
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A set of different expression hosts (E. coli, P. pastoris and different mammalian cells) was established 
as production systems. Thus, it should be possible to determine the influences of the respective 
protein folding and quality control machineries, while the use of different antibody formats should give 
insight into the influence of intrinsic domain interactions.  To test the transferability of the previous 
results and their to different antibody formats, both the wild-type (WT) and the best engineered variant 
(called M throughout this work) were converted to the Fab or full-length IgG format and investigated for 
their expression characteristics and biophysical properties. In addition, the established expression 
systems were used to distinguish how various cellular hosts deal with aggregation-prone proteins in 
general and to compare the biophysical properties of the corresponding antibodies.  As one major 
challenge encountered in the development of antibody-based therapeutics is their aggregation 
susceptibility under formulation conditions
108; 109
 and in vivo, special attention was paid to this feature. 
Since irreversible aggregation generally leads to reduced bioactivity
110
 and presents an increased risk 
of immunogenicity,
111-116
 engineering IgG to reduce or eliminate its self-association is of great 
importance and might further extend the potential of therapeutic ant ibodies. 
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Abstract 
Recombinant antibodies and their derivatives are receiving ever increasing attention for many 
applications. Nonetheless, they differ widely in biophysical properties, from stable monomers to 
metastable aggregation-prone mixtures. Previous work from our laboratory presented the combination 
of structure-based analysis with family consensus alignments as being able to improve the properties 
of immunoglobulin variable domains. We had identified a series of mutations in the variable domains 
that greatly influenced both the stability and the expression level of scFv fragments produced in the 
periplasm of E. coli. We now investigated whether these effects are transferable to Fab fragments and 
IgG produced in bacteria, Pichia pastoris and mammalian cells. Taken together, our data indicate that 
engineered mutations can increase functional expression levels only for periplasmic expression in 
prokaryotes. In contrast, stability against thermal and denaturant-induced unfolding is improved by the 
same mutations in all formats tested, including scFv, Fab and IgG, independent of the expression 
system. The mutations in VH also influenced the structural homogeneity of full-length IgG, and the 
reducibility of the distant CH1-CL inter-chain disulfide bond. These results confirm the potential of 
structure-based protein engineering in the context of full-length IgGs and the transferability of stability 
improvements discovered with smaller antibody fragments.  
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Introduction 
Since the emergence of murine monoclonal antibodies as diagnostic and therapeutic agents in the late 
1970s, the possibility to generate recombinant human and engineered antibodies by many 
technologies has led to their greatly accelerated adoption. The reliable and inexpensive production of 
various antibody formats in recombinant form has remained one of the major objectives for antibody 
engineering, as antibodies differ widely in their biophysical properties. Small antibody species like 
single-chain Fv (scFv) or Fab expressed in Escherichia coli
1-3
 have been pivotal research 
intermediates in essentially all antibody engineering projects, but by far most antibodies used in the 
clinic today have been converted to the immunoglobulin G (IgG) format.
4-6
 The main reason is that 
most clinical applications rely upon the effector function of the IgG Fc region. Even if the expression of 
full-length IgG has been performed successfully in E. coli,
7-9
 therapeutic antibodies generally are 
produced in mammalian cells, since only this expression system can carry out the posttranslational 
modifications and introduce the complex glycosylation necessary for most of the functional activities of 
IgG molecules. 
 
Compared to conventional small molecules, antibody drugs offer advantages concerning their 
extended half-life in vivo and their ability for initiating host immune responses such as antibody-
dependent cellular cytotoxicity (ADCC) or complement-dependent cytotoxicity (CDC).
10
 The long half-
life of IgG molecules is due to the pH-dependent binding of the CH2-CH3 interface to the neonatal 
receptor FcRn, a major histocompatibility complex (MHC) class I-like molecule expressed on the 
vascular endothelium. Binding to FcRn protects antibodies from degradation by enabling recycling of 
the molecules and thereby increases their serum persistence.
11,12
 
 
Residues located in the hinge region and the CH2 domain contact the Fcγ receptors, and among them 
especially the activating FcγRIIIa is responsible for triggering ADCC by recruiting immune cells that 
lead to phagocytosis or lysis of the targeted cells.
10,13-16
 The latter interaction requires the complex 
glycosylation provided by mammalian expression systems, which is not provided by yeast and plant 
expression systems.
17,18
 In CDC, antibodies activate the complement cascade at the cell surface, 
upon being triggered by C1q binding to the CH2 domain — eventually killing the targeted cells.
19
 
 
IgGs are composed of various domains, all of them possessing the characteristic immunoglobulin fold 
consisting of two antiparallel β-sheets forming a β-sandwich,
20,21
 which can aggregate, probably 
involving the β-strands, as in many aggregates of other proteins.
22
 The overall stability of the full-
length IgG molecule depends on both the intrinsic stabilities of the individual domains as well as on 
the stability of the corresponding interfaces.
23-26
 The various IgG domains are known to feature 
intrinsic differences in their conformational stability and therefore might also be responsible to different 
degrees for the biophysical properties of the antibody as a whole.  
 
The IgG’s antigen binding sites are formed by the complementarity determining regions (CDRs) within 
the N-terminal variable regions of both the light chain (VL) and heavy chain (VH) coming together and 
generating the unique surface that specifically recognizes and binds the corresponding antigens.
27
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The remaining framework of the variable domains is quite conserved in both sequence and structure. 
Nonetheless, different families of variable domains with varying framework sequences have shown 
quite distinct biophysical properties (see below). The particular arrangement of the antigen binding 
region within the CDRs thus permits re-engineering of the framework residues without jeopardizing 
antigen binding, at least to a first approximation.  
 
Due to the great sequence diversity within their variable regions, antibodies show a wide range of 
biophysical properties.
28-30
 Favorable properties are important for a number of reasons.
31
 First, an 
aggregation-prone molecule would run the danger of leading to unspecific binding in vivo, premature 
clearance, loss of clinical efficacy and the danger of eliciting a T-cell-independent immune 
response.
32,33
 Second, the aggregation-tendency would be potentiated in fusion proteins with 
additional aggregation-prone domains or multimerized constructs, rendering many antibody fusions 
impossible to be produced efficiently. Finally, low stability and a tendency to aggregate will decrease 
the expression level, and may thus make otherwise promising molecules economically not viable. 
 
In previous work,
28
 we discovered surprising differences in the biophysical properties of the germline 
families of human VH domains, as well as both human domains encoding the κ and λ light chain (Vκ 
and Vλ, respectively). By sequence comparison of the human consensus VH domains, particular 
mutations could be identified (Fig. 3.1.1a) that proved to be responsible for the favorable biophysical 
properties of families 1, 3 and 5, as well as for the less favorable properties of families 2, 4 and 6. 
Subsequently, these sequence differences were transplanted from a VH3 consensus framework to the 
very poorly stable and poorly expressing VH6 framework.
34
 Briefly, two non-glycine residues with 
positive φ angles in the Ramachandran plot were converted to glycines (positions 16 and 76; 
numbering scheme according to Honegger and Plückthun,
35
 inducing a positive effect on both 
thermodynamic stability and functional expression in E. coli. Since functional periplasmic expression 
levels are limited by folding,
28
 they constitute an excellent measure of aggregation during in vivo 
folding. In addition, two residues with non-optimal β-strand forming features were exchanged to amino 
acids possessing higher β-sheet propensity (Q5V and S90Y), both affecting functional expression, but 
only the first having a significant thermodynamic equilibrium effect. The removal of a buried non-
hydrogen-bonded OH group (T58I) led to a very large increase in thermodynamic stability, but no 
effect on folding yield. Conversely, the mutation of a solvent-exposed hydrophobic residue to a 
hydrophilic one (V72D) increased the in vivo folding yield but had very little effect on thermodynamic 
stability. 
 
All the selected mutations (Q5V, S16G, T58I, V72D, S76G and S90Y) were located within the VH 
framework and not in the CDR regions, as these mutations were intended to be as generally 
applicable as possible and unlikely to affect antigen binding. As intended, the combined mutations 
conferred properties almost identical to the favorable VH3 framework on the VH6 framework,
34
 which 
afterwards experienced a dramatic increase in both expression yield and thermodynamic stability 
without having altered binding properties.  
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Fig. 3.1.1. Alignment of VH sequences. (a) Comparison of HuCAL-derived wild-type (WT) VH3 and VH6 
sequences (two upper most sequences). The VH6 domain, having aggregation-prone behavior and the 
lowest midpoint of denaturation, was brought closer to the VH3 sequence as described before,
34
 leading to 
the engineered M variant (lower line). This mutant holds the following six amino acid exchanges: Q5V, 
S16G, T58I, V72D, S76G and S90Y. Only mutated amino acids are highlighted and color-coded according 
to residue type:  aromatic (orange), hydrophobic (yellow), uncharged hydrophilic residues (green) and 
acidic (red). The numbering scheme is according to Honegger and Plückthun.
35
 (b) Summary of the two 
different IgG constructs 2C2 and 6B3 analyzed in this study. (c) SDS-PAGE analysis of equal amounts of 
the Protein A-purified IgG constructs under reducing conditions stained with Coomassie Blue. 
 
 
These data were recorded for two model antibody scFvs named 2C2 and 6B3 that had originally been 
selected from the HuCAL library
36
 by panning against the peptide M18 coupled to transferrin or 
myoglobin from horse skeletal muscle, respectively. We chose these molecules as both are 
representatives of the human VH6 framework family whose members are known to have a rather 
aggregation-prone behavior and the lowest thermodynamic stability of all human VH domains.
28
 2C2 
and 6B3 have different CDR-H3 loops, while otherwise their VH sequence is identical. In addition, the 
two antibodies (compared in Fig. 3.1.1b) differ in their respective light chain, with 2C2 having a Vκ3 
and 6B3 containing a Vλ3 light chain. Importantly, the detected improvements were independent of 
both the VL domain as well as the sequence and length of the CDR-H3, as both constructs gave 
similar results.
34
 
 
These improvements were uncovered and investigated with antibody constructs small enough to 
untangle the contributions of the individual domains with spectroscopic investigations, using scFv 
constructs which consist of just two domains. However, the question arose, whether the rather 
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dramatic effects of these mutations might somehow be dampened in a larger assembly, such as a 
whole IgG, and whether the eukaryotic secretory quality control
37
 might overcome all folding issues 
seen in E. coli. Thus, we now tested the influence of these well-characterized mutations in the context 
of full-length human IgG1 or Fab molecules expressed in eukaryotic systems. Both the wild-type (WT) 
and best engineered variant (carrying all six mutations described above, called "M" for "mutant" in the 
present study) were converted to the Fab or full-length IgG format and investigated for their 
biophysical properties and expression characteristics upon production in HEK293 cells (HEK) and the 
yeast Pichia pastoris (PP).  
 
To be able to carry out such studies with whole IgGs or Fab fragments, eukaryotic expression systems 
were required where functional expression yields would exclusively depend on the protein sequence. 
Therefore, these systems must rely both on homologous recombination to exactly the same locus and 
on constitutive expression to eliminate complication from the induction strategy. For Fab and IgG 
production in HEK293 cells, stable cell lines were created using the Flp-In system (Invitrogen). These 
cell lines expressed and secreted the antibody constructs under control of the constitutive 
cytomegalovirus (CMV) promoter in sufficient amounts, allowing the purification and subsequent 
biophysical analysis of these proteins. As P. pastoris does not maintain episomal vectors, expression 
cassettes were anyway designed for integration into the yeast genome. To ensure a comparable 
expression setup, the constitutive GAP promoter was used. 
 
In the present study, we compare the effects of the previously described mutations on the biophysical 
properties of antibodies in the IgG and Fab format, produced in mammalian and yeast cells, using a 
wide array of biophysical techniques. We also analyze the effect of the mutations on the expression 
levels in bacteria, yeast and mammalian cells — allowing a rough differentiation of how the various 
cellular hosts deal with aggregation-prone proteins in general.  
 
 
Results 
 
Expression levels of engineered Fab and IgG formats 
We first analyzed the secretion levels of correctly assembled antibodies in the Fab and IgG format by 
ELISA (depicted in Fig. 3.1.2). They show the expected behavior in reducing SDS gels (Fig. 3.1.1c). 
To compare the improvements caused by the mutations, the expression yields are normalized relative 
to the yield of the corresponding WT variants. While for the scFv fragments produced in E. coli the 
engineered M variant previously showed an increase in yield of 4.2- or 4.3-fold,
34
 respectively (Fig. 
3.1.2a), the variable domain mutations only had a slight influence on the expression level of antibodies 
in eukaryotic expression systems. While for the Pichia system (Fig. 3.1.2d), the M variants still were 
secreted at 15 - 40% increased levels, no difference could be detected for the expression of either Fab 
fragments or full-length IgGs in the HEK system (Fig. 3.1.2b and 3.1.2c).  
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To ensure that these results were not distorted by molecules still trapped within the cell due to an 
overload of the secretory pathway, the secreted IgG amounts were compared to the intracellular levels 
(Supplementary Data Fig. S3.1.1a). Considering that the secreted samples of each construct were 
diluted 1:6 compared to the corresponding intracellular fractions, the blot unambiguously indicated that 
the majority of molecules were secreted for both IgG variants. Similar results were obtained when 
analyzing the intra- and extracellular IgG levels in the Pichia system (data not shown). Interestingly, 
the analysis of IgG levels secreted to the periplasm of E. coli had quite a different outcome 
(Supplementary Data Fig. S3.1.1b): the comparison by western blot clearly showed increased 
expression levels for the M variants even in the IgG format in the prokaryotic system. 
 
 
Fig. 3.1.2. Influence of mutations on secretion levels of antibody constructs. Secreted antibody 
levels of either scFv, Fab or IgG constructs detected by ELISA. For a better comparison, the secretion 
yield of soluble protein is normalized relative to the yield of the corresponding WT construct. The WT 
constructs are displayed in blue and the M variants in red. (a) Levels of scFv fragments found in the 
periplasm of E. coli.
34
 (b) Amounts of Fab fragments secreted by stable HEK clones. (c) IgG levels found 
in the supernatant of stable HEK clones. (d) IgG amounts detected in the supernatant of stable Pichia 
clones.  
 
 
Analysis of biophysical properties of full-length IgG molecules 
For an analysis of their biophysical properties, IgGs were expressed either in the HEK or PP system in 
large scale and purified by Protein A affinity chromatography. The samples were of high purity and 
gave rise to both expected bands under reducing conditions (see Fig. 3.1.1c; the heavy chain was 
detected at ~ 50 kDa and the respective light chains in the range of 23 - 27 kDa). As depicted in 
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Supplementary Data Fig. S3.1.2 in extracts for the HEK produced IgGs, the purified WT and M 
molecules behaved as monomers in size exclusion chromatography (SEC) but showed different 
elution profiles in reverse phase HPLC (RP-HPLC) and cation exchange chromatography (CIEX). 
These differences, however, could be accounted for by the introduced mutations themselves, 
influencing both the hydrophobicity as well as the charge of the engineered M variants. The net 
hydrophobicity of the engineered M variants was slightly increased by the two mutations Q5V and 
T58I, while only being lowered by a single mutation (V72D). The analysis of reduced samples by RP-
HPLC (depicted in the lower halves of Supplementary Data Fig. S3.1.2c and S3.1.2d) clearly indicated 
that the difference in the running behavior was caused by the mutated heavy chains, as the 
corresponding light chains — eluting earlier than the heavy chains due to their lower hydrophobicity — 
led to identical signals for both variants. The additional negative charge through the V72D mutation 
influenced the CIEX running behavior of the engineered IgG, causing the M variants to elute at higher 
volumes (Supplementary Data Fig. S3.1.2e and S3.1.2f).  
 
Finally, the binding affinity of the IgG molecules towards their corresponding antigens was confirmed 
to be fully retained (Supplementary Data Fig. S3.1.3). From microscale thermophoresis 
measurements,
38
 the KD for the HEK IgG 2C2 was calculated to be 217 ± 54 nM and 270 ± 76 nM for 
the WT and M variants, respectively, while the analogous variants for the 6B3 constructs showed 
affinities of 15.7 ± 4.8 nM and 14.5 ± 3.8 nM, respectively. The slight differences of these KD values 
are all within the experimental error range. 
 
To confirm that the mutations did not influence the overall structure of the new antibody molecules, 
HEK and PP produced IgGs were analyzed by circular dichroism (CD). As shown in Fig. 3.1.3a and 
3.1.3b, the new M constructs still possessed the β-sheet structure typical for IgG molecules with only 
slight alterations. Since the signals stemming from the IgG's β-sheets and random coil essentially 
canceled out to zero at 208 nm, thermal denaturation of the IgG molecules was determined at this 
wavelength as a function of temperature (Fig. 3.1.3c - f). The abrupt upward jumps seen between 
75°C and 90°C in most of the depicted CD vs. temperature curves were caused by the formation of 
insoluble aggregates in the respective samples. Interestingly, the used expression system (HEK vs. 
PP) not only caused a slightly different temperature of unfolding onset, but, unexpectedly, also 
resulted in very different aggregation susceptibilities of the IgGs — with the 6B3 variants expressed in 
Pichia not exhibiting any detectable aggregation at all (Fig. 3.1.3f). These effects, caused by 
differences in the N-linked glycosylation and by an incomplete processing of the α-factor pre-pro 
sequence at the yeast constructs, have been studied extensively and reported in chapter 3.2 and 
elsewhere.
39
 For the present study, however, we concentrated on the comparison of WT and M 
variants. For the 2C2 construct, no significant difference in stability between WT and M could be 
detected for IgGs produced in either expression system, and the different signal level in Fig. 3.1.3c for 
the M variant was caused by its slightly off-set curve as also depicted in Fig. 3.1.3a. We currently do 
not know what causes this offset. For the 6B3 M construct, however, increased stabilities of about 
2.5°C were seen compared to 6B3 WT expressed in either the HEK or the PP system, as shown in 
Fig. 3.1.3d and 3.1.3f. 
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Fig. 3.1.3. Analysis of IgG constructs by circular dichroism (CD). Signals derived from WT variants 
are displayed in blue while those of the mutant M are represented in red. (a) CD spectra of different IgG 
2C2 variants produced in mammalian cells (HEK) or in the yeast Pichia pastoris (PP), respectively. The 
values are reported as mean residue ellipticity (MRE). (b) CD spectra of different IgG 6B3 variants 
analogous to panel (a). (c) Thermal denaturation curves of IgG 2C2 produced in mammalian cells. The 
denaturation was followed by CD, plotting the signals at 208 nm as a function of temperature. The values 
are reported as mean residue ellipticity (MRE). The abrupt upward jump at about 85°C in the signals is 
caused by the formation of insoluble aggregates. (d) Thermal denaturation curves of HEK IgG 6B3 analog 
to panel (c). The onset temperature of aggregation for this construct was found to be lowered to about 
75°C. (e) Thermal denaturation curves of Pichia-produced IgG 2C2 variants. (f) Thermal denaturation 
curves of Pichia-produced IgG 6B3 variants. 
 
 
Since the method of analyzing thermal stabilities by CD averages all changes observed over the whole 
IgG molecule and thus does not allow to attribute them to particular domains, samples were further 
analyzed by intrinsic tryptophan fluorescence (ITF) as a function of temperature. Since ~70% of the 
tryptophan residues of the studied IgGs are localized in the Fab fragments, this method should be 
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more sensitive to small changes in the stability of these parts of the molecule. As shown in Fig. 3.1.4a 
and 3.1.4b, the data derived from CD spectroscopy could be confirmed by ITF, validating the 
increased stability of the M variants. A clear difference in stabilities could be seen for the 6B3 
constructs (Fig. 3.1.4b), where the IgG and Fab WT variants exhibited their transition at 67.6° ± 0.1°C 
and 69.7° ± 0.1°C and thus at lower temperatures compared to their engineered M counterparts with 
transition at 70.8° ± 0.1°C and 74.2° ± 0.2°C, respectively. For the 2C2 constructs, the advantages of 
the M variants, however, were considerably less pronounced (Fig. 3.1.4a).  
 
To probe whether differences in the temperature-induced unfolding of 2C2 might have been masked 
by inter- or intramolecular aggregation, the same IgG samples were analyzed in the presence of 
guanidine hydrochloride (GdnHCl). After an overnight incubation in 1 M GdnHCl before being exposed 
to increasing temperature still in the presence of 1 M GdnHCl, both IgG variants were clearly 
destabilized and started to unfold at lower temperatures (Fig. 3.1.4c) — however, the M variant 
showed a slightly increased stability of the second transition at 71.8° ± 0.2°C, compared to its WT 
counterpart with 70.4° ± 0.3°C.  
 
 
Fig. 3.1.4. Biophysical characterization of IgG and Fab constructs produced in mammalian cells by 
intrinsic tryptophan fluorescence (ITF). (a) Thermal denaturation curves measured by ITF. The curves 
were obtained from the intensity ratio of the emission spectrum at 330 nm (F330) and 350 nm (F350) upon 
excitation at 295 nm, plotted as a function of temperature. A comparison between the different mammalian 
IgG 2C2 (continuous lines) and Fab 2C2 (dotted lines) variants is shown. (b) Thermal denaturation curves 
of IgG 6B3 and Fab 6B3 measured analogous to the method used in panel (b). (c) ITF analysis of HEK 
IgG 2C2 in the presence of 1 M guanidine hydrochloride (GdnHCl). (d) pH dependence of thermal 
denaturation. The midpoints of the denaturation curves for HEK IgG 6B3 WT and M were determined at 
various pH and plotted as a function of pH. 
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To finally challenge the stability of the engineered variant with yet another parameter, the thermal 
stabilities of the 6B3 WT and M molecules were determined over a broad pH range. As shown in Fig. 
3.1.4d, the increased stability of the engineered IgG proved true in all tested buffer systems having pH 
values between 4 and 10. On average, the stabilities of the M variants were 3.3° ± 0.6°C higher than 
those of the corresponding WT molecules.  
 
The increased stability of the M variant over its WT counterpart was further investigated with respect to 
denaturant-induced unfolding. For this purpose, antibody molecules were incubated in various 
concentrations of GdnHCl and analyzed by ITF after an overnight incubation (Fig. 3.1.5). To better 
identify the signals derived from unfolding of the CH2 domains, glycan knock-out T299A mutants were 
also examined (data not shown). Previous studies
39
 presented in chapter 3.2 had clearly shown a 
decreased CH2 stability for unglycosylated IgGs, and thus, the first transition e.g. at 2 M GdnHCl in 
Fig. 3.1.5a could be assigned to CH2, as it shifted to even lower GdnHCl in the glycan knock-out 
mutant.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 3.1.5. Guanidine hydrochloride (GdnHCl)-
induced denaturation of IgGs expressed in 
mammalian cells. The denaturation of various 
antibody variants was followed by plotting the 
F330/F350 ratio as a function of increasing GdnHCl 
concentration for (a) HEK IgG 2C2, (b) HEK IgG 
6B3 and (c) HEK Fab 6B3.  
 
 
 
 
 
For all analyzed antibody variants, the introduced mutations caused an increased stability compared to 
the respective wild type. The second transition of the unfolding curves could be assigned as belonging 
to the Fab fragment. Whereas this transition was detected in the WT variants of the 6B3 and 2C2 
constructs at 2.0 and 2.5 M GdnHCl, the engineered mutants showed an increased Fab stability of 2.6 
and 3.8 M, respectively. The same results were also obtained when the Fab 6B3 fragments were 
analyzed by themselves, i.e. as a produced Fab fragment (Fig. 3.1.5c). The kinetics of unfolding was 
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considerably different between M and WT for some conditions and thus amplified the stability 
differences. As illustrated in time-dependent unfolding studies displayed in Supplementary Data Fig. 
S3.1.4, the presence of e.g. 4.5 M GdnHCl was sufficient to denature the 2C2 WT variant completely 
within ~10 min while IgG 2C2 M was not fully unfolded in the same GdnHCl concentration even after 
2 h. Analogous results were obtained for the 6B3 constructs in the presence of e.g. 3.5 M of 
denaturant. 
 
 
Analysis of the antibody molecules on the domain level 
Finally, we aimed to investigate the effect of the VH mutations within the antibody at the level of 
individual domains or interacting folding units. The methods of choice for these studies are differential 
scanning calorimetry (DSC) or differential scanning fluorimetry (DSF). DSF has the advantage of small 
sample requirements and easy sample preparation, making it suitable for high-throughput applications 
and initial screens. However, the nature of transitions are much more difficult to assign, and changes 
in later transitions (i.e. more stable domains) are more difficult to detect. For IgGs, the transition of the 
CH2 unfolding detected at 72°C emerged to be the most dominant signal, making the detection of later 
transitions involving the most relevant part of the molecule, the Fab fragment, quite difficult or even 
impossible (Fig. 3.1.6). 
 
While the transition of a second domain could still be clearly seen for the 6B3 construct (74.5°C vs. 
77°C for WT and M variants, respectively, as depicted in Fig. 3.1.6b), DSF showed apparent 
limitations in the analysis of Fab fragments with very high stabilities. In the 2C2 variants only slight 
differences were detectable at ~84°C in Fig. 3.1.6a. For comparison, also the corresponding first 
derivatives (dF/dt) were plotted in Fig. 3.1.6c and 3.1.6d, highlighting again the differences in the 
second domain transition for the 6B3 IgGs (73.8°C vs. 76.3°C). These signals could be definitely 
attributed to the corresponding Fab domains, as they matched the data obtained from the 
corresponding recombinant Fab fragments (Fig. 3.1.6e and 3.1.6f). For the 6B3 Fab variants, the 
transitions were determined to be 72.8°C or 77.3°C and thus 4.5°C apart. 
 
As DSF proved to be limited in its analytical potential of domains with much higher stabilities than the 
first transition, antibody samples were subjected to DSC analysis (Fig. 3.1.7). These analyses require 
more time and sample, but can resolve three major transitions originating from the CH2, CH3 and Fab 
fragments, as is typically seen for IgG.
29
 Yet for most of our samples, some of these peaks were 
overlapping. However, combining the results from both 2C2 and 6B3 constructs as well as from the 
T299A glycan knock-out mutants with their lowered CH2 stability (Fig. 3.1.7e), clear assignments could 
be made. While the transitions of the glycosylated CH2 and of the CH3 domains were detected at 
70.1°C or 81.3°C, respectively, the signals of the different WT and M Fab fragments were found 
between 70°C and 88°C for the 6B3 and 2C2 construct.  
 
In agreement with the results from other analysis techniques detailed above, the Fab fragment of the 
engineered 6B3 M variant was of higher stability than its WT counterpart (on average 2.5°C). This 
3.1 Transferability of engineered biophysical properties 
 
35 
could be detected for the IgGs produced in HEK (Fig. 3.1.7b), in Pichia (Fig. 3.1.7d) as well as for the 
HEK-produced Fab fragments (Fig. 3.1.7f). Interestingly, for the first time also small differences in the 
thermodynamic stability could be demonstrated for the 2C2 Fab construct (Fig. 3.1.7a and 3.1.7c). The 
signals of the mutated Fab fragments showed a melting temperature which was ~1.8°C higher than 
that of the WT variants and this difference was found for IgGs expressed in either the HEK or PP 
system, respectively. A comparison of the DSF and DSC derived data is presented in Supplementary 
Data Fig. S3.1.5. 
 
 
Fig. 3.1.6. Characterization of HEK-produced antibodies by differential scanning fluorimetry (DSF). 
Comparison of normalized DSF signals of HEK-produced antibody WT (blue) and M (red) variants. For the 
IgGs, the transition of the CH2 unfolding is the dominant signal detected. DSF spectra were recorded for 
(a) IgG 2C2 and (b) IgG 6B3. For an easier comparison, the corresponding normalized first derivatives 
(dF/dt) of the signals in (a) and (b) are shown in (c) for IgG 2C2 and in (d) for IgG 6B3. The dF/dt graphs 
for the corresponding Fab-fragments are depicted in (e) for Fab 2C2 and in (f) for Fab 6B3. 
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Fig. 3.1.7. Analysis of IgG domain stability by differential scanning calorimetry (DSC). Signals 
derived from WT variants are shown in blue while those of the mutant M are represented in red. DSC 
curves were recorded for (a) HEK IgG 2C2, (b) HEK IgG 6B3, (c) PP IgG 2C2, (d) PP IgG 6B3, (e) HEK 
IgG 6B3 T299A and (f) HEK Fab 6B3. 
 
 
Electrophoretic analyses of various IgG variants  
When full-length IgGs were run on a gradient gel under non-reducing conditions and without prior 
heating (Fig. 3.1.8a), clear differences for the WT and M variants were encountered. Independent of 
whether the IgGs had been purified from HEK or PP cultures, WT IgGs usually could not be detected 
as a clear band at the corresponding size of 150 kDa, but rather as a smear or overlay of several 
individual bands. In contrast, the M variant gave rise to one clear and distinct band on Coomassie-
stained gels (especially the 6B3 constructs, shown on the right side of the gel in Fig. 3.1.8a). To 
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investigate this peculiar difference in running behavior between WT and M versions of the IgGs in 
more detail and at greater resolution, the same samples were run under identical conditions on low 
percentage (7.5%) SDS polyacrylamide gels (Fig. 3.1.8b). Again, the engineered mutants could be 
detected as one distinct band, while for the WT variant several bands became visible. Interestingly, all 
these WT bands ran at slightly higher apparent molecular weights than the M counterparts — a feature 
that could be observed independent of whether the IgGs have been purified from stable HEK or Pichia 
cells.  
 
 
Fig. 3.1.8. Analysis of running behavior of IgGs on SDS-PAGE and IEF. (a) SDS-PAGE of equal 
amounts of the Protein A-purified HEK and Pichia constructs stained with Coomassie Blue. Samples were 
run under non-reducing conditions without heating prior to loading onto NuPAGE gradient gels. (b) SDS-
PAGE analysis of the same samples as in panel (a) run on a low-percentage (7.5%) gel under the same, 
non-reducing conditions. (c) Western blot analysis of IgG variants detected with antibodies specific for the 
respective light chains. Samples were obtained from the supernatant of Chinese hamster ovary cells 
(CHO) after transient transfection and from HEK293 cells after transient (HEKt) or stable (HEKs) 
transfection, respectively. (d) Comparison of HEK IgG variants to their non-glycosylated counterparts 
(T299A glycan knock-outs) by non-reducing SDS-PAGE. (e) Isoelectric focusing of HEK-produced 6B3 
variants. Non-reduced IgG, IgG T299A and Fab were separated based on their isoelectric point (pI). A pI 
standard is shown in the right lane, with the corresponding pI values denoted next to it.  
 
 
To ensure that these differences between WT and M were not caused by effects of protein purification 
or storage, we also analyzed the non-processed supernatants of Chinese hamster ovary cells (CHO) 
after transient transfection and compared it to that of HEK293 cells after transient (HEKt) or stable 
(HEKs) transfection, respectively. As can be seen in Fig. 3.1.8c, the same banding patterns were 
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observed in all cases and further confirmed for the yeast system as well (data not shown). To ensure 
that the differences in the running behavior were not caused by variations in the glycan moiety 
attached to the CH2 domain of the IgG, antibodies with a glycan knock-out T299A mutation were also 
analyzed by SDS-PAGE. While, as expected, the unglycosylated IgGs ran generally at slightly lower 
apparent molecular weights, the banding pattern was not altered (Fig. 3.1.8d).  
 
To test for covalent heterogeneities, we subsequently performed isoelectric focusing (IEF) analyses. In 
this method, the samples were neither heated nor modified but just analyzed on pH gradient IEF gels. 
Since the isoelectric points (pI) of the 2C2 constructs were rather high, only the 6B3 constructs could 
be analyzed by IEF. As shown in Fig. 3.1.8e, all 6B3 constructs (IgG, IgG T299A as well as the Fab 
fragments) were focused in single major bands at positions of the gel corresponding to their pI, 
indicating that charge heterogeneity in the molecules was not the reason for the different running 
behavior on SDS-PAGE. The homogeneity of the samples was also confirmed by mass spectroscopy 
after prior reduction (data not shown), and is consistent with reducing SDS-PAGE (Fig. 3.1.1c) where 
no differences in the IgG chains between WT and M had been detected.  
 
To further elucidate the reasons for the different running behaviors of the IgG variants, samples were 
once more studied by non-reducing SDS-PAGE (Fig. 3.1.9). This time, however, the samples were 
partly heated for 5 min at 95°C or alkylated prior to loading. While the heating of the sample to 95°C 
eliminated the different running behavior of the variants (Fig. 3.1.9a), alkylation of samples by three 
different alkylation reagents did not change these characteristics (Fig. 3.1.9b).  
 
We next considered the possibility that in the WT variants one or more disulfides might not have 
formed correctly and thus the molecules could have undergone disulfide shuffling, facilitated by 
sample heating. Previous studies showed that multiple bands for IgG samples on SDS-PAGE in 
principle can also arise from loss of disulfide-linked chains after disulfide scrambling.
40
 Therefore, we 
wished to elucidate whether the different individual bands seen for the WT variants consisted of 
distinct covalent isoforms or whether all these bands were in equilibrium. For this reason, IgG 2C2 WT 
was run on a regular non-reducing 7.5% SDS-gel (after incubation in the absence or presence of 
alkylation reagent) and afterwards analyzed by a non-reducing second SDS-PAGE in a perpendicular 
orientation (see Fig. 3.1.9c and 3.1.9d and Materials and Methods for details). The silver-stained 
bands clearly indicated that the molecules found in each of the various individual bands in the first 
dimension differentiated again in the second dimension and gave rise to the usual banding pattern, 
independent of whether the samples had been alkylated beforehand or not. This finding would not be 
consistent with disulfide shuffling.  
 
To test more rigorously whether the distinct bands of the WT are really in equilibrium, distinct bands of 
the WT and M variants were cut from the first gel and placed into the pockets of the second one (Fig. 
3.1.9e). Again, the previously distinct bands re-divided into the original banding pattern. Due to the 
increased sensitivity of the silver staining procedure, even small amounts of the higher molecular 
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weight bands could be detected for the M variant under these conditions. We thus can rule out 
disulfide shuffling as the source of the multiple bands detected for the WT IgG. 
 
 
 
 
Fig. 3.1.9. One- and two-dimensional SDS-PAGE analysis of the different running behavior of WT 
and M variants. (a) Analysis of non-reduced IgG samples. Shown are the banding patterns of various IgG 
constructs after incubation in SDS-loading buffer at either room temperature or 95°C for 5 minutes prior to 
loading. (b) Influence of alkylation on banding patterns. IgG 2C2 samples were incubated with a 50-fold 
molar excess of N-ethylmaleimide (NEM), iodo-acetamide (IAA) or iodoacetic acid (IA-A) in 100 mM Tris 
pH 8 (pH 7 for NEM) at 37°C for 3 h prior to analysis by non-reducing SDS-PAGE. (c) 2D-SDS-PAGE 
analysis of HEK IgG 2C2 WT. After the samples had been separated by regular non-reducing SDS-PAGE 
(shown on top, corresponding to the sample run on lane #1 of the gel depicted in panel (a)), the 
corresponding lane was isolated and re-run on a second SDS-PAGE in a perpendicular orientation. The 
final gel was silver-stained. (d) 2D-SDS-PAGE of the same sample as in panel (c). However, prior to the 
first SDS-PAGE, the sample was incubated in the presence of 5 mM NEM for 1 h. (e) 2D-SDS-PAGE of 
HEK IgG 2C2 WT and M. The bands were individually cut out from a first gel, as depicted in the inlay, and 
run in separate lanes on the second gel (corresponding to the band numbers in the first gel), and the gel 
was silver-stained. 
 
 
While both in the present study and the one reported previously
40
 multiple bands of IgG have been 
seen under non-reducing conditions, there are important differences pointing to a different origin of the 
phenomena. Most importantly, in the experiments reported here the multiple bands disappear when 
the samples are heated to 95°C (Fig. 3.1.9a), while Liu et al. observed an increase of the banding 
pattern (i.e. faster running bands) after prolonged heating and at high pH. Furthermore, in the 
reequilibration experiments described above (Fig. 3.1.9c-e), all bands can be generated from all other 
bands (Fig. 3.1.9e), while Liu et al. observed an irreversible increase of smaller bands, consistent with 
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a loss of chains from the H2L2 molecule. We therefore propose that the phenomena seen here are due 
to conformational rearrangements and precede any chain loss due to disulfide scrambling or 
progressive β-elimination.
40
 This is consistent with the western blots, which indicate the presence of 
both chains in the high MW bands in Fig. 3.1.9, and the generation of a 100-kD band (representing H2) 
only after prolonged mild reduction (see below). In summary, the conformational changes seen here 
are happening under much milder conditions than the chain loss described previously
40
 and represent 
conformational transitions of the intact IgG. 
 
 
Capillary electrophoresis  
To finally exclude that any particular effect of SDS-PAGE itself was causing the multiple band 
behavior, we also analyzed IgG samples by capillary electrophoresis. In this setup, the detection of the 
proteins was achieved using SDS micelles containing a provided fluorescent dye.
41
 Upon binding to 
hydrophobic regions on the analyzed proteins, these SDS-dye-complexes are protected from 
disassembly in the performed dilution step, generating a fluorescent signal clearly above background. 
 
Also in this setup, multiple signals could be detected for the non-reduced, non-heated WT variants, as 
depicted for the IgG 6B3 WT in lane 1 in Fig. 3.1.10a and for IgG 2C2 WT in Fig. 3.1.10b. Strikingly, 
the M variants were not detectable at all under these conditions (lane 2 in Fig. 3.1.10a). Only once 
they had either been heated and/or reduced, equimolar amounts of the loaded M-type became visible 
in the corresponding chromatograms (Fig. 3.1.10c and 3.1.10d). Thus, the inability to detect the M 
variant under the initial conditions was not caused by too low IgG amounts loaded onto the chip, but 
rather hinted at a higher stability or improved folding of this molecule, preventing access to 
hydrophobic regions by the fluorescent dye used for detection in capillary electrophoresis. Thus, it did 
not bind to the native M protein, but only to the WT.  
 
 
Partial reduction of IgG variants indicates differences in conformational stability 
As these results indicated differences in the structural stability of the non-reduced, non-heated 
antibody molecules between their WT and M form, we analyzed HEK-produced IgGs by partial 
reduction. For this purpose, samples were shortly incubated in the presence of the strongly reducing 
tris(2-carboxyethyl)phosphine (TCEP) without any further heating prior to loading onto SDS-gels. We 
reasoned that the hydrophilic nature of TCEP should not allow it to easily penetrate into the 
hydrophobic cores of the IgG domains where the intradomain disulfides are located, without prior 
partial unfolding of the domains. Therefore, such partial reduction experiments represent an indicator 
for the compactness of these domains as well as the packing of the VH-VL interface.  
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Fig. 3.1.10. Analysis of HEK IgGs by capillary electrophoresis. (a) HEK IgG 6B3 WT and M variants 
were analyzed in the absence or presence of reducing agent upon incubation in the loading buffer either at 
25°C or 75°C (presented as a virtual gel). The same data are presented as chromatograms in panels (c) 
and (d). (b) Chromatogram of HEK IgG 2C2 WT, illustrating the occurrence of similar differences in the 
banding pattern as detected by SDS-PAGE. (c) Chromatograms of IgG 6B3 samples analyzed under non-
reducing conditions. H2L2 indicates the completely assembled IgG. (d) Chromatograms of the same 
samples as in (c), analyzed after incubation in the presence of DTT. H2 indicates a heavy chain dimer and 
H or L the monomeric heavy or light chain molecules, respectively. 
 
 
 
As depicted in the Coomassie-stained gel and the corresponding anti-light chain western blot in Fig. 
3.1.11a and 3.1.11b, respectively, incubation of the samples in the presence of TCEP seemed to 
disrupt the disulfide bond between the light and the heavy chain for both the 6B3 and the 2C2 
constructs. Interestingly, a much more dramatic effect was observed for the WT constructs than for the 
M variants. While IgG molecules containing a light chain could still be detected for the 6B3 construct 
after TCEP reduction, all the HEK IgG 2C2 WT molecules were converted into homo-dimers of the 
heavy chain only (H2 molecules), completely lacking the light chains and therefore not being 
detectable in Fig. 3.1.11b, but only on the Coomassie-stained gel.  
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Fig. 3.1.11. Partial reduction of antibody variants. (a) Non-reducing SDS-PAGE of HEK constructs 
stained with Coomassie Blue. Samples were incubated in the absence or presence of 30 mM TCEP for 10 
min at 25°C prior to loading. (b) Western blot analysis of the same samples as in panel (a) detected with 
an antibody mixture specific for both light chains. (c) Non-reducing SDS-PAGE of partially reduced HEK 
IgG 2C2 variants labeled with 5-iodoacetamidofluorescein (5-IAF). Samples were incubated in the absence 
or presence of the stated molar equivalent of TCEP for 1 h at room temperature prior to labeling with a 5-
fold molar excess of 5-IAF for 2 h. The upper gel shows the fluorescence image, the lower picture the 
same gel after staining with Coomassie Blue. (d) Images of the same samples as in (c) run under reducing 
conditions. (e) Comparison of WT and M variants reduced by 2 molar equivalents of TCEP for 1 h prior to 
labeling with a 5-fold molar excess of 5-IAF overnight. The upper gel shows the fluorescence image of a 
reducing gel, the lower one the Coomassie-stained gel. 
 
 
To confirm this observation, partly reduced 2C2 samples were treated with 5-iodoacetamido-
fluorescein (5-IAF) to fluorescently label free cysteine residues. Samples were incubated with very low 
TCEP concentrations, corresponding to only 2 - 10-fold molar equivalents, as higher concentrations 
were found to interfere with the subsequent 5-IAF coupling. Still, clear differences could be seen in the 
fluorescent images of non-reducing and reducing gels (Fig. 3.1.11c and 3.1.11d, top gels). Only the 
WT variant was labeled quantitatively at 2 molar equivalents and to a much higher extent at 10x 
conditions. Beneath the fluorescent images, the corresponding Coomassie-stained gels confirm that 
equal antibody amounts were loaded on the gels. Especially after overnight labeling with a 5-fold 
molar excess (Fig. 3.1.11e), the difference between WT and M variants became clearly visible, as the 
WT variant was labeled both on its heavy and light chain, while no fluorescence was detectable for the 
M counterpart.  
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Taken together, these data suggest that the introduced variable domain mutations, all located within 
VH, affected the packing of the VH-VL and CH1-CL interface and thus protected the intermolecular 
disulfide bond. It is likely that this improved structural integrity potentially also contributed to the 
increased stability of the engineered M variants as a whole IgG molecule.  
 
 
Discussion 
The aim of this study was to analyze whether sequence engineering, previously found capable of 
considerably improving the biophysical properties of antibodies as scFv fragments,
42
 would have a 
similar effect on whole antibodies in the IgG format. The original work was carried out in single 
domains and smaller assemblies
23; 28; 34; 42-44
 as the extremely complex unfolding mechanism of IgGs
45-
47
 with their 12 immunoglobulin domains interacting with each other would have made an elucidation 
of individual domain contributions and mutations impossible to untangle in the context of the whole 
antibody.  
 
Despite the appeal of our previous reductionist approach, it was not clear a priori, whether the 
previous findings would be transferable from the scFv to the IgG format. It might be possible that the 
presence of the constant domains of the Fab fragment, especially when linked via an intermolecular 
CH1-CL disulfide bond,
26
 overcome stability problems within the variable domains themselves and/or at 
the VH/VL interface. Furthermore, the previous experiments were carried out with antibody fragments 
produced in functional form by secretion to the periplasm of E. coli. Since whole IgGs are 
predominantly secreted from eukaryotic cells (although functional expression of IgG in E. coli has been 
reported as well;
7-9
 it had to be investigated how the eukaryotic quality control system influences both 
the level and the properties of the resulting molecules, and whether it would be able to somehow 
compensate for the previously observed differences. 
 
Thus, in this study we aimed to address these questions on two levels: first, the biophysical properties 
of the resulting proteins in isolation, and second, the influence of the expression systems used. To 
tackle these questions, we made use of an exceptionally well characterized set of mutants,
34
 where 
prior knowledge for each individual substitution (see Introduction) regarding their effect on 
thermodynamic stability or folding efficiency was available, measured by functional expression in E. 
coli. As an intermediate between scFv and IgG, we also constructed recombinant Fab fragments. To 
ensure meaningful results regarding the eukaryotic expression levels, we used homologous 
recombination into the same chromosomal location of the host cells as well as constitutive promoters 
for both the Pichia pastoris or HEK293 system. 
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Influence of the expression system 
Unlike scFv produced in the bacterial periplasm, IgGs and Fab fragments expressed in both eukaryotic 
systems did not show any significant differences in their secretion yields found in the respective 
supernatants (Fig. 3.1.2). We also ensured that almost all of the antibody amounts synthesized by the 
cells were secreted (Supplementary Data Fig. S3.1.1a), excluding a bottleneck in secretion. Thus, 
these results derived from HEK and Pichia expression indicate that the eukaryotic secretory quality 
control system equalizes the expression yields of the WT and stabilized VH6 variants, independent of 
the antibody format used. Interestingly, the leveling of expression yields is only partial in Pichia 
pastoris (with the stabilized mutants still producing slightly more antibody) but almost complete in the 
mammalian cells. Similar results had been previously obtained when engineered anti-tetanus toxoid 
Fab fragments were converted into the IgG format.
48
 Also for these Fab molecules the differences in 
the expression levels seen upon production in E. coli were not reflected in different levels of IgG found 
in mammalian expression.  
 
We could show that the equalized expression levels are due to the eukaryotic host, and not the used 
IgG or Fab format. When comparing the periplasmic expression levels of full-length IgG in E. coli, we 
found the same increased expression levels for the engineered IgG molecules compared to WT as for 
the engineered scFv in the same system (Supplementary Data Fig. S3.1.1b). However, since the 
expression levels of correctly assembled IgG were generally low, no quantitative ELISAs could be 
performed, and these findings had to be obtained from western blot analysis. 
 
Taken together, all these data indicate that stability engineering can improve bacterial expression and 
secretion of functional antibodies in all formats tested — single domain scFv, Fab, up to intact IgG — 
by mutations that prevent aggregation during periplasmic folding.
34; 43; 48-50
 However, the eukaryotic 
quality control can "rescue" such aggregation-prone IgGs and secrete them at comparable level as the 
engineered mutants. 
 
 
Analysis of biophysical properties of WT and M 
To analyze whether the previously found improvements of the biophysical properties stayed true for 
various antibody formats produced in eukaryotic systems, sufficient quantities of the corresponding 
antibodies were purified and analyzed (1-2 mg/L from Pichia pastoris, 4-8 mg/L from HEK293 cells), 
even though the constitutive expression systems were chosen for consistency, and not maximal 
yields.  
 
Increased stabilities of the engineered IgGs (M variants) were observed by all analysis methods (Figs. 
3.1.3 - 7). The data derived from thermal denaturation measured by ITF, DSF and DSC as well as 
those from GdnHCl unfolding are summarized in Supplementary Data Table S1 for the HEK-produced 
IgG and Fab fragments. Since the various methods emphasize different factors, the results listed are 
based on very different phenomena. Therefore, it is useful to briefly summarize what they actually 
indicate. In general, both CD and ITF measure averaged features of the whole antibody molecule — 
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either the overall secondary structure or the averaged tryptophan fluorescence, respectively. In 
contrast, DSF and DSC have the ability, at least in principle, to distinguish different transitions in 
multidomain proteins (such as IgGs) which are averaged in the previously described spectroscopic 
methods. 
 
The mid-points of thermal denaturation determined with CD and ITF were in quite good agreement 
with each other, with the ITF-recorded temperatures being of slightly lower values. Already at these 
lower temperatures, solvent may start penetrating into the protein core and may thereby make the 
environment of at least some tryptophans more hydrophilic, while the overall secondary structure 
measured by CD still is mainly intact. However, the increase in stability determined by both methods 
for HEK IgG 6B3 M over its WT counterpart gave very similar ΔT results of 2.5° or 3.2°C, respectively. 
These stability improvements were in good agreement with the data recorded for the Fab fragments by 
DSF and DSC, even though the measured absolute transition temperatures were of higher value, 
since the least stable CH2 domain is not present in the Fab fragment und thus not taken into the 
average.  
 
For IgGs, DSC analyses generally resulted in three distinguishable transitions, while in the DSF results 
often only the transition of the CH2 unfolding could be clearly assigned (for comparison, see 
Supplementary Data Fig. S3.1.5). This finding can be explained by the fact that DSF measurements 
are based on intensity changes of the fluorescence of the dye SYPRO Orange as a function of its 
environment. Its fluorescence is weak in aqueous and hydrophilic environments, but strongly 
increases upon binding to hydrophobic patches that become accessible in denaturing proteins.
51
 After 
reaching a maximum, the signal decreases at higher temperatures. This is most likely caused by 
precipitation and aggregation of the analyzed protein, removing SYPRO Orange binding sites from 
solution. Therefore, the detection of high-temperature transitions, e.g. that of a very stable Fab within 
the IgG, is very challenging or even impossible.  
 
In contrast, DSC measures the enthalpy of unfolding
52
 due to heat denaturation and thus allows the 
individual detection of various transitions. The DSC results clearly and directly confirmed the increased 
stabilities of the engineered IgG 2C2 and 6B3 molecules and could assign the effect, as expected, to 
the Fab fragment within the IgG. 
 
Interestingly, the gain in thermal stability caused by the insertion of the six point mutations was always 
higher in the context of the isolated Fab fragments compared to the gain recorded within the full-length 
IgGs. Not just the ITF data revealed a change of 4.5°C compared to only 3.2°C for the IgG molecule, 
but also the DSC data, allowing to clearly point to a Fab transition, showed an increase of 4°C for the 
stabilized isolated Fab fragment and 2.2°C for the Fab fragment in the context of the M IgG (Fig. 
3.1.7f). At the moment, we have no definite explanation for this phenomenon, and want to stress that 
these data are derived from irreversible unfolding experiments, where the formation of aggregates 
could potentially affect the recorded data. We cannot exclude, however, that Fab unfolding might be 
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influenced by interactions with the Fc part of the IgG, or that kinetic barriers are different for the Fab in 
isolation and within the IgG — a hypothesis that has been discussed controversially before.
53-55
 
 
 
Comparing the antibodies 2C2 and 6B3 
The overall stabilities of the 2C2 and 6B3 constructs varied significantly, with the 2C2 construct in its 
wild-type state being already of quite high overall stability. Both antibodies differ in their light chains, 
with 2C2 containing a κ-light chain with Vκ3. This VL domain had been shown previously
28
 to be of 
considerably higher stability when expressed individually than members of the Vλ3 family, which are 
present in the 6B3 construct. This difference in stability apparently stayed true in the context of single 
VL domain, scFv, Fab and IgG, as shown in this study.  
 
Thus, the two antibody constructs analyzed in this study covered a broad range of stabilities, from 
rather unstable (6B3 constructs) to extremely stable (2C2 constructs). This allowed us to show not 
only that our engineering strategy was successful in both cases, but also to evaluate analytical 
methods for detecting the effect in a stable and unstable IgG molecule. We found that most methods 
were unsuitable to characterize the stability gain of 2C2 M vs. 2C2 WT. Only for thermal denaturation 
measured by DSC as well as for GdnHCl-induced unfolding, improved stability characteristics of the 
2C2 M molecules could be detected. For thermal unfolding studied by ITF, conclusive data could only 
be obtained in the presence of GdnHCl. For the 2C2 construct, however, the increase in stability was 
less pronounced with only ~1.6°C compared to ~2.5°C measured on average for the 6B3 constructs.  
 
In GdnHCl-induced unfolding, the engineered variant of 6B3 denatured at a GdnHCl concentration 
0.6 M higher than that of the WT counterpart, while this difference was ~1.3 M for the 2C2 constructs. 
These data could also be confirmed by the analysis of the glycan knock-out T299A mutants (data not 
shown) and the individual Fab fragments. This difference in stability gain seems puzzling at first, as in 
thermal stability (measured by a variety of techniques) the impact of the mutations was more 
pronounced for the 6B3 constructs. However, we must consider two aspects, one regarding the 
measurements, the other regarding the denaturant: First, the unfolding of a multi-domain protein 
followed by ITF is very difficult to untangle in either temperature- or denaturant-induced unfolding, 
since the transitions are not separated and an intra- or intermolecular association of partially unfolded 
domains will influence tryptophan fluorescence. Second, GdnHCl may prevent such association of 
partially unfolded domains. Furthermore, the high ionic strength of concentrated GdnHCl may 
modulate electrostatic contributions during the unfolding. The two analyzed antibody constructs 2C2 
and 6B3 possess rather different pI values and thus differ in their charge at any given pH. For these 
reasons, thermal unfolding may not necessarily be mirrored in GdnHCl unfolding.
56
 
 
While increased stabilities against thermal and denaturant-induced unfolding were also detected for M 
variants upon expression in Pichia pastoris (Fig. 3.1.3f or Fig. 3.1.7c and 3.1.7d), the melting points of 
IgGs produced in this system were generally lower than for the same IgG produced in mammalian 
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cells. These different stabilities could be pinpointed to the CH2-domains and proven to be caused by 
different glycan moieties, as described in details in chapter 3.2. and elsewhere.
39
 
 
 
Inhomogeneity of WT but not M in SDS-PAGE 
We noticed a consistent ladder formation of WT IgGs on non-reducing SDS-PAGE, while the mutants 
engineered for stability showed the expected unique band corresponding to a molecular weight of 
150 kDa (Fig. 3.1.8a and 3.1.8b). Interestingly, also some commercially available antibodies like 
Omnitarg
®
 (Pertuzumab, Genentech) showed similar banding patterns in our analyses (data not 
shown). Proteolysis could be ruled out as a cause considering the results from reducing SDS-PAGE 
(Fig. 3.1.1c). Similarly, heterogeneity of the glycan structure could be excluded by both IEF analysis 
(Fig. 3.1.8e) and the fact that the multiple band pattern was preserved in non-glycosylated T299A 
mutants (Fig. 3.1.8d). 
 
We thus focused our attention on disulfide heterogeneities and/or scrambling, a problem reported to 
occur for some IgG4 molecules.
57
 Yet, alkylation of the samples prior to loading did not affect the 
running behavior of the IgG (Fig. 3.1.9b). Thus, if different disulfide bond linkages were the reason for 
the detected phenotypes, they must have been already present in the purified samples. Such 
observations had been reported previously for a member of the IgG2 family.
58
 To test this possibility, 
we devised a non-conventional 2D-SDS-PAGE (Fig. 3.1.9c - e), in which non-reducing SDS-PAGE 
was carried out in both dimensions. In this setup, whole lanes or single bands were cut out and re-
applied to a new gel. These experiments showed that the different bands could not be separated from 
each other but re-equilibrated in the second dimension, independent of whether the samples had been 
previously alkylated or not. We thus can conclude that the multiple bands are not due to disulfide 
heterogeneity. 
 
This conclusion was further confirmed both by the analysis of unpaired cysteines within the IgG 
molecules as well as by MS measurement. Quantification of free thiols using the 4-DPS method 
described by Hansen and colleagues
59
 did not indicate any detectable free sulfhydryl groups for the 
WT and M variants (data not shown), even though this had been detected in other IgG molecules.
60
 In 
addition, analyzing the disulfide patterns of enzymatically fragmented variants using LC-MS coupled to 
a combination of collision induced dissociation (CID) and electron-transfer dissociation (ETD) 
fragmentation
61
 did not provide any indications that wrong disulfide connectivities were present in any 
of the IgG variants (data not shown).  
 
 
Stability probed by dye binding 
Stabilized mutants and WT IgGs could be further distinguished by their accessibility either to a 
fluorescent dye from SDS micelles or to reducing agents. In capillary electrophoresis, which relies on 
detection of the proteins with SDS micelles containing a provided fluorescent dye,
41
 the IgG WT, but 
not the M variant could be observed under non-reducing, non-heated conditions (Fig. 3.1.10). 
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However, after heating and/or reduction both variants were equally well detected. These results could 
not be merely attributed to the very slightly increased hydrophobicity of the M variant, as it was 
increased only by one amino acid. Therefore, these results rather indicated that the engineered M-type 
IgGs are more densely packed and, consequently, less label-containing SDS micelles can bind to or 
penetrate into their structure.  
 
These capillary electrophoresis experiments have some similarity to DSF analyses. However, while in 
DSF experiment the IgG is heated and the binding of the SYPRO Orange dye is followed as a function 
of temperature, capillary electrophoresis is isothermal and thus can be carried out below the 
denaturation temperature. At this temperature, SDS seems to allow access of the dye only to the WT, 
but not to the stabilized mutant. This is remarkable, since the DSC experiments showed that the CH2 
domains denatured first, and these domains are identical for WT and M. Thus, the significant 
differences detected for M and WT variants in the capillary electrophoresis experiment must be due to 
the dye’s accessibility to binding sites within the Fab fragment.  
 
 
Stability probed by partial reduction 
Intermediates in the denaturation and reduction of IgGs have been monitored before, both by SDS-
PAGE and by capillary electrophoresis.
62; 63
 However, we believe that the present study is the first to 
compare point mutants in the IgG format using these techniques. In partial reduction experiments with 
TCEP, clear differences in the accessibility of the inter-chain H-L disulfide bond could be detected. 
The WT variants, but not their M counterparts were losing their light chains (which were identical in 
both mutants) either to a large extent or completely, as confirmed by both western blot analysis and 
fluorescent labeling of the liberated thiol groups. This finding was rather astonishing, since all 
introduced mutations are located within the VH domain, while the disulfide bond connects the distal 
ends of CH1 and CL. Thus, these data suggest a weakening of the H/L interface which is felt 
throughout the whole Fab fragment. 
 
Taken together, these results support our assumption that the performed mutations do not just 
influence the stability of the resulting IgGs, but also a domain other than the one where the mutations 
are localized (VH), thus affecting the overall integrity and structural homogeneity of the IgG molecules. 
It is well established that IgG domains other than the CH2 (due to its glycosylation) interact strongly in 
a lateral fashion, forming VH-VL, CL-CH1 and CH3-CH3 modules, respectively.
26
 In contrast to these 
strong lateral interactions, longitudinal interactions generally are reported to be rather weak or even 
nonexistent. Nonetheless, the ball and socket joints between the VH and CH1 or VL and CL domains, 
respectively, combined with some movement within the VH-VL interface provide some structural 
variation to the Fab fragment
64
 that could partially explain the detected results. 
 
Whether, however, structural changes within the Fab fragment can be transmitted to the constant 
domains within the Fc part has been controversially discussed for a long time.
26; 65-68
 Our results do not 
indicate such interactions in the native molecule, and the observations may be explained without 
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postulating them. Mutations within the VH domain could affect the VH-VL interface, which by the 
coupling within the Fab fragment
26
 could lead to the observed facilitated reduction of the CH1-CL 
disulfide. Antibodies having lost their light chains may subsequently show a different susceptibility to 
reducing agents in the hinge region and other domains in the Fc part. As a corollary, we can consider 
the variable domains as a potentially weak link, and the engineering of this domain can make a 
decisive improvement in stability — even for the whole IgG molecule, as shown by this study. 
 
 
 
Conclusions 
 
Taken together, the present data clearly indicate that the mutations introduced into the VH6 framework 
have beneficial effects not just in the scFv context but also in the IgG format. While an increase in 
expression levels was only detectable for periplasmic expression in E. coli, increased stabilities both 
with respect to thermal and denaturant-induced unfolding of both Fab fragments and full-length IgG 
were seen, independently of the expression host. These mutations proved to be beneficial 
independent of the nature of the light chain and could be applied to IgGs of rather distinct 
characteristics concerning their pI values and Fab stabilities. The mutations also influenced the 
structural integrity and homogeneity of the engineered IgG molecules independently of any wrong 
disulfide bond connectivity. Presumably through an improved VH-VL packing, the reduction of the 
intermolecular CH1-CL disulfide was greatly slowed down in the stabilized variant. These results 
confirm the potential of structure-based protein engineering in the context of full-length IgGs and the 
transferability of improvements discovered in a systematic study of smaller antibody fragments. 
Furthermore, it extends the engineering of intact antibodies to the variable regions, which has mostly 
been concentrated on the constant Fc part. 
 
 
 
Materials and Methods 
 
Cell culture 
 
Materials and cultivation of mammalian and Pichia cells 
All media and supplements for mammalian expression were purchased either from Sigma-Aldrich 
(MO, USA), Invitrogen (CA, USA) or Amimed (BioConcept, Switzerland). The antibiotics Zeocin
TM
 and 
Hygromycin B were bought from Invitrogen or PAA (Austria), respectively. All solutions used were 
either delivered sterile or sterilized by filtration through 0.22 µm filters (Millipore, MA, USA). Stably 
transformed human embryonic kidney (HEK) 293 cells were maintained in Dulbecco's Modified Eagle 
Medium (DMEM, Sigma-Aldrich; high glucose: 4.5 g/l) supplemented with 10% v/v heat-inactivated 
Fetal Bovine Serum (FBS, Amimed) in a humidified incubator with 5% carbon dioxide at 37°C. 
Expression of IgGs was carried out in DMEM supplemented with 5% v/v FBS (instead of the more 
commonly used 10%). For secretion of IgGs, derivatives of the vector pcDNA5 (Invitrogen) containing 
constitutively active CMV promoters upstream of the native IgG signal sequences were used (see 
below). 
For all work with Pichia pastoris, the strain SMD1163 (his4 pep4 prb1; Invitrogen) was used. All media 
and supplements for this work were purchased either from Sigma-Aldrich or Invitrogen. All work was 
done in a sterile laminar flow bench, and yeast growth was performed at 30°C. Selection of clones 
stably expressing the IgGs was based on Zeocin
TM
 resistance. For secretion of IgGs, derivatives of the 
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pGAPZαB vector (Invitrogen) containing the constitutively active P. pastoris GAP promoter followed by 
the α-factor pre-pro (αMFpp) region were used. Yeast extract-peptone-dextrose (YPD) medium 
containing 20 g/l peptone, 10 g/l yeast extract and 20 g/l D-glucose (plus 20 g/l agar for YPD-agar) 
was used for routine growth and subculturing of Pichia cells. Zeocin
TM
 was added to a final 
concentration of 100 µg/ml. IgG expression was performed in the phosphate-buffered medium with 
glycerol for yeast (BMGY) (20 g/l peptone, 10 g/l yeast extract, 100 mM potassium phosphate pH 6.0, 
1.34% yeast nitrogen base (YNB) without amino acids, 1% w/v glycerol, 400 µg/l biotin) in the absence 
of antibiotic. 
 
Construction of Expression Plasmids 
Unless stated otherwise, all molecular biology methods were performed according to standard 
protocols.
69
 All enzymes used for cloning were purchased from New England Biolabs (MA, USA) or 
Fermentas (Germany). In general, cloning and propagation of all plasmids was carried out in 
Escherichia coli DH5α (Life Technologies, CA, USA), grown at 37°C in low salt LB Broth (10 g/l Bacto-
tryptone, 5 g/l yeast extract, 5 g/l NaCl, pH 7.5) containing 25 µg/ml Zeocin
TM
 for the Pichia plasmids 
or in 2YT broth (16 g/l Bacto-tryptone, 10 g/l yeast extract, 5 g/l NaCl, pH 7.5) containing 100 µg/ml 
Ampicillin (AppliChem, Germany) for mammalian vectors.  
 
The construction of expression vectors is described in detail in the Supplementary Material. Briefly, 
expression vectors for mammalian HEK293 cells were derived from the pMORPH
®
 vector series 
(MorphoSys), in which heavy or light chain are separately expressed. For the establishment of stable 
cell lines using the Flp-In system (Invitrogen), the two expression cassettes for H and L, each retaining 
its own promoter and poly-A sequence, were combined into a single vector based on the pcDNA5/FRT 
series (Invitrogen). The creation of Fab expression vectors was performed likewise, in this case 
however, the VH/CH1 chain was fused to a myc-tag and (his)6-tag at its C-terminus for detection and 
purification purposes. 
The Pichia expression vectors are based on the vector pGAPZαB (Invitrogen). The sequences for the 
light chains and the different heavy chain variants were amplified from the pMORPH
®
 vectors and thus 
placed behind the α-factor pre-pro (αMFpp) sequence and under the control of the constitutive GAP 
promoter. Before stable integration into the Pichia pastoris genome, the two expression cassettes for 
H and L, each retaining its own promoter and termination sequence, were combined onto one plasmid. 
  
Construction of glycan knock-out mutants T299A 
To analyze the influence of the glycan moiety attached to Asn297 in the CH2 domain of the heavy 
chains, the glycan knock-out construct T299A was constructed, described in detail in chapter 3.2 and 
elsewhere.
39
 Briefly, ACG coding for the threonine in the glycosylation motif Asn297-Ser298-Thr299, was 
mutated to alanine-encoding GCG using the QuikChange
®
 site-directed mutagenesis kit from 
Stratagene (acquired by Agilent, USA) according to the manufacturer’s instructions.  
 
Creation of stable cell lines 
Flp-In HEK293 cell lines (Invitrogen), stably expressing the IgG of interest and secreting it into the 
culture medium, were generated according to the instructions of the Flp-In system manual. For this 
purpose, the expression cassettes for both the heavy and light chain genes were cloned into the 
pcDNA5/FRT vector and finally inserted at a specific location in the genome by the Flp recombinase 
within the cell. After selection, ten single clones of each construct were tested for expression of the 
desired IgG by Western blot analysis of the supernatant. More than 90% of the analyzed clones were 
positive.  
For the Pichia constructs, the corresponding plasmids containing both genes for the light and heavy 
chain under the control of constitutively active GAP promoters within one plasmid were linearized by 
BglII and integrated into the yeast genome upon transformation of competent P. pastoris.
70
 Finally, 
several colonies per construct were re-plated on fresh YPD-agar plates containing Zeocin
TM
 and 
subsequently analyzed for IgG expression by Western blot. 
 
 
3.1 Transferability of engineered biophysical properties 
 
51 
Expression of IgG 
Large scale expression in the mammalian and the yeast system is described in detail in chapter 3.2 
and elsewhere.
39
 Prokaryotic expression of IgG was performed in Escherichia coli SB536 (WG1 ΔfhuA 
ΔhhoAB
71
) in small scale. Both chains were placed in a bicistronic ORF within pMORPH
®
X7 
derivatives (MorphoSys;
72
 under an inducible lac promoter/operator. Pre-cultures of 5 ml 2YT medium 
containing 1% glucose were inoculated with a single colony and incubated at 37°C overnight. The 
expression cultures (10 ml 2YT with 0.1% glucose) were inoculated with the pre-cultures at an OD600 
of 0.1 and grown at 30°C for 20 h. IgG synthesis was not actively induced by adding inducer but rather 
driven from the leaky expression once all glucose was consumed. IPTG addition only marginally 
increased the amount of full-length IgG but lead to more partially assembled molecules (like HL and 
H2L intermediates). The next day, the cultures were OD-normalized and molecules in the periplasmic 
space were extracted by incubation of the cell pellet for 2 h at 4°C in the presence of 200 mM boric 
acid, 160 mM NaCl, 2 mM EDTA, pH 8.0. Finally, the expression levels of WT and M variants were 
compared by western blots using anti-light chain-specific antibodies as described below. 
 
 
Biophysical and biochemical analysis 
 
Purification of IgGs 
Antibodies were purified from culture supernatants by Protein A affinity chromatography. For this 
purpose, the supernatants were loaded onto HiTrap Protein A columns (GE Healthcare, USA) at 4°C 
at a flow rate of 1 ml/min. Chromatography was performed using an ÄKTA PrimePlus chromatography 
system (GE Healthcare) at 4°C. After loading, the column was washed with 100 mM sodium 
phosphate buffer pH 8.0 containing 150 mM NaCl. Elution of IgG was accomplished by using 0.1 M 
glycine pH 2.7, followed by immediate neutralization of each fraction to pH 7.5 using 1 M Tris, pH 8.0. 
The concentrations of the sample fractions were determined by UV-spectroscopy at 280 nm with a 
NanoDrop ND-1000 spectrophotometer (Thermo Scientific), assuming a mass extinction coefficient of 
1.37 for a 1 mg/ml solution of IgG. The samples with the highest protein concentration were pooled 
and dialyzed twice against PBS (Sigma-Aldrich; 10 mM Na2HPO4, 1.8 mM KH2PO4, 2.7 mM KCl, 137 
mM NaCl, pH 7.1) at 4°C. After dialysis, the samples were filtered through 0.22 µm filters (Millipore) 
and stored at 4°C. 
 
SDS-PAGE and Western blotting 
Sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) was performed using either 
NuPAGE precasted 4-12% gradient gels (Invitrogen) according the manufacturer’s instructions or self-
made Tris-glycine 7.5% or 12% gels for non-reduced or reduced samples, respectively. Gels and 
samples were prepared according to standard protocols
73
 and 1.5 µg of IgG antibody was loaded per 
lane. Non-reduced samples were only mixed with loading buffer, while for reduced samples 
dithiothreitol (DTT) was added to a final concentration of 16 mM, followed by incubation for 5 min at 
95°C. As molecular mass marker the PageRuler prestained protein ladder (Fermentas) was used. The 
gels were stained using Coomassie following standard protocols or by silver staining according to the 
manufacturer’s instructions (Invitrogen). 
For the specific detection of the IgGs, the proteins were transferred to a polyvinylidene difluoride 
(PVDF) membrane (Millipore) after their separation by SDS-PAGE. Blotting was performed following 
the semi-dry method within a Trans-Blot SD cell (BioRad, CA, USA) for 60 minutes at 11 V, using a 
Tris-glycine buffer (20 mM Tris, 150 mM glycine, 10% methanol). After blocking the membrane in 5% 
MPBST (5% w/v skimmed milk dissolved in PBST (PBS with 0.05% Tween-20) for at least 1 h, the 
membrane was incubated for another hour in 2.5% MPBST containing the appropriate detection 
antibody conjugated to alkaline phosphatase. For detection of the light chains, an anti-human lambda-
light chain-specific antibody (Sigma-Aldrich, #A2904; 1:1,500 dilution) or an anti-human kappa-light 
chain-specific antibody (Southern Biotech, #2060-04; 1:3,000 dilution) were used. Bands were 
detected by the addition of NBT-BCIP solution (nitro-blue tetrazolium chloride with 5-bromo-4-chloro-
3'-indolyphosphate p-toluidine salt; Sigma-Aldrich) in 100 mM Tris pH 9.5, 5 mM MgCl2, 100 mM NaCl. 
The development was terminated when the first bands became clearly visible by rinsing the membrane 
in ultra high pure water.  
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Isoelectric focusing 
Determination of the isoelectric point of the constructs was carried out in IEF Ready Gels (pH 5-8; Bio-
Rad, CA, USA) according to the manufacturer's instructions on a Mini-PROTEAN II vertical cell system 
(Bio-Rad), using increasing voltages (100 V for 1 h, 250 V for 1 h, and 500 V for 30 min). Next to the 
samples, an IEF standard (Bio-Rad) was co-electrophoresed. The cathode and anode buffers were 
20 mM lysine / 20 mM arginine or 7 mM phosphoric acid, respectively. Following electrophoresis, the 
proteins were visualized by Coomassie Blue - Crocein Scarlet staining (0.04% w:v Coomassie R-250 
and 0.05% w:v Crocein Scarlet 3B in 27% isopropanol / 10 % acetic acid) for 45 min and destaining 
(40% methanol / 10% acetic acid). 
 
Capillary electrophoresis 
Capillary electrophoresis was performed on the chip-based Lab-Chip 90 instrument (Caliper Life 
Sciences, MA, USA) under non-reducing and reducing conditions following the manufacturer’s 
instructions with slight modifications. Briefly, 5 µl sample containing 2.5 µg IgG was mixed with 35 µl of 
denaturation solution and incubated either at 25°C or 75°C for 5 min. The denaturation solution was 
prepared according to the provided protocol either without any reducing agent or by the addition of 
DTT in the recommended concentration. 70 µl distilled water were added to each sample prior to 
analysis and the analysis chip was primed according to the manufacturer's instructions. The 
automated protein analysis generated both a chromatogram (showing migration time) as well as a 
virtual gel (mimicking a Coomassie stained gel) as output. 
 
2D-electrophoresis with SDS-PAGE in both dimensions 
To analyze whether the different banding patterns in WT and M samples consist of species which can 
be separated or species which re-equilibrate, a 2D-SDS-PAGE was devised. Gels were run in a cold 
room. Duplicates of 4 µg IgG samples were run for the first dimension on an SDS-PAGE gel on two 
identical halves. While one half of the gel (containing one of the duplicates each) was used for 
Coomassie staining of the protein bands, the second half was stored temporarily in SDS-running 
buffer. After the bands were clearly visible, either the corresponding positions or whole lanes on the 
un-stained gel half were cut and placed on top of the second SDS polyacrylamide gel in perpendicular 
orientation. This resulted in the re-separation based on the size of the proteins in the second 
dimension as well. To prevent air bubbles to influence the running behavior, the placed pieces of gel 
were mounted with regular stacking gel material poured round the gel pieces. The final gel was 
stained using the Silver Quest kit (Invitrogen) according to the manufacturer’s instructions. 
 
Analysis of IgG and Fab expression levels by enzyme linked immunosorbent assay (ELISA) 
To analyze the influence of the performed mutations on the antibody expression and secretion levels, 
the same number of HEK293 cells stably expressing the corresponding IgG or Fab constructs were 
seeded in 12-well plates. Upon reaching confluency, the medium was removed and replaced by 1 ml 
expression medium, containing 5% FBS. 24 h later, the supernatant was analyzed for its IgG or Fab 
content by ELISA. For the Pichia-produced IgGs, OD-normalized aliquots were taken after 24 h 
expression for ELISA analysis. For the IgG detection ELISA, a capture antibody recognizing the 
human IgG heavy chain (Jackson ImmunoResearch, PA, USA; #209-005-098) was immobilized on 
MaxiSorb plates (Nunc) overnight at 4°C. For detection of Fab fragments in the supernatant, an anti-
myc capture antibody (Sigma-Aldrich, #M4439; 1:2,000 dilution) was coated on the plates. After 1 h 
blocking in 5% skimmed milk in PBST, 100 µl of P. pastoris- or HEK-derived supernatant (diluted in a 
range of 1:25 to 1:100 in fresh BMGY or DMEM media) was incubated for 1 h at room temperature. 
The expressed IgG or Fab molecules were detected by incubating with an anti-human lambda-light 
chain specific antibody conjugated to alkaline phosphatase (Sigma-Aldrich, #A2904; 1:2,000 dilution) 
for 1 h and subsequent addition of p-nitrophenyl phosphate (Sigma-Aldrich). Absorbance at 405 nm 
was measured using a Perkin Elmer HTS 7000 Plus plate reader by sampling up to 1 h.  
To analyze the levels of IgG still present within the cells, cells stably expressing the IgG constructs 
were cultured in 12-well plates for three days in duplicates. The supernatant was harvested, the cells 
washed twice with PBS and finally 250 µl of radioimmuno precipitation assay (RIPA) buffer (50 mM 
Tris pH 7.5, 150 mM NaCl, 1% NP40 and 0.25% Na-deoxycholate) added to the cells before the plates 
were placed at -80°C for 2 h. After this freezing-thawing step, the cells were scraped off and the 
extracts were subsequently analyzed by SDS-PAGE followed by Coomassie staining or by western 
blotting. To allow the simultaneous detection of IgG in the supernatant and the cellular extracts on the 
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same gel, only 1/6 of the corresponding supernatant was loaded compared to the cellular extract, and 
all samples were heated to 95°C for 5 min prior to loading. 
 
Circular dichroism spectroscopy 
Circular dichroism (CD) measurements were performed on a Jasco J-810 Spectropolarimeter (Jasco, 
Japan) equipped with a computer-controlled water bath (refrigerated circulator FS18, Julabo, 
Germany), using a 0.5 mm cylindrical thermocuvette. CD spectra were recorded from 200 to 250 nm 
with a data pitch of 0.5 nm, a scan speed of 20 nm/min, a response time of 4 s, and a bandwidth of 2 
nm. Measurements were performed at 25°C and each spectrum was recorded three times and 
averaged. The CD signal was corrected by buffer subtraction and converted to mean residue ellipticity 
(MRE, θ) using the concentration of the sample determined spectrophotometrically at 280 nm. Heat 
denaturation curves were obtained by measuring the CD signal at 208 nm at temperatures increasing 
from 25°C to 90°C (heating rate 1°C/min; response time 4 s; bandwidth 2 nm). Data were collected 
and processed as described above. CD spectra and denaturation curves of the purified IgGs were 
measured in PBS (Sigma-Aldrich, pH 7.1) at a protein concentration of 5 µM. 
 
Intrinsic tryptophan fluorescence 
Intrinsic tryptophan fluorescence (ITF) was measured with a Jobin-Yvon Fluoromax-4 
spectrofluorimeter (Horiba Scientific, NJ, USA) equipped with a Peltier-controlled cuvette holder. The 
temperature was controlled by an LFI3751 5A digital temperature control instrument (Wavelength 
Electronics Inc., MT, USA). Upon excitation at 295 nm, Trp emission spectra were recorded from 300 
to 400 nm (Δλ = 1 nm, scan rate 1 nm/s) in 0.5°C steps from 25°C to 90°C. The sample cuvette was 
equilibrated for 2 min at each temperature to ensure that the desired temperature was reached within 
the cell. Protein concentrations were 1 µM in every case, and all measurements were performed in 
PBS (pH 7.1). The intensity of the emission spectrum at 330 nm (F330) and 350 nm (F350) was 
determined at each temperature, the ratio F330/F350 calculated and subsequently plotted as a function 
of temperature.  
For the analysis of the midpoints of denaturation at various pH, IgGs were dialyzed overnight and 
analyzed at the conditions described above in the following buffers. For pH 4 and 5: 25 mM sodium 
acetate, 130 mM NaCl; for pH 6, 7 and 8: 25 mM sodium phosphate, 130 mM NaCl; for pH 9 and 10: 
25 mM sodium carbonate, 130 mM NaCl. 
 
Guanidine hydrochloride-induced equilibrium unfolding 
Guanidine hydrochloride (GdnHCl)-induced denaturation measurements were carried out with 
protein/GdnHCl mixtures containing a final protein concentration of 1 µM and denaturant 
concentrations ranging from 0 to 5 M (99.5% purity, Fluka, MO, USA). These mixtures were prepared 
from a 6 M GdnHCl stock solution (in PBS, pH adjusted to 7.1) and equilibrated overnight at 25°C. 
Each final concentration of GdnHCl was determined by measuring the refractive index. The intrinsic 
fluorescence emission spectra were then recorded from 300 to 400 nm with an excitation wavelength 
of 295 nm in an Infinite M1000 reader (Tecan, NC, USA). Individual GdnHCl blanks were recorded and 
automatically subtracted from the data. The emission ratio F330/F350 was calculated and plotted as a 
function of GdnHCl concentration. Time-dependent unfolding was recorded with the same setup in a 
Jobin-Yvon Fluoromax-4 spectrofluorimeter (Horiba Scientific, NJ, USA), recording full spectra every 
two minutes for 5.5 h, starting at the time of GdnHCl addition without any previous incubation. 
 
Size-exclusion chromatography  
SEC experiments were performed using a Superdex 200 PC 3.2/30 column (GE Healthcare). The runs 
were performed in PBS buffer (Sigma-Aldrich, pH 7.1) at a flow rate of 0.06 ml/min at 25°C on an 
ÄKTA Micro system (GE Healthcare). Samples of 50 µl containing 6.7 µM IgG were injected and 
protein elution was monitored at 280 nm. Cytochrome c (12.4 kDa), albumin (66 kDa) and β-amylase 
(200 kDa) were used as standards to calibrate the column. 
 
RP-HPLC analysis 
HPLC analyses were performed according to Dillon and colleagues
74
 on an Agilent 1100 HPLC 
system equipped with a binary pump. Samples were separated on a Zorbax SB300 C8, 3.5 µm at 
75°C with a flow rate of 0.25 ml/min. The following setup was used for all runs: Solvent A: 0.1% TFA, 
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solvent B: 0.09% TFA / 9.9% water / 20% acetonitrile / 70% isopropanol. The column was initially 
equilibrated with 90% mobile phase A and 10% mobile phase B for 5 min followed by a 2 min step 
gradient from 10 to 25% B. Elution was achieved with a linear gradient of 25 - 40% B over 18 min. 
Afterwards a final flush of 90% B was performed for 5 min and the system set back to initial conditions 
and equilibration for 11 min prior to the next run (total run time = 45 min). Reduced samples were 
adjusted to 4.2 M GdnHCl / 70 mM Tris / 3.5 mM EDTA, pH 8.6 in the presence of 50 mM DTT and 
incubated at room temperature for 2 h prior to analysis. 
 
Cation-exchange chromatography  
Cation-exchange chromatography was carried out on an Agilent 1100 binary pump LC system 
equipped with a TSKgel CM-STAT column, 7 µm, 4.6 × 100 mm column (Tosoh Bioscience, Japan). 
30 µg of purified IgGs were injected onto the column equilibrated in buffer A (25 mM sodium 
phosphate pH 6.0). Antibodies were eluted by a linear gradient to 30% buffer B (25 mM sodium 
phosphate pH 6.0, 1 M sodium chloride) over a 30 min time period with detection at 280 nm. The 
column temperature and flow rate were maintained at 25°C and 0.5 ml/min, respectively.  
 
Differential scanning calorimetry  
Differential scanning calorimetry (DSC) measurements were performed using a VP-Capillary DSC 
system (Microcal Inc., acquired by GE Healthcare). The antibody concentrations were adjusted to 
0.5 mg/ml prior to the measurement. The corresponding buffer was used as a reference. The samples 
were heated from 15°C to 100°C at a rate of 1°C/min after initial 8 min of equilibration at 15°C. A 
filtering period of 10 s was used and data were analyzed using Origin 7.0 software (OriginLab1 
Corporation, MA, USA). Thermograms were corrected by subtraction of buffer-only scans and then 
normalized to the molar concentration of the protein. The final excess heat capacity thermogram was 
obtained by interpolating a cubic baseline in the transition region. The midpoint of a thermal transition 
temperature (Tm) was obtained by analyzing the data using Origin 7 software provided with the 
instrument. As all measured transitions are irreversible, all the experimental values reported in this 
study for melting temperatures have to be regarded as ʺapparentʺ values. 
 
Differential scanning fluorimetry  
Differential scanning fluorimetry (DSF) was performed using the Rotor-Gene Q real-time PCR cycler 
(QIAGEN) and fluorescence data were collected using the instrument's HRM channel settings 
(λex 460 nm; λem 510 nm). The SYPRO Orange dye (Molecular Probes; see Volkova et al.
75
 for a 
partial structure) in DMSO was diluted 500-fold from the supplied stock solution into the appropriate 
buffers just prior to being added to the protein solutions. The samples with a final protein concentration 
of 3.5 µM in 20 µl reaction mixture were subjected to a temperature ramp from 30°C to 90°C at a 
heating rate of 1°C/min and at 0.5°C increments with an equilibration time of 30 s at each temperature 
prior to measurement. The Tm was determined as the temperature corresponding to the maximum 
value of the first derivative of the fluorescence changes, calculated by the software. When multiple 
unfolding transitions were observed, only the Tm value of the first transition could be accurately 
determined, as the transitions at higher temperatures overlap. Prior to the DSF analysis, several IgGs 
were analyzed by fluorescence spectroscopy in the presence or absence of SYPRO Orange. In 
agreement with the literature, the dye did not induce any changes in the thermal stability determined 
by ITF, as long as the final dye concentration was lower than a 1:200 to 1:500-fold dilution of the 
original reagent. 
 
Microscale thermophoresis measurements 
Binding affinities of purified IgGs to their antigen myoglobin (Sigma-Aldrich) or M18-Transferin (Jerini 
GmbH, Germany) respectively were measured using microscale thermophoresis (MST, NanoTemper, 
Germany) as described previously.
38
 Myoglobin or M18-Transferin was fluorescently labeled according 
to the manufacturer’s instructions with a reactive NT-647 dye using N-hydroxysuccinimide (NHS) 
ester-chemistry which reacts with primary amines to form dye-protein conjugates. For each analyzed 
construct, a titration series with constant antigen concentration (20 µM) and varying IgG 
concentrations between 10
-11
 and 10
-5
 M was prepared in PBS. The mixed samples were equilibrated 
for 1 h at room temperature and approximately 4 µl of each sample was loaded in the capillary. An 
infrared laser diode within the Monolith NT.115 instrument (NanoTemper, Germany) was used to 
increase the temperature by 4 K in the beam center. Throughout the measurement, the fluorescence 
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inside the capillary was recorded by a CCD-camera and the normalized fluorescence was plotted 
afterwards against the IgG concentrations. The KD values were subsequently obtained from fitting the 
binding curves using Prism 5 (GraphPad, CA, USA). 
 
Partial reduction 
Partial reduction of IgGs was performed by incubating the samples in 30 mM tris(2-
carboxyethyl)phosphine (TCEP) for 10 min at 25°C. Afterwards, the samples were analyzed without 
further heating by non-reducing SDS-PAGE and either stained by Coomassie or analyzed by western 
blot. 
Fluorescent labeling of free sulfhydryls with 5-iodoacetamidofluorescein (5-IAF, Thermo Fischer) was 
performed after incubation of IgG with low µM concentrations of TCEP (corresponding to 2-10 molar 
equivalents; higher concentrations interfered with the subsequent 5-IAF coupling) for 1 h at room 
temperature. Afterwards the partially reduced samples were incubated with 5-fold molar excess of 5-
IAF for 2 h at room temperature protected from light. Afterwards the samples were separated by non-
reducing or reducing SDS-PAGE and the fluorescently labeled bands detected using the LAS3000 
chemiluminescence detection system (Fuji, Japan). Finally, all protein bands were visualized by 
Coomassie staining. 
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Supplementary Material for Chapter 3.1 
 
 
Construction of Expression Plasmids 
 
Expression vectors for mammalian HEK293 cells were first designed for the independent expression 
of heavy or light chain, respectively, using the pMORPH
®
 vector series (MorphoSys).
1
 The VH and VL 
genes of the previously analyzed scFv fragments
2
 were amplified and inserted into 
pMORPH
®
2_h_IgG1f, pMORPH
®
2_h_Igκ or the pMORPH
®
2_h_Igλ2 vectors. These vectors led to the 
expression of correctly assembled full-length IgG into the supernatant of mammalian cells upon co-
transfection. These proteins carry no tags. The creation of Fab expression vectors was performed 
likewise, in this case however, the VH/CH1 chain was fused to a myc-tag and (his)6-tag at its C-
terminus for detection and purification purposes. 
 
For the establishment of stable cell lines using the Flp-In system (Invitrogen), the two expression 
cassettes for H and L, respectively, were combined in a single vector based on the pcDNA5/FRT 
series (Invitrogen). After removal of the intrinsic MfeI cleavage site by site-directed mutagenesis (using 
primers MfeI_del_for: 5′ - GGC AAG GCT TGA CCG ACA GTT GCA TGA AGA ATC TGC - 3′ and 
MfeI_del_rev: 5′ - GCA GAT TCT TCA TGC AAC TGT CGG TCA AGC CTT GCC - 3′ to create the 
pcDNA5/FRT/-MfeI plasmid), the final vectors were constructed as follows. The heavy chain gene was 
amplified from the corresponding pMORPH
®
 vector using the primers HC_NheI_for (5′ - CCC AAG 
CTG GCT AGC GCC ACC ATG AAA CAC C - 3′) and HC_XbaI_rev (5′ - GCG TCC TCT AGA GCG 
TAC CCA ATT CAA CAG GC - 3′). The resulting amplicon contained the complete coding sequence of 
the heavy chain as well as a poly A sequence derived from the human growth hormone, but no CMV 
promoter. The amplification of the light chain gene was performed using LC_XbaI_for (5′ - GCG TCC 
TCT AGA CGC GAT GTA CGG GCC AGA TAT ACG - 3′) and LC_ApaI_rev (5′ - GCC ACC CGT TTA 
AAC GGG CCC C - 3′), resulting in an amplicon containing a CMV promoter, the complete coding 
sequence of the light chain, but no poly A sequence. Regions complementary to the sequences found 
in the parental vectors are underlined, while nucleotides allowing the cleavage by NheI, XbaI or ApaI 
are printed in italics. After double-digesting the heavy chain amplicon with NheI-XbaI and the light 
chain amplicon with XbaI-ApaI, the resulting fragments were ligated into the NheI-ApaI digested 
pcDNA5/FRT/-MfeI plasmid. Since this vector already contained one intrinsic CMV promoter and a 
poly A sequence (derived from bovine growth hormone), both the sequences coding for the heavy as 
well as for the light chain were finally present as complete expression cassettes including CMV 
promoter and poly A sequences of their own. The final vectors were sequenced and tested by 
transient transfection for their functionality before being used for the establishment of stable cell lines. 
 
The Pichia expression vectors are based on the vector pGAPZαB (Invitrogen). The sequences for the 
light chains and the different heavy chain variants were amplified from the pMORPH
®
 vectors 
described above. Since for expression in Pichia pastoris a plasmid has to be integrated into the 
genome, also these genes were combined within one single vector, retaining them as independent 
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expression cassettes, each with its own GAP promoter and termination sequence. To assemble the 
final vectors, the cloning of intermediate vectors was necessary. First, two pGAPZαB derivatives were 
constructed for each construct: one containing the gene encoding the corresponding light chain, the 
other one holding the heavy chain gene as complete expression cassettes. All expression vectors 
were obtained by inserting a PCR-amplified fragment from the pMORPH
®
 vectors containing the 
sequence coding for the mature heavy or light chain into the multiple cloning site (MCS) of pGAPZαB. 
In these vectors, the POI is placed behind the α-factor pre-pro (αMFpp) sequence and under control of 
the constitutive GAP promoter. 
 
As restriction enzymes, EcoRI introduced downstream of the N-termini and XbaI introduced upstream 
of the C-termini of the corresponding genes were used. The heavy chain fragment was amplified using 
either PP_WT_for (5′ - GCG TCC GAA TTC AA CAG GTG CAA TTG CAA CAG TC - 3′) or PP_M_for 
(5′ - GCG TCC GAA TTC AA CAG GTG CAA TTG GTA CAG TC - 3′) in combination with PP_HC_rev 
(5′ - GCG TCC TCT AGA TCA CTA TCA TTT ACC CGG AGA CAG GG - 3′). The light chain 
fragments were created in the analogous manner using the oligonucleotides PP_λ_for (5′ - GCG TCC 
GAA TTC AA GAT ATC GAA CTG ACC CAG CC - 3′) and PP_λ_rev (5′ - GCG TCC TCT AGA TCA 
CTA TGA ACA TTC TGT AGG GGC CAC - 3′) for the lambda light chain and PP_κ_for (5′ - GCG TCC 
GAATTC AA GAT ATC GTG CTG ACC CAG AG - 3′) and PP_κ_rev (5′ - GCG TCC TCTAGA TCA 
CTA AAC ACT CTC CCC TGT TGA AGC TC - 3′) for the kappa counterpart. Regions complementary 
to the N- or C-termini of the heavy or light chain, respectively, are underlined, while nucleotides 
allowing the cleavage by EcoRI or XbaI are printed in italics. Two consecutive additional stop codons 
were introduced into the construct by the dotted underlined triplets. The AA doublet in the forward 
primers completed to original sequence from the MCS to encode the four additional residues AGIQ 
upstream of the mature N-terminus of either the light or heavy chains, respectively. These additional 
amino acids were removed in a later step from the heavy chain construct by assembly PCR using the 
following primers: WT_AGIQdel_for (5′ - GA GAG GCT GAA GCT CAG GTG CAA TTG CAA CAG 
TCT GGT CCG GG - 3′) and WT_AGIQdel_rev (5′ - G CAA TTG CAC CTG AGC TTC AGC CTC TCT 
TTT CTC GAG AGA TAC CC - 3′) or M_AGIQdel_for (5′ - GA GAG GCT GAA GCT CAG GTG CAA 
TTG GTA CAG TCT GGT CCG GG - 3′) and M_AGIQdel_rev (5′ - C CAA TTG CAC CTG AGC TTC 
AGC CTC TCT TTT CTC GAG AGA TAC CC - 3′). The AGIQ-coding sequences of the light chains 
were removed by conventional cloning using the unique XhoI-NcoI cleavage sites, employing the 
oligonucleotides λ_AGIQdel_for (5′ - GCG TCG CTC GAG AAA AGA GAG GCT GAA GCT GAT ATC 
GAA CTG ACC CAG CC - 3′) or κ_AGIQdel_for (5′ - GCG TCG CTC GAG AAA AGA GAG GCT GAA 
GCT GAT ATC GTG CTG ACC CAG AGC - 3′) in combination with LC_AGIQdel_rev (5′ - CCG GAA 
CGG CAC TGG TCA ACT TGG C - 3′). Regions complementary to the N-termini of the light chains are 
underlined, while nucleotides allowing the cleavage by XhoI or NcoI are printed in italics. 
 
Finally, the two vectors (each coding for either the heavy or light chain, respectively) were combined in 
a single vector for integration into the Pichia genome. This step was performed on the basis of the 
methods described by Ogunjimi and co-workers.
3
 Briefly, the vectors containing the heavy or light 
chain gene was double-digested with either MluI-BamHI or MluI-BglII, respectively. As digestion with 
BamHI-BglII resulted in compatible overhangs, the subsequent ligation eliminated the used BglII 
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cleavage site, leading to only one remaining BglII cleavage site in the final plasmid, which was 
subsequently used for linearization of the plasmid for genomic integration. This vector contained both 
independent expression cassettes but only one origin of replication as well as only one Zeocin
TM
 
resistance marker. 
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Fig. S3.1.1. Comparison of secreted IgG amounts with intracellular levels and IgG expression in E. 
coli. (a) Western blot analysis of IgG 2C2 WT and M variants found in the supernatant (SN) and 
intracellularly (IC) in stable HEK cells. Samples were taken in duplicates and the cells were lysed with 
RIPA-lysis buffer containing 1% NP40 and Na-deoxycholate. The supernatant was diluted 6x to allow the 
detection of the significantly lower intracellular IgG levels on the same blot. Samples were heated to 95°C 
for 5 min and the detection performed with antibodies specific for the respective light chain. (b) Western 
blot analysis of full-length IgGs expressed in E. coli. The OD-normalized periplasm was isolated and 
separated by non-reducing SDS-PAGE. 
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Fig. S3.1.2. Chromatographic analysis of HEK produced IgG variants. Signals derived from WT IgG 
are shown in blue, those of the mutant M in red. (a) Size exclusion chromatography (SEC) analysis of 2C2 
variants. Dotted lines indicate elution volumes of molecular mass standards (from left to right): β-amylase 
(200 kDa), bovine serum albumin (66 kDa) and cytochrome c (12.4 kDa). Also shown are the void volume 
V0 and the total volume Vtot. (b) SEC of IgG 6B3 variants analyzed analogous to panel (a). (c) Analysis of 
IgG 2C2 WT and M by reverse phase HPLC (RP-HPLC). Changes in the elution profiles are attributed to 
the increased hydrophobicity of the M variant. The upper panel shows the chromatogram recorded under 
non-reducing conditions, the lower one after reduction. (d) RP-HPLC of IgG 6B3 variants analog to panel 
(c). (e) Cation exchange chromatography (CIEX) of IgG 2C2 variants. Differences in the elution profile of 
the M variant are caused by the additional negative charge introduced by the V72D mutation. (f) CIEX of 
IgG 6B3 variants analog to panel (e). 
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Fig. S3.1.3. Binding affinity of IgG mutants obtained from mammalian expression. Direct interaction 
studies between purified IgGs and their fluorescently labeled antigens (M18-transferrin for IgG 2C2 and 
myoglobin for IgG 6B3, respectively) analyzed using microscale thermophoresis technology. Normalized 
fluorescence [‰] is plotted against the IgG concentration titrated from 0.03 nM to 10,000 nM. The fitted KD 
values lie within the experimental error range and indicate that the binding is fully retained for (a) the IgG 
2C2 variants and (b) IgG 6B3 WT and M, respectively. 
 
 
 
 
 
 
 
Fig. S3.1.4. Real-time analysis of GdnHCl-induced denaturation of IgGs. The graphs were obtained 
from the F330/F350 ratio plotted as a function of time. Shown are the signals derived from IgG sample in the 
presence of various GdnHCl concentrations. Real-time unfolding was recorded over a period of 5.5 h for 
(a) HEK IgG 2C2 WT, (b) HEK IgG 2C2 M, (c) HEK IgG 6B3 WT and (d) HEK IgG 6B3 M. 
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Fig. S3.1.5. Comparison of DSF and DSC data from figures 3.1.6 and 3.1.7. To allow an eased 
comparison of domain stabilities, data recorded by DSF (displayed as continuous lines) and DSC (dotted 
lines) are combined within one single graph. Comparative graphs were generated for (a) HEK IgG 2C2, (b) 
HEK IgG 6B3, (c) PP IgG 2C2 and (d) PP IgG 6B3. 
 
 
 
                               
 
        ITF GdnHCl DSF DSC   
                                         
 
  IgG 2C2 WT   70.4°C* 2.5 M n.d. 86.0°C   
 
 
    M   71.8°C* 3.8 M n.d. 87.8°C   
                     
 
      Δ =  1.4°C 1.3 M - 1.8°C   
                     
                    
 
  IgG 6B3 WT   67.6°C 2.0 M 74.5°C 72.1°C   
 
 
    M   70.8°C 2.6 M 77.0°C 74.3°C   
                     
 
      Δ =  3.2°C 0.6 M 2.5°C 2.2°C   
 
 
                  
 
 
  Fab 6B3 WT   69.7°C 2.0 M 76.5°C 72.6°C   
 
 
    M   74.2°C 2.6 M 80.0°C 76.6°C   
                     
 
      Δ =  4.5.°C 0.6 M 3.5°C 4.0°C   
 
 
                  
 
           Fig. S3.1.6. Overview of stabilities determined by different methods. Indicated are the melting 
temperatures measured in Centigrade (°C) as well as the difference between the M and WT construct (Δ). 
For the DSF and DSC data, the temperatures derived from the respective Fab fragment are listed. For the 
denaturant-induced unfolding, the GdnHCl concentration (in M) is specified which correlates to the 
midpoint of transition of the corresponding graphs shown in Fig. 3.1.5. 
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Abstract 
 
Aggregation is an important concern for therapeutic antibodies, since it can lead to reduced bioactivity 
and increase the risk of immunogenicity. In our analysis of immunoglobulin G molecules (IgGs) of 
identical amino acid sequence but produced either in mammalian cells (HEK293) or the yeast Pichia 
pastoris, dramatic differences in their aggregation susceptibilities were encountered. The antibodies 
produced in Pichia were much more resistant to aggregation under many conditions, a phenomenon 
found to be mainly caused by two factors. First, the mannose-rich glycan of the IgG from Pichia, while 
slightly thermally destabilizing the IgG, strongly inhibited its aggregation susceptibility, compared to the 
complex mammalian glycan. Second, on the Pichia produced IgGs amino acids belonging to the α-
factor pre-pro sequence were left at the N-termini of both chains. These additional residues proved to 
considerably increase the temperature of the onset of aggregation and reduced the aggregate 
formation after extended incubation at elevated temperatures. The attachment of these residues to 
IgGs produced in cell culture confirmed their beneficial effect on the aggregation resistance. Secretion 
of IgGs with native N-termini in the yeast system became possible after systematic engineering of the 
precursor proteins and the processing site. Taken together, the present results will be useful for the 
successful production of full-length IgGs in Pichia pastoris, give indications on how to engineer 
aggregation-resistant IgGs and shed new light on potential biophysical effects of tag sequences in 
general.  
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buffered saline; pI, Isoelectric point; POI, Protein of interest; PP, Pichia pastoris; scFv, Single-chain 
variable fragment of an antibody; SEC, Size-exclusion chromatography; SDS-PAGE, Sodium dodecyl 
sulfate-polyacrylamide gel electrophoresis 
 
  
3.2 Engineering aggregation resistance in IgG by two independent mechanisms 
 
67 
Introduction 
Antibodies and their derivatives have found a broad range of applications, from basic research to 
medical therapy. Using many different techniques for their generation
1
 several therapeutic 
immunoglobulins, usually in the whole IgG format, have been FDA-approved and applied to the 
treatment of a wide range of diseases.
2-4
 One major challenge encountered in the development of 
antibody-based therapeutics, however, is their aggregation susceptibility under both formulation 
conditions
5; 6
 and in vivo, where aggregation is involved in a significant degradation pathway for 
monoclonal antibodies.
7
 Irreversible aggregation thereby leads to reduced bioactivity
8
 and presents an 
increased risk of immunogenicity.
9-14
 Aggregation of even only a few percent of the administered 
therapeutic antibody can cause severe problems, as already low amounts of aggregates have long 
been known to cause anaphylactoid reactions.
15; 16
 Therefore, engineering IgG to reduce or eliminate 
its self-association is of great importance and might further extend the potential of therapeutic 
antibodies. 
Since nearly all recombinant therapeutic antibodies are expressed in the IgG format, choices must be 
made in the molecular composition and expression system. Currently, all approved therapeutic 
antibodies are produced in mammalian cells,
17
 since only this expression system can introduce the 
complex glycosylation which is necessary for the interaction of the antibodies with some of the 
activating Fcγ receptors.
18
 IgGs normally possess a single N-linked glycosylation at Asn297 in the CH2 
domain, maintaining these domains at a critical distance to bind to the Fcγ receptors.  
In some cases, however, this FcγR interaction is neither needed nor wanted, thus opening the range 
of possible production hosts also to Pichia pastoris. In the past, this methylotrophic yeast has been 
widely used for the expression of both secreted and intracellular eukaryotic proteins.
19
 While it is able 
to carry out efficient disulfide bond formation and isomerization using the eukaryotic secretion quality 
control machinery,
19-21
 Pichia expression generates mannose-rich glycosylation of IgG.
22
 The attached 
glycan moieties differ markedly from the product of mammalian cells, resulting in antibodies that lack 
FcγR binding capacity. However, recently, Pichia pastoris has also been engineered to introduce 
complex, human-like glycosylation.
23-26
 
Due to its respiratory growth, P. pastoris can grow to very high cell densities,
27
 and therefore express 
high levels of recombinant protein through efficient and tightly regulated promoters, accounting for up 
to 30% of the total cell protein.
28
 Moreover, comparatively few endogenous proteins are secreted by 
this yeast system, which offers further advantages for subsequent protein purification and downstream 
processing.
29
 Since Ridder and colleagues reported the first successful production of functional 
antibody fragments in Pichia,
30
 more than 50 reports have been published describing antibody 
expression in this system.
31
 While most of these molecules were scFv fragments and fusions thereof, 
several Fab fragments have been produced in Pichia as well.
32-34
 Interestingly, until today P. pastoris 
has only been used as an expression host for a handful of full-length IgGs.
25; 26; 35
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Almost all heterologous proteins produced in P. pastoris have been expressed under the control of the 
methanol-inducible alcohol oxidase 1 (AOX1) promoter.
20; 36
 However, throughout this study the 
constitutive glyceraldehyde-3-phosphate dehydrogenase (GAP) promoter
37
 was used, since the ability 
to compare mutant proteins for their expression and aggregation tendencies was crucial. The GAP 
promoter is usually considered to result in lower protein yields compared to AOX1,
38
 even though 
some reports describe the GAP promoter to be superior to AOX1 for certain proteins,
39; 40
 including 
Fab fragments.
41
 A potential reason could be the lower rate of expression which might better match 
the corresponding folding rate and, thus, reduces the stress level for the cells.  
Previously, our laboratory analyzed sequence modifications in the variable domain in various antibody 
formats for aggregation propensity and conformational stability.
42-44
 To carry out such studies for whole 
IgGs, eukaryotic expression systems are required where functional expression yields can be 
compared and mutant proteins can be isolated and biophysically characterized. Therefore, it is vital 
that isogenic strains can be produced, only differing by the sequence of the protein to be tested. As a 
first step, we investigated homologous recombination in HEK293 cells
45
 and Pichia pastoris. As P. 
pastoris does not maintain episomal vectors, the expression cassettes are generally designed for 
integration into the yeast genome, thus leading to stable cell lines expressing the protein of interest 
(POI). In initial experiments, we were very surprised to find large differences between the aggregation 
behaviors of purified IgG protein from both systems, even though their amino acid sequence was 
identical: the same recombinant IgG expressed in HEK293 cells was much more aggregation-prone 
than its counterpart from Pichia pastoris. 
Here, we describe our investigations of this phenomenon and pinpoint it to differences in the 
processing of the precursor proteins, as well as to differences between the unequal glycosylations. As 
an initial model system, an antibody was used that had originally been selected from the HuCAL 
library
46
 by panning against myoglobin from horse skeletal muscle
 
and subsequently been stability-
engineered.
47
 For this study, it was converted to a full-length IgG and investigated for its processing 
and expression in mammalian HEK293 cells and in the yeast Pichia pastoris.  
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Results 
Comparison of various IgG constructs 
In this study, we compared IgGs of identical amino acid sequence, but produced in different eukaryotic 
expression systems. Unexpectedly, these molecules revealed dramatic differences in some of their 
biophysical properties. To monitor changes in their structure as a function of temperature, purified 
IgGs were analyzed by circular dichroism (CD). Since the signals stemming from the IgG's β-sheets 
and random coil essentially canceled out to zero at 208 nm, thermal denaturation of the IgG molecules 
was determined at this wavelength as a function of temperature. These analyses indicated that the 
IgGs produced in human embryonic kidney cells (HEK) and in Pichia pastoris (PP) not only had a 
slightly different temperature of unfolding onset, but, unexpectedly, also showed very different 
aggregation susceptibilities (Fig. 3.2.1a). The abrupt jump upwards in the respective CD vs. 
temperature curve indicates that the antibody expressed in mammalian cells started to aggregate at a 
temperature higher than ~75°C, whereas the corresponding construct produced in the Pichia pastoris 
system did not exhibit any detectable aggregation at all. This finding could also be visually observed, 
as the mammalian antibodies had turned into a turbid sample after the experiment, compared to a 
clear solution for the yeast IgG (Fig. 3.2.1b, inset: PP samples left and HEK293 samples right). To 
further confirm these results, an aggregation assay based on light scattering (Fig. 3.2.1b) was 
performed in a fluorimeter: when both excitation and emission wavelengths were set to 500 nm, the 
different IgG molecules showed clear differences in the intensity of scattered light upon exposure to 
increasing temperatures. Only the molecules produced in mammalian cells aggregated, forming 
complexes large enough to measurably scatter the incoming light from about ~75°C onwards. In 
contrast, the Pichia-produced IgG did not show any detectable light scattering at all. 
While the protein sequences of the mature IgG H and L chains are identical, different sugar moieties 
are attached to the CH2-domain of the heavy chain in yeast and in mammalian cells. Therefore, glycan 
knockout mutants were designed by replacing the glycosylation motif Asn297-Ser298-Thr299 in the 
CH2-domain by an Asn297-Ser298-Ala299 sequence. The resulting unglycosylated T299A mutants 
were analyzed for their behavior in the aggregation assay in comparison to their glycosylated 
counterparts. As can be seen in Fig. 3.2.1c, the glycan moieties did influence the temperature of IgG 
aggregation onset substantially - however, they seemed to be not the only cause of the different 
aggregation behavior: the unglycosylated IgG produced in the yeast system did show aggregation, 
seen as a clear increase in light scattering at 81.3 ± 0.1°C, while their unglycosylated mammalian 
counterparts already aggregated at 77.3 ± 0.1°C. Glycosylated HEK IgG thus aggregates at a 
temperature ~3.2°C higher than the non-glycosylated HEK IgG.  
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Fig. 3.2.1. Aggregation behavior of IgGs produced in eukaryotic expression systems. (a) Thermal 
denaturation curves of IgGs produced in mammalian cells (HEK293) or in the yeast Pichia pastoris (PP), 
respectively. The denaturation was followed by circular dichroism (CD), plotting the signals at 208 nm as a 
function of temperature. The values are reported as mean residue ellipticity (MRE, θ). The abrupt jump 
upwards at about 79°C in the HEK-derived signal is caused by the formation of insoluble aggregates. (b) 
Aggregation of IgG constructs as a function of temperature measured by light scattering at 500 nm. 
Emission was recorded at the same wavelength as excitation was performed. The insert shows PP (left) 
and HEK293 (right) samples after the measurement. (c) Aggregation susceptibility of glycosylated and 
deglycosylated (glycan knockout T299A) IgGs, analyzed by light scattering at 500 nm. (d) Structures of 
CH2-attached glycans of IgGs produced by either the HEK or the PP system, as determined by ESI-MS. 
GlcNAc - N-acetyl-D-glucosamine, Man - mannose, Fuc - fucose, Gal - galactose. 
 
We determined the different glycan structures present in the IgGs from both the mammalian and yeast 
expression systems by mass spectrometry (MS). This was achieved by subtracting the experimentally 
determined weight of the T299A constructs (49,798.5 Da) from that of the original, glycosylated variant 
(51,274 Da), correcting it for the Thr to Ala mutation (- 30 Da). From the resulting mass difference of 
1445.5 Da (Fig. 3.2.2a), the glycan structure of HEK IgG schematically shown in Fig. 3.2.1d can be 
deduced - the Gal(GlcNAc)2(Man)3(GlcNAc)2Fuc composition typically found for proteins expressed in 
human cell culture.
48
 The yeast glycan, on the other hand, was found to have a mass of 2,035 Da 
(52,399 Da - 50,334 Da – 30 Da) and to be rich in mannose units, the total number of which varied 
between 9 and 15, with the majority of molecules possessing 10 mannose units (molecular formula 
(Man)9-15(GlcNAc)2. These different glycan structures between Pichia and mammalian cells were found 
to be the reason for the slightly decreased temperature of the onset of unfolding recorded in Fig. 
3.2.1a for the Pichia-produced IgG. It could be shown in various experiments that the yeast glycan 
destabilizes the CH2-CH2 domain interface compared to the mammalian counterpart and thereby 
decreases the thermal stability of the whole IgG (Supplementary Data Fig. S3.2.1). Yet, at the same 
time, it largely prevents irreversible aggregation (Fig. 3.2.1c). 
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Since the different glycan structures were not the only cause of the different aggregation 
susceptibilities of the HEK- and Pichia-produced IgGs, both molecules were further analyzed by MS in 
their native and PNGase F deglycosylated form. As listed in Fig. 3.2.2a, not even in their 
deglycosylated forms did they correspond to the theoretical expectation from the aa sequence. 
However, considering that the heavy chains of mammalian IgGs generally lack their C-terminal Lys 
residues (-146 Da),
49
 possess pyroglutamate residues at their N-termini (leading to the loss of a water 
molecule (-18 Da))
50; 51
 and exhibit oxidation of their methionine residues (+16 Da),
52
 the underlined 
calculated masses, which are in excellent agreement with the measured ones, offer a plausible 
explanation for the posttranslational modifications of the mammalian IgG heavy chain. The light chain 
showed the expected mass without any major post-translational modifications.  
The results for the Pichia-produced IgGs, however, indicated the existence of large additional 
modifications at both the heavy and the light chain. Edman sequencing of their respective amino-
termini verified the presence of the tetrapeptide Glu-Ala-Glu-Ala (EAEA) in front of the genuine N-
terminus of the proteins, accounting for the additional 400 Da measured by MS (double underlined). 
Minor fractions with one or both EA-pairs deleted were not detected. Since these four amino acids are 
remains of the α-factor pre-pro sequence (αMFpp) used in the expression setup, the maturation 
process of secreted proteins within the yeast system was analyzed in more detail. This secretion 
system consists of a 19-aa signal (pre) sequence followed by a 66-residue (pro) sequence, the latter 
containing three consensus N-linked glycosylation sites.
53
 Directly following a dibasic Kex2 
endopeptidase processing site, a spacer peptide of four residues (EAEA) is located upstream of the 
genuine N-terminus of the mature α factor peptide. This spacer was included in the present IgG 
construct as well. As schematically illustrated in Fig. 3.2.2b for the heavy chain, proteins fused to the 
αMFpp sequence undergo various processing steps until being fully matured. Several studies have 
shown that dipeptidyl aminopeptidase A (DPAPase A) has problems in fulfilling its task in protein 
overexpression, thereby often leaving residual EAEA residues on the protein to be secreted.
54-56
 This 
also was the case for the Pichia-produced IgG of this study, which therefore will be referred to ʺH-E / 
L-Eʺ from now on (with the suffix ʺEʺ representing the EAEA tetrapeptide), having this extension on 
both chains. 
 
N-terminal engineering of Pichia constructs 
To investigate whether antibody chains with genuine N-termini can be produced in Pichia pastoris, 
yeast variants were designed lacking the EAEA tetrapeptide on the mature heavy and light chain, 
respectively. The EAEA coding sequence was deleted from the DNA encoding both chains - either in 
the individual coding sequences or for both chains simultaneously (depicted in Fig. 3.2.2d, exemplified 
for the light chain).  
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Fig. 3.2.2. Overview of detected IgG masses and Pichia processing. (a) Summary of molecular 
masses of HEK- and Pichia-produced IgGs, analyzed under reducing conditions by ESI-MS and calculated 
based on the amino acid sequence of the individual protein chains. All masses are stated in Da. (b) 
Schematic overview (not drawn to scale) of N-terminal processing of secreted proteins fused to the α-
factor pre-pro sequence (αMFpp) by the endopeptidase Kex2 and the dipeptidyl aminopeptidase A 
(DPAPase A, product of the STE13 gene). The residue numbers of the different regions of the precursor 
protein are shown below the top construct. After the pre-region is cleaved off by signal peptidase upon 
entering the endoplasmic reticulum, the pro-region containing protein is glycosylated and is further 
processed in the Golgi apparatus during the translocation process. Once the Kex2 endopeptidase, 
encoded by the KEX2 gene, has cleaved off the 66 residues of the pro-region, the dipeptidyl 
aminopeptidase A (DPAPase A, encoded by the STE13 gene) removes both EA-dipeptides upstream of 
the mature terminus of the proteins. Afterwards, the mature proteins are released, the IgG assembled and 
finally secreted from the cell into the supernatant. (c) Sequence details of the junction between the αMFpp 
and the gene coding for the light chain. Arrows indicate the cleavage sites of Kex2 and DPAPase A. (d) 
Schematic drawing (not to scale) of the L-E and L construct for Pichia expression. The suffix ʺEʺ 
corresponds to the tetrapeptide Glu-Ala-Glu-Ala (EAEA) derived from the pro-region of the αMFpp. In the L 
construct the coding sequence for the EAEA-tetrapeptide was removed at the DNA level. 
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Surprisingly, upon analysis of purified IgGs by non-reducing SDS-PAGE (Fig. 3.2.3a), no distinct band 
corresponding to the full length IgG could be detected for the H / L-E and H / L constructs, both lacking 
the EAEA coding sequence for the heavy chain. Since this is due to a non-homogeneous composition 
of the heavy chain sample as will be described below, these constructs will be referred to as H* from 
now on. In contrast, deletion of the tetrapeptide from the light chain alone (construct H-E / L) still 
resulted in a clear band for the full-length IgG at the expected size. Detailed analysis of all constructs 
by reducing western blots (Fig. 3.2.3b) with antibodies specific for the heavy chain, for the α-factor pro 
sequence (αMFp) or for the lambda light chain indicated a possible explanation. In the H-E containing 
constructs (left four lanes in Fig. 3.2.3b, middle panel), no αMFp is detected (the light background 
signal is derived from the secondary antibody used which apparently cross-reacts with the human 
IgG), whereas in the H* containing lanes (right four lanes in Fig. 3.2.3b, middle panel) a strong signal 
is found. This appeared as a smear, when left untreated, but distinct bands become visible upon 
treatment with PNGase F. Thus, part of the heavy chain still possesses the complete α-factor pro 
signal sequence at an apparent deglycosylated size of ~57 kDa and thus almost 7,000 Da too high 
compared to the correctly processed heavy chain. The presence of the complete pro-region also 
explains the undetectable band for these constructs in Fig. 3a: due to the heterogeneous glycosylation 
of the pro-region, the IgG molecules appeared rather as a broad smear than as a single band.  
The presence of the pro-region could be further confirmed by sequencing the N-termini of the 
respective heavy chain proteins. Edman degradation and MS analyses (Fig. 3.2.3c) clearly indicated 
that deleting the EAEA tetrapeptide from the heavy chain resulted in a heterogeneous sample with 
three major species. Next to the previously mentioned portion still having the complete pro-region 
attached to it (named ʺpro-regionʺ, blue arrow in Fig. 3.2.3d) and a minor correctly processed protein 
fraction named ʺmatureʺ (green arrow in Fig. 3.2.3d), also a third ʺwrongʺ species was found. This 
latter fraction was derived from an alternative cleavage site at position 57 of the pro-region (see red 
arrow in Fig. 3.2.3d). These molecules possess additional nine residues of the C-terminus of the pro-
region and could also be detected by SDS-PAGE, once the gels were run long enough to provide 
sufficient separation (lane 2 in Supplementary Data Fig. S3.2.2c). Comparing the relative signal 
intensities of the Edman sequencing results, the fraction containing a correctly matured amino-
terminus was determined to be only approximately 20%.  
We also investigated whether the processing of the heavy chain can be improved by charge 
engineering, i.e., making it more similar to the beginning of the light chain (Fig. 3.2.3c) (see 
Supplementary Data for details). However, since the charge engineering did not have the desired 
effect of creating homogeneous processing of the heavy chain (see Supplementary Data Fig. S3.2.2), 
the complete pro-region was deleted from the heavy chain construct (illustrated in Fig. 3.2.4a). The 
resulting construct, named ʺH-pro-delʺ, has the signal sequence (pre-region) fused directly to the N-
terminus of the mature heavy chain. Examination of the new H-pro-del construct in its native and 
deglycosylated form by Western blot (Fig. 3.2.4b) revealed that its expression resulted in 
homogeneous chains of the correct size, which was also subsequently confirmed by MS analysis and 
Edman sequencing (data not shown).  
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Fig. 3.2.3. Analysis of P. pastoris produced IgG variants. (a) SDS-PAGE analysis of equal amounts of 
the Protein A-purified Pichia constructs under non-reducing conditions stained with Coomassie Blue. The 
suffix ʺEʺ on the heavy (H) or light (L) chain construct denotes the tetrapeptide Glu-Ala-Glu-Ala (EAEA) 
derived from the pro-region of the αMFpp. As the constructs without the EAEA turned out to be 
heterogeneous at their N-terminus (see main text), they are marked by an asterisk (*). (b) Western blot 
analysis of IgGs after incubation in the absence or presence of PNGase F. Shown are the blots detected 
with antibodies specific for the heavy chain (α-H), for the α-factor pro-region (α-αMFp) and for the lambda 
light chain (α-L). (c) Overview of the measured masses of heavy and light chains. All masses are stated in 
Da. The penultimate column shows the corresponding N-terminal protein sequence determined by Edman 
sequencing. A vertical dashed line indicates the position of enzymatic cleavage within the maturation 
process. The color code highlights the charge of the individual amino acids (blue, positive charge; red, 
negative charge). The names mentioned in the last column are in agreement with those of Supplementary 
Data Fig. S3.2.2. (d) Schematic representation of the amino acid sequence of the α-factor pre-pro-region 
and the adjacent heavy chain protein. Arrows indicate the sites of Kex 2 cleavage, resulting in the ʺpro-
regionʺ variants (blue arrow), ʺwrongʺ variants (red arrow) and correct ʺmatureʺ protein chains (green 
arrow). 
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Fig. 3.2.4. Design of correctly processed IgG heavy chain in Pichia. (a) Schematic representation (not 
drawn to scale) of the H-E and H-pro-del construct for Pichia expression. The latter construct was 
designed by deleting the complete pro-region at the DNA level. (b) Western blot analysis of IgG constructs 
after incubation in the absence or presence of PNGase F. Shown are the blots detected with antibodies 
specific to the heavy chain (α-H) and to the lambda light chain (α-L). (c) Secreted IgG levels of various 
Pichia constructs, detected by sandwich ELISA in the supernatant of stable Pichia clones. H* indicates the 
incorrectly processed, heterogeneous heavy chain; H-pro-del indicates the deletion of the complete pro-
region from the heavy chain construct; L-pro-del implies that this region is also deleted from the light chain. 
(d) Secretion level of corresponding Fab fragments expressed in stable Pichia clones analyzed by ELISA. 
 
 
We also wanted to determine how the amounts of the correctly assembled IgG constructs found in the 
supernatant compared to all other previously described constructs (Fig. 3.2.4c). These levels could be 
analyzed by sandwich ELISA, capturing the secreted IgGs by antibodies specific for the heavy chain 
and detecting the recombinant IgG with antibodies specific for the light chain. Using this assay, it could 
be guaranteed that only correctly assembled IgGs were detected and, e.g., no light chain dimers 
affected the results. Strikingly, the heterogeneous H* constructs were found to be secreted at 
approximately only half the yield of the original H-E / L-E construct (49.3% for the H* / L-E and 59.3% 
for the H* / L construct, respectively). The new H-pro-del variant, however, seemed to overcome this 
limited expression and led to a total IgG amount even improved by ~25%, compared to the original H-
E / L-E construct. Interestingly, the additional omission of the pro-region from the light chain (”H-pro-
del / L-pro-del” construct) led to a further decrease in the IgG yield found in the supernatant of the 
yeast cultures.  
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To confirm these findings, the effects of the different pro-regions attached to the heavy chain were 
analyzed in the context of the corresponding Fab fragment as well (Fig. 3.2.4d). In these Fab 
fragments, the heavy chain VH-CH1 domains are connected to the complete lambda light chain by a C-
terminal disulfide bond. In agreement with the data derived from the full-length IgGs, the expression of 
the H* / L Fab construct resulted in molecules having the complete pro-region attached at the N-
terminus of the heavy chain (data not shown) and expression levels of only half the level of the original 
H-E / L-E variant (52.6%). The H-E / L-E level could again be increased by 41.3% by using the H-pro-
del version. 
 
Expression and analysis of mammalian IgG constructs 
To examine the influence of the EAEA tetrapeptides on the aggregation susceptibilities of various IgG 
constructs, the corresponding molecules needed to be generated independent of the processing 
preferences of the expression system. Therefore, new constructs for HEK expression were designed. 
Since the process of protein maturation in the mammalian system is comparatively simple (Fig. 3.2.5a) 
different extensions could easily be attached to the amino-termini of both protein chains.  
Figure 3.2.5b compares the variations made apart from the EAEA tetrapeptide. To examine whether 
just any random tetrapeptide might influence the biophysical characteristics of aggregation or whether 
the Pichia-produced EAEA is of special relevance, the completely unrelated and uncharged control 
peptide Ala-Gly-Ile-Gln (AGIQ; represented by the suffix ʺAʺ) was also attached to both the heavy and 
light chain in different combinations. Furthermore, the light chain variant L-EA, carrying both 
tetrapeptides combined in the orientation depicted, was included in the study to analyze the potential 
importance of steric proximity of the charged residues to the original N-terminus. Various combinations 
of these heavy and light chain variants were created and stable HEK cell lines were established for all 
of them. All constructs could be expressed and resulted in proteins of expected size and banding 
pattern (reducing SDS-PAGE analysis in Fig. 3.2.5c; MS data not shown). To investigate the influence 
of the different amino-terminal extensions on the level of secreted IgGs, the amount of IgG found in 
the supernatant of the stable cell lines was determined by the same sandwich ELISA used for the 
yeast-produced IgGs. The extended mature N-terminus of the analyzed IgG chains only minimally 
influenced the levels of secreted IgGs (Fig. 3.2.5d). After 24 hours of expression, the level of H-E / L-E 
found in the media reached almost 90% of the amount derived from the original H / L construct. This is 
in clear contrast to the yeast αMFpp system, as detailed above. 
The main biochemical and biophysical characteristics of the N-terminal extension mutants from 
mammalian and yeast origin were analyzed to determine potential impacts of the various tetrapeptides 
on the IgG structures and stabilities. The addition of the EAEA tetrapeptides was found not to 
influence the binding of the resulting IgGs to their antigen myoglobin (see Supplementary Data Fig. 
S3.2.3). The different KD values derived from microscale thermophoresis measurements are all within 
the experimental error of each other.  
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Fig. 3.2.5. Overview of different IgG constructs expressed in mammalian cells. (a) Schematic 
overview (not drawn to scale) of N-terminal processing of proteins in mammalian cells. Sign. seq. indicates 
the signal sequence. (b) Comparison of the mature N-terminal amino acid sequences of different 
mammalian heavy (H) and light (L) chain variants analyzed in this study. The suffix ʺAʺ corresponds to the 
control tetrapeptide Ala-Gly-Ile-Gln (AGIQ), the tetrapeptide Glu-Ala-Glu-Ala (EAEA) derived from the pro-
region of the αMFpp is abbreviated as ʺEʺ. The combination of both letters indicates the presence of all 
eight additional residues in the order presented. Red colored amino acids are negatively charged. (c) SDS-
PAGE analysis of HEK-produced IgG variants under reducing conditions, stained by Coomassie Blue. H 
and L indicate the respective chains. (d) Secretion level of IgG variants expressed by stably transformed 
HEK293 cells detected by ELISA.  
 
 
Figure 3.2.6 compares structural characteristics of some selected HEK-produced IgGs under native 
conditions and their behavior under thermal and chemically-induced unfolding. CD spectra recorded at 
room temperature for different mammalian variants are practically superimposable, indicating that the 
N-terminal extensions had no effect on the overall structure of the IgG, as expected (Fig. 3.2.6a). On 
the other hand, slight differences for the various E-variants were revealed in thermal denaturation 
experiments measured by intrinsic tryptophan fluorescence (Fig. 3.2.6b). The unfolding curves were 
derived from the intensity ratio of the emission spectrum at 330 nm (F330) and 350 nm (F350) upon 
excitation at 295 nm, plotted as a function of temperature.
57
 One of the biggest advantages of this 
technique is the fact that this ratio is fairly robust against the loss of intensity due to light scattering 
from soluble aggregates. As can be seen in Fig. 3.2.6b, the addition of the EAEA tetrapeptide to the 
light chain seemed to slightly decrease the overall stability of the IgGs.  
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Fig. 3.2.6. Biophysical characterization of IgG constructs produced in mammalian cells. (a) CD 
spectra of different IgGs produced in mammalian cells. The values are reported as mean residue ellipticity 
(θ). (b) Thermal denaturation curves measured by intrinsic tryptophan fluorescence. The curves were 
obtained from the intensity ratio of the emission spectrum at 330 nm (F330) and 350 nm (F350) upon 
excitation at 295 nm, plotted as a function of temperature. A comparison between the different mammalian 
IgG variants is shown. (c) Differential scanning calorimetry (DSC) of the H / L and H-E / L-E construct. 
Indicated by the lines under the curves are the regions in which the individual domains (CH2 domain, Fab 
fragment and CH3 domain) undergo their transitions. (d) Guanidine hydrochloride (GdnHCl)-induced 
denaturation of IgGs expressed in mammalian cells. The denaturation was followed by plotting the 
F330/F350 ratio as a function of increasing GdnHCl concentration. 
 
 
To further investigate this finding, the H / L and the H-E / L-E constructs were examined by differential 
scanning calorimetry (DSC) (Fig. 3.2.6c). This method is especially suitable for distinguishing different 
transitions in multidomain proteins (such as IgGs) that are often “silent” or overlapping in 
spectroscopic methods like intrinsic tryptophan fluorescence. The previous results of a slightly 
decreased IgG stability could be validated, indicating that the H-E / L-E Fab fragment has its transition 
maximum at 74.5°C, compared to 75.8°C for H / L. These results are comparable to those obtained by 
guanidine hydrochloride (GdnHCl)-induced denaturation (Fig. 3.2.6d). In these experiments, the 
denaturation was followed by plotting the F330/F350 ratio as a function of increasing GdnHCl 
concentration. These curves again suggested a slightly reduced stability for those constructs 
containing the EAEA tetrapeptide located at the N-terminus of the light or heavy chain. This overall 
tendency of a slightly reduced stability of the H-E / L-E constructs could further be confirmed by the 
analysis of thermal and chemically-induced unfolding of Pichia-produced IgGs (Supplementary Data 
Fig. S3.2.4).  
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Determination of the aggregation susceptibilities of various IgG constructs 
To test whether the EAEA tetrapeptides are indeed the reason for the very different aggregation 
susceptibilities of HEK- and Pichia-produced IgGs (Fig. 3.2.1), the mammalian variants (equipped with 
these N-terminal extensions) were analyzed by thermal unfolding recorded by CD at 208 nm. For 
clarity, Figure 3.2.7 only compares the signals derived from the most important variants containing the 
EAEA tetrapeptides. Further data from all tested variants including the AGIQ controls can be found in 
Supplementary Data Fig. S3.2.5. The thermal scans provided in Fig. 3.2.7a clearly indicate a dramatic 
increase in the temperature of aggregation onset for those variants carrying the EAEA appendix at the 
N-terminus of their light chain. Interestingly, the H-E / L construct, having the identical appendix but at 
its heavy chain, only showed a minor increase of its aggregation onset temperature (+0.5°C). The 
addition of the control tetrapeptide (Supplementary Data Fig. S3.2.5) even slightly increased the 
aggregation susceptibility of mammalian IgGs (-0.5°C). This indicates that EAEA specifically - and not 
any random peptide - has this beneficial effect detailed above. Panel (a) in Supplementary Data Fig. 
S3.2.5 demonstrates that all constructs represented by reddish symbols have a higher temperature of 
aggregation onset and carry the EAEA tetrapeptide at their light chain.  
 
Fig. 3.2.7. Aggregation behavior of different IgGs obtained from mammalian expression. Shown are 
the signals derived from the most important variants containing the EAEA-tetrapeptides. Further data from 
additional variants can be found in Supplementary Data Fig. S3.2.5. (a) Thermal denaturation curves. The 
denaturation was followed by CD measurements, plotting the signals at 208 nm as a function of 
temperature. A comparison of different mammalian IgG variants is shown and the values are reported as 
MRE. (b) The high tension (HT) voltage signals corresponding to the curves shown in (a) recorded by the 
photomultiplier connected to the CD spectrometer are a measure of sample transparency and thus 
aggregation and subsequent clearance by aggregate precipitation. The values were normalized by setting 
the initial and the highest values of the curves as 0 and 1, respectively. (c) Aggregation of IgG constructs 
measured by light scattering at 500 nm, with excitation and emission at this wavelength. 
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The differences in aggregation susceptibilities could also be verified by the analysis of the signals 
recorded by the photomultiplier connected to the CD spectrometer denoted as high tension voltage 
(HT). The HT signals shown in Fig. 3.2.7b belong to the curves shown in Fig. 3.2.7a (further curves 
can be found in Supplementary Data Fig. S3.2.5a and b). The changes in the HT signals confirmed 
the formation of aggregates which induced scattering of the UV light. As this led to the reduction of the 
number of photons reaching the detector, the HT voltage was increased. The drop of signal intensity 
following the maximum was finally caused by precipitation of the aggregates. The temperatures for the 
maximal HT signal were determined to be 76.5°C for the H / L, 77°C for the H-E / L, 81.5°C for the H / 
L-E and 82.5°C for the H-E / L-E construct, respectively. These results were comparable to those 
derived from the aggregation assay observed in Fig. 3.2.7c. By this method, it could once more be 
shown that the addition of EAEA to the light chain - but not to the heavy chain - resulted in an 
apparent increase in the temperature of aggregation onset for the H / L-E construct by ~5°C, 
compared to the H / L variant. 
The results obtained from the mammalian cell-produced IgGs could be confirmed by the analysis of 
their counterparts produced in the yeast Pichia pastoris. Supplementary Data Fig. S3.2.6 shows the 
analysis of the aggregation behavior of various Pichia-produced IgGs, analyzed by CD spectroscopy 
and the aggregation assay. In agreement with the data derived from HEK IgGs, the presence of the 
EAEA tetrapeptide in the yeast sequences resulted in IgG variants with decreased aggregation 
tendencies - emphasizing that the effect of this peptide on aggregation susceptibility required its 
location specifically at the N-terminus of the light chain. 
To investigate the effect of the four extraneous amino acids at the light chain under more physiological 
conditions, the formation of aggregates after extended incubation of freshly prepared IgGs was 
measured by static multi-angle light scattering (MALS), coupled to size exclusion chromatography 
(SEC). Panels (a) and (b) in Figure 3.2.8 display the normalized light scattering measured for the 
HEK-expressed H / L and H / L-E variants, respectively, after a five day incubation at either 4°C, 37°C 
or 50°C. Incubation at elevated temperatures dramatically increased the light scattering of the control 
IgG (H / L) for an aggregate peak eluting at ~8 ml (panel (a)). This larger signal was due to both an 
increased amount as well as the larger size of these aggregates. Consequently, the monomeric peak 
at ~13 ml decreased in its intensity. This was, however, also partly due to the disassembly of both light 
chains from the antibody, detectable as a little shoulder towards higher elution volumes and in SDS-
PAGE (data not shown). Quite different results were obtained once the EAEA tetrapeptide was 
attached to the light chain. As depicted in panel (b), the amount (i.e. intensity) of the aggregation peak 
did hardly change even under more stressful conditions (50°C) and only a minimal increase in the size 
of aggregates (i.e. a shift towards smaller elution volumes) was detected. As for H / L, the monomeric 
IgG peak, however, still was slightly diminished due to IgG disassembly.  
To get further insights into the effect of the EAEA peptide on long-term stability, IgG samples were 
also incubated for six months at 4°C and afterwards run on an analytical SEC as illustrated in Fig. 
3.2.8c. Although only a small fraction of the sample turned into aggregates (and eluted at ~0.9 ml), a 
clear difference in intensity could be seen for the various constructs. While the H / L variant exhibited 
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an aggregated fraction of almost 3%, this peak was noticeably decreased for the H-E / L-E construct, 
adding up to only 0.5% of the total protein.  
 
Fig. 3.2.8. Aggregation of different IgGs upon incubation at 4°C, 37°C or 50°C analyzed by MALS 
and SEC. (a) Light scattering of the IgG H / L construct, analyzed by multi-angle light scattering (MALS), 
coupled to size exclusion chromatography (SEC). Samples were previously incubated for five days at 4°C, 
37°C or 50°C, respectively. (b) Light scattering of the IgG H / L-E construct. Plotted are the signals 
obtained from samples incubated for five days at 4°C, 37°C or 50°C, respectively. (c) SEC of various HEK-
produced IgG constructs after storage at 4°C for six months. Note that (a) and (b) were done with a 24 ml 
Superdex 200 10/300 GL column, while in (c) a 2.4 ml Superdex 200 PC 3.2/30 column was used. 
 
 
Influence of pH values on the temperature of aggregation onset 
Since the difference between the EAEA peptide and the ineffective control peptide AGIQ are two 
negative charges, the influence of pH values on the aggregation susceptibilities was examined more 
closely. As depicted in Fig. 3.2.9a, even minor changes of the pH value dramatically influenced the 
temperatures of aggregation onset. While the H / L-A construct aggregated at 78.8 ± 0.1°C at the 
same pH as in all previous analyses (pH 7.1), changing it to pH 7.4 increased this temperature to 
80.3 ± 0.1°C, and even further to 81.4 ± 0.1°C in PBS adjusted to pH 7.7. Using a web-based protein 
calculator (www.scripps.edu/ ~cdputnam/protcalc.html) the net charge of the different IgG constructs 
at various pH values was computed. In the second column of Fig. 3.2.9b, the net charges of full-length 
IgG consisting of both heavy and light chains are shown for various pH values. Adding the EAEA 
extension to the light chain (third column) had the same effect on the protein's overall charge as 
increasing the pH by 0.35 units, namely adding four negative charges to the molecule (two for each 
light chain). This addition of negative charge had such a dramatic effect on aggregation susceptibility 
since the charge of the H / L construct is minimally positive at the pH values generally used throughout 
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this study (pH 7.1). Therefore, lowering the overall charge by four units has a rather profound effect on 
the net charge of the whole molecule.  
 
 
Fig. 3.2.9. Influence of the pH on the aggregation of IgG. (a) Aggregation of IgG H / L-A construct 
measured by light scattering at 500 nm. Samples were previously equilibrated in PBS buffer at the 
indicated pH. (b) Overview of the overall charge of the different IgG constructs at various pH values. 
Analyses were performed using the web-based protein calculator (www.scripps.edu/~cdputnam/ 
protcalc.html). In the first three columns, the results for the full-length IgG consisting of two heavy and light 
chains (including indicated N-terminal appendices) are shown. Two additional negative charges have been 
considered due to the formation of N-terminal pyroglutamate residues at the heavy chain, thus lacking the 
positively charged N-terminal amino group. The last column specifies the charges derived from analyzing 
only one light chain.  
 
 
 
Transfer of findings onto a second IgG construct 
Finally, we analyzed to which extent our findings could be transferred to other IgG constructs. Since 
the effect seemed to be related to the overall charge of the molecule, we chose a completely unrelated 
IgG as an alternative model system. Having very different CDR regions in its kappa light chain and 
thereby a comparatively high isoelectric point (pI) of 6.9 (the previously used lambda light chain has a 
pI of 4.9 due to its acidic CDRs), this construct had a completely different range of overall IgG 
charges. When tested in the aggregation assay (Fig. 3.2.10a), the yeast-produced version with its 
different glycan moiety indeed aggregated at higher temperatures compared to its mammalian 
counterparts (88.4 ± 0.1°C vs. 82.2 ± 0.1°C), indicating that this glycan effect seems to be general. 
However, once the glycans were removed by PNGase F treatment, only minor differences in the 
temperature of aggregation onset were observed (Fig. 3.2.10b; 86.4 ± 0.1°C vs. 85.5 ± 0.3°C). The 
reason for this might be that the overall charge of this new IgG construct is more positive than for the 
first analyzed IgG, such that the addition of the EAEA tetrapeptide has a less profound influence on 
the overall charge in this case (Fig. 3.2.10c).  
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Fig. 3.2.10. Aggregation behavior of a second, kappa-light chain containing IgG. Comparison of a 
different IgG expressed in either P. pastoris or mammalian cells. The mammalian construct is of the H / L 
design whereas the IgGs from the Pichia system are still of the H-E / L-E format. Shown are the light 
scattering data of (a) the original and (b) the PNGase F-deglycosylated IgGs. The additionally detectable 
light scattering signal starting at ~56°C is due to the unfolding and aggregation of the PNGase F enzyme. 
(c) Overview of the overall charge of the second IgG constructs at various pH values. Analyses were 
performed using the web-based protein calculator (www.scripps.edu/~cdputnam/protcalc.html) (as in Fig. 
3.2.9b). Two additional negative charges have been considered due to the formation of N-terminal 
pyroglutamate residues at the heavy chain, lacking the positively charged N-terminal amino group. 
 
 
Discussion 
When immunoglobulin G molecules of identical amino acid sequence were produced in different 
eukaryotic systems, dramatic differences in their aggregation susceptibilities were encountered. This 
observation turned out to be due to two major factors: (i) differences in the glycan structures and (ii) 
residues remaining from the Pichia secretion system used, the α-factor pre-pro sequence (αMFpp).  
 
Glycan structures 
Antibodies of the IgG format are N-glycosylated at the Asn297 position in their CH2 domains. These 
domains, having the lowest stability within the IgG molecule,
58
 are the only ones not having any direct 
protein-protein interaction and solely contact each other by their sugar moieties. The attached glycans 
have proven to fulfill multiple roles in the maturation and function of IgGs. In general, glycosylation is a 
means of "quality control" in the eukaryotic ER.
59; 60
 Indeed, the glycosylation of the antibody’s CH2 
domain has recently been shown to be a critical step in antibody folding.
61; 62
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In the mammalian IgG molecule, the sugars have further taken on the functional role of enabling the 
antibody to bind to the activating Fcγ receptors.
18
 This has been interpreted as the sugars mediating 
both the distance and the relative mobility of the domains towards each other, which is necessary 
since Fcγ receptors bind the CH2 domains near the hinge region.
63-66
 Even one single fucose residue 
can decrease the affinity of IgG for FcγRIII as it sterically interferes with the receptor's own 
oligosaccharide,
67
 while fucosylated IgGs still bind to the inhibitory FcγRII equally well, having 
important consequences for glycoengineering. 
Nonetheless, an increasing number of therapeutic programs are not aiming for FcγR activation, but 
indeed actively avoiding it.
68
 Thus, it is worthwhile to consider alternative expression systems for IgG 
production, including the yeast Pichia pastoris. For this production system, however, the role of 
glycosylation for the stability of the native IgG under storage and in vivo conditions has to be 
considered. When comparing IgGs with complex glycosylation from HEK293 cells to those containing 
Pichia-produced mannose-rich glycosylation, we found two decisive differences. First, the melting 
temperature of the corresponding CH2 domain and thereby of the whole IgG is lowered when 
produced in Pichia, as can be seen by three independent techniques: circular dichroism (Fig. 3.2.1a), 
intrinsic tryptophan fluorescence (Supplementary Data Fig. S3.2.1f) and differential scanning 
fluorimetry (DSF, Supplementary Data Fig. S3.2.1d). In the latter technique, which like DSC offers 
increased resolution of the thermal unfolding of different domains, the shift in the stability of the CH2 
domain to lower temperatures due to the Pichia glycosylation is clearly visible. The second difference, 
however, is more than counterbalancing this negative effect: As detailed above, IgGs with Pichia 
glycosylation are much less prone to aggregation.  
In agreement with our data, Pichia glycans carry more sugar units and are known to be rich in 
mannose units,
22
 which may sterically block the initial docking of IgGs to each other at the onset of 
aggregation. It is also known that these oligosaccharides may contain several mannosylphosphates, 
transferred to both the core and outer sugar chains.
21; 22; 69; 70
 However, our analysis showed that our 
IgGs produced in Pichia pastoris carried no negative charge - and thus no mannosylphosphate - in 
their oligosaccharides. We arrived at this conclusion by isoelectric focusing (IEF) analysis of the IgGs. 
It revealed that the isoelectric points (pI) of both Pichia and HEK produced antibodies before and after 
deglycosylation by PNGase F were almost identical (see Supplementary Data Fig. S3.2.7). If a 
negative charge had been removed from the IgGs produced in Pichia, this would have been seen as a 
shift upwards to less negative pI upon deglycosylation. In addition, the running behavior of Pichia 
produced IgGs on ion exchange chromatography did not change upon deglycosylation (data not 
shown) – an effect that would have been expected if a certain fraction of the resulting Pichia glycans 
had possessed negative charges on their mannose units. Therefore, the beneficial effect of the Pichia 
glycans conferring resistance to aggregation does not seem to be based on any glycan contribution to 
the protein's overall charge.  
To highlight the importance of the glycan moiety, we have included unglycosylated T299A IgG 
constructs in our studies, confirming the role of the sugars for stability and in protection against 
aggregation (Supplementary Data Fig. S3.2.1 and Fig. 3.2.1c). Unglycosylated IgGs melt at lower 
temperatures and are more aggregation prone than IgGs glycosylated with either Pichia or mammalian 
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oligosaccharides - a finding consistent with previous observations.
71
 Fig. 3.2.11 compares the 
aggregate formation for IgGs with identical primary sequences and N-terminal extensions (H-E / L-E 
constructs) made in either expression system. Upon deglycosylation by PNGase F, the molecules 
should be of identical composition, whether expressed in either mammalian or Pichia cells, except for 
the removal of the C-terminal lysine from the heavy chains in mammalian cells, which was not 
observed to occur for the Pichia constructs. Indeed, the curves indicating the aggregation behavior are 
almost identical. 
 
Fig. 3.2.11. Aggregation behavior of the same IgG constructs produced in different mammalian 
expression systems. (a) Aggregation of the IgG H-E / L-E construct produced in either P. pastoris (PP) or 
mammalian cells (HEK293). Having identical amino acid sequences, these samples only differ with respect 
to their post-translational modifications such as glycosylation. Aggregation was measured by light 
scattering at 500 nm and plotted as a function of temperature. (b) Aggregation of the same IgGs as in (a) 
in their deglycosylated state. Samples were treated by PNGase F prior to analysis by light scattering.  
 
Taken together, the Pichia glycosylation has the surprising effect of protecting the IgG against 
aggregation better than the mammalian complex sugar moiety. For future applications, this must of 
course be weighed against the therapeutic necessity of FcγR activation. Recently, glycoengineered 
Pichia strains have been developed and meanwhile successfully applied to the production of 
monoclonal antibodies, such that options for both types of glycosylation exist.
23-26
  
 
Processing in Pichia pastoris 
Most secreted recombinant proteins produced in P. pastoris are constructed as fusions to the α-factor 
pre-pro sequence (αMFpp) derived from S. cerevisiae.
72
 The α-factor peptide itself is separated by a 
EAEA spacer from the pro-sequence, necessitating a two-step cleavage by Kex2 and DPAPaseA.
73
 
Next to making the Kex2 processing site accessible, the spacer could also help to keep the resulting 
product more aggregation-resistant by providing charged extensions. While the natural α-factor 
peptide is soluble, the precursor contains several copies of the mature peptide, and thus it is 
conceivable that some intermediate processing products will benefit from increased solubility. 
Once a recombinant protein is to be secreted with this system, the question arises whether this spacer 
should be included or not. It has previously been shown that its inclusion can increase the amount of 
correctly processed material by preventing steric hindrance of the Kex2 cleavage site.
74
 Whether this 
is necessary for the specific POI may depend on its primary sequence around the cleavage site,
75
 its 
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structure and thus the accessibility to Kex2, and potentially its aggregation tendency, as postulated in 
this study. While the inclusion of the spacer generally enhances the cleavage efficiency of this 
endopeptidase specific for dibasic sites, several studies have demonstrated problems with the 
subsequent proteolytic processing of the EA repeats.
54-56; 76
 Apparently, the quantity and / or activity of 
the STE13-encoded dipeptidyl aminopeptidase A in the secretory pathway is not sufficient to process 
these repeats for large amounts of recombinant protein expressed under strong promoters. The 
resulting secretion of molecules with amino-terminal EAEA extensions was also observed for both the 
heavy and the light chain of the initial IgG constructs expressed in the Pichia system in this study.  
Since the presence of these amino-terminal extensions can be undesirable for many applications and 
even might create a new immunogenic epitope,
77
 the omission of the EAEA tetrapeptides was 
evaluated, aiming to achieve authentic N-termini at both the heavy and light chain. This simple 
strategy worked well for the expression of the light chain components, leading to proteins of the 
correct sequence, while causing only a slight reduction of the total amount of secreted IgGs (Fig. 
3.2.4c: H-E / L-E vs. H-E / L).  
However, deleting the EA dipeptides from the heavy chain constructs caused severe problems in its 
maturation process. Three species of resulting heavy chain proteins were observed: (i) a fraction 
containing the complete and unprocessed pro-region, (ii) molecules containing the last nine amino 
acids of the pro-region on its N-terminus (resulting from incorrect processing), and (iii) the correctly 
processed heavy chain. Similar results were achieved when analogous changes were carried out with 
Fab fragments (data not shown). The underlying decreased Kex2-cleavage efficiency in the absence 
of a spacer is in agreement with previous studies reporting that expression of proteins without the 
EAEA spacer peptide led to the secretion of incompletely or incorrectly processed proteins.
78-80
 
Remaining precursor was observed when onconase was fused to the αMFpp without the EAEA 
spacer.
81
 The problem of uncleaved pro-regions seems not to be specific for the Pichia system, as 
similar findings had already been observed earlier for the expression of an insulin precursor in 
S. cerevisiae with the αMFpp system in the absence of any EAEA spacer.
82
  
The presence of an additional cleavage site within the pro-region was also previously described for a 
different single-chain antibody in VH-linker-VL orientation.
55
 However, in that case, eleven residues 
from the carboxy-terminus of the pro-region were found to be attached to the protein, resulting from a 
cleavage at position 57 of the pro-region between ..-I-A║A-K... (where ║ indicates the Kex2 cleavage 
site). In our case, this cleavage was shown to have occurred between ..-A-K ║ E-E-.. and thereby two 
residues further downstream in the pro-region, resulting in an extension of only nine residues. This site 
actually seems to be more reasonable for Kex2 cleavage, taking into account that the ʺoriginalʺ Kex2 
cleavage site (..-K-R ║ E-A-..) has a similar charge distribution, possessing a basic amino acid in the 
P1 position just upstream of the cleavage site and an acidic residue in the adjacent P1’ position. While 
general DPAPase A processing can probably be increased by just overexpressing the enzyme, it 
would be expected that this incorrect cleavage would remain as a side reaction, and thus DPAPase A 
overexpression might not lead to homogeneous product either. 
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Secretion without the pre-pro-α-factor pro sequence 
In principle, the signal sequence alone is sufficient for antibody secretion to the medium in eukaryotic 
cells and the pro-sequence of the α-factor is not needed. The role of the pro-region for efficient 
secretion has been investigated before for other proteins like the lipase Lip1p.
75
 This protein could be 
expressed and secreted either under the direction of the α-factor pre or pre-pro sequence - however, 
the highest level of secretion was achieved by the construct with the full pre-pro sequence. In contrast, 
here the deletion of the complete pro-region from the heavy chain did not only lead to a product with 
the correct N-terminus, but also increased the amount of correctly assembled antibody found in the 
cell supernatant by 25% or 40% for the IgG or Fab fragment, respectively (Fig. 3.2.4c and d). While 
this study revealed that deleting the pro region is the only option for the heavy chain to obtain 
homogeneous protein with the genuine N-terminus, correctly processed light chain can be produced 
either with the pro-region (in the absence of EAEA) or even in the absence of the pro-region. Yet, for 
the light chain, the deletion of the pro-region resulted in a reduction of total protein yield by ~30% (ʺH-
pro-del / Lʺ vs. ʺH-pro-del / L-pro-delʺ constructs, see Fig. 3.2.4c). Thus, the highest yield of genuine 
IgG without N-terminal extensions can be obtained after deletion of the complete pro-region for the 
heavy chain, and the presence of the pro-region but absence of the EAEA tetrapeptide for the light 
chain (Fig. 3.2.4c).  
 
The tetrapeptide extensions influence protein aggregation but not stability 
To analyze the impact of various amino-terminal extensions on the biophysical characteristics of the 
IgGs, the ability to attach any extension to the N-terminus of any chain was crucial. Therefore, these 
constructs were expressed in HEK293 cells. Analysis of the sequences of the new constructs (Fig. 
3.2.5b) by the signal sequence prediction software SignalP 3.0
83
 (www.cbs.dtu.dk/services/SignalP) 
predicted that all variants should be processed correctly. Indeed, all constructs could be expressed 
and were confirmed to be homogeneous and in agreement with their design by mass spectrometry, 
SDS PAGE and sandwich ELISA. Nonetheless, compared to the H / L construct, slightly lower levels 
of IgG were found in the supernatant (~70% for the H / L-E and H-E / L constructs and 88% for the H-
E / L-E variant, respectively) (Fig. 3.2.5d). Further investigations will have to clarify which step in 
biosynthesis is responsible for these differences.  
Once stable cell lines were established for all mammalian constructs, their biophysical properties could 
be analyzed in detail. As expected, the amino-terminal extensions of either the heavy or the light chain 
- individually or combined in the same construct - only very slightly influenced these characteristics 
(Fig. 3.2.6). Only a slight decrease of ~1°C was encountered for H-E / L-E compared to the original 
H / L construct in the Fab transition within the IgG in differential scanning calorimetry (Fig. 3.2.6c, 
Supplementary Data Fig. S3.2.4). A dramatic difference, however, became apparent for the 
aggregation susceptibilities of the different constructs. As depicted in Fig. 3.2.7, the presence of the 
amino-terminal EAEA tetrapeptide at either N-terminus generally enhanced the temperature of 
aggregation onset. Strikingly, this increase was more pronounced for the EAEA extension on the light 
chain. From a comparison with the extension with the AGIQ control tetrapeptide (Supplementary Fig. 
3. Results 
 
88 
S3.2.4), these findings indicate that the two negative charges of the EAEA extension could be partially 
responsible for the reduced susceptibility of the resulting IgG molecules towards aggregation.  
 
The influence of charge and location on the effect of the EAEA extension 
Our data indicate that the EAEA tetrapeptide extension has more influence on preventing aggregation 
once it is added to the light chain rather than to the heavy chain of the antibody studied (Fig. 3.2.7c). 
One obvious difference between the two chains is the presence of pyroglutamate as the N-terminal 
residue of the heavy chain produced in mammalian cells. MS data and the results of Edman 
sequencing indicated that the encoded glutamine is indeed converted into pyroglutamate, as 
commonly seen for IgGs in general.
51
 Since pyroglutamate formation from glutamine results in the loss 
of the positively charged N-terminal amino group, it slightly lowers the isoelectric point of the antibody.  
If any tetrapeptide (either AGIQ or EAEA) is N-terminally attached to the heavy chain, the cyclization 
reaction forming pyroglutamate cannot take place anymore and the new construct will carry this 
original positive charge at its glutamine residue again plus any charges introduced by the peptide side 
chains. Therefore, the addition of AGIQ adds an additional positive charge to the IgG, while the 
addition of the EAEA tetrapeptide to the heavy chain introduces only one new net negative charge (the 
second one is canceled out by the positive charge of the free N-terminal amino group). Interestingly, 
the newly N-terminally located glutamic acid of the EAEA tetrapeptide was not found to have 
undergone the cyclization reaction into pyroglutamate (data not shown), even though the formation of 
pyroglutamate from N-terminal glutamate should in principle be possible as well.
84
  
When the EAEA extension is present on the light chain, which carries an N-terminal amino group, both 
its negative charges are added to the protein's net charge. Taking all findings together, it seems that 
the EAEA tetrapeptide with its two negative charges is beneficial for the IgG’s resistance to 
aggregation. In general, its exact location within the molecule might per se not be of great importance, 
as the H / L-EA construct (where the EAEA extension is spaced by the AGIQ tetrapeptide from the N-
terminus of the light chain) also exhibited an increased aggregation resistance. However, the loss of 
the pyroglutamate residue might reduce the effect of this extension at the heavy chain. 
Our hypothesis that the positive impact of the EAEA tetrapeptide is very likely based on its effect on 
the overall charge of the antibody molecule was further corroborated by the observation that the exact 
temperature of aggregation onset depends on the pH of the sample (Fig. 3.2.9). As the charge of the 
H / L construct is almost neutral at the pH value generally used throughout this study (pH 7.1), this 
sequence extension has a rather dramatic effect, causing the whole molecule to possess a clearly 
negative net charge. The only marginally negative charge of the original constructs at pH 7.1 
originates from the nature of their CDR regions. While the isoelectric points (pI) of the backbones are 
8.2 and 5.5 for the heavy and light chain, respectively (determined by the analysis tool on the ExPASy 
server http://web.expasy.org/compute_pi), the basic pI of the CDRs within the heavy chain are 
"compensated" by a very acidic pI of the light chain’s CDRs (9.2 and 4.1, respectively). The reason for 
the pH affecting mostly the net charge of the heavy chain lies in its larger number of histidine groups. 
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Application aspects of these findings 
The beneficial effect of the EAEA tetrapeptide on the aggregation susceptibilities of the analyzed 
antibodies was not only seen when the IgGs were analyzed by gradual heating. When freshly 
produced IgG variants were incubated for five days at various temperatures, clear differences in the 
formation of aggregates could be detected by MALS analyses (Fig. 3.2.8). Aggregate accumulation 
was seen for the H / L construct, while for the EAEA containing H / L-E construct neither the amount 
nor the size of aggregated IgGs noticeably increased. Also, when the antibodies were stored at 4°C 
for several months and subsequently analyzed by SEC, the H-E / L-E construct possessed the 
smallest aggregated fraction. The percentages derived from comparing this fraction’s aggregates with 
that of H / L aggregates (0.5% vs. 3%) might sound insignificant and negligible - however, it should be 
kept in mind that the samples were stored at a relatively low protein concentration of 1 mg/ml. Since 
antibodies administered in the clinic are generally stored and used at much higher concentrations, this 
small difference might then increase dramatically. 
To transfer the results of this study to other antibodies, it is important to understand to what degree the 
findings can be generally applied. Using another unrelated IgG, whose pI is substantially higher due to 
its CDR regions (light chain alone: 6.9 vs. 4.8; complete IgG: 8.9 vs. 7.2) and which is thereby more 
positively charged at pH 7.1, we found that there was only a small influence of the EAEA tetrapeptide 
(Fig. 3.2.10b). To test these effects, the IgGs were produced in HEK293 cells (which leads to correct 
processing to the genuine N-terminus) or in Pichia pastoris, where the EAEA tetrapeptide was still 
attached on both chains, and subsequently analyzed in the glycosylated and deglycosylated state. 
Compared to the previously analyzed antibody, this IgG has a substantial positive net charge at 
neutral pH (Fig. 3.2.10c), and even though its charge is diminished by the EAEA extension, this has 
only a very small effect. It thus implies that the EAEA extension will be most promising for antibodies 
whose net charge can be boosted significantly by this extension. 
The results obtained from the second IgG, however, also indicated the transferability of the other 
finding of this study. The glycosylated Pichia-produced IgG generally showed a higher resistance to 
aggregation compared to its counterpart from mammalian cells. This result suggests that the improved 
aggregation protection by the mannose-rich oligosaccharide is seen in this antibody too, despite its 
high isoelectric point. It is thus likely to be a general phenomenon that might be transferable to other 
molecules as well.  
Taken together, the present finding indicate that the convenient production in the host Pichia pastoris 
has an unexpected benefit, as it leads to antibodies being more resistant to aggregation due to both 
the Pichia glycosylation as well as the residual tetrapeptides left by the α-factor pre-pro secretion 
system. Importantly, through these modifications, aggregation of the IgG was also prevented under 
physiological conditions, such as after an extended time at 37°C. Nonetheless, the magnitude of these 
effects will be antibody-dependent, with the net charge seemingly being a good predictor. 
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Comparison with other proteins 
The present findings are in agreement with previous analyses showing that the solubility of proteins 
can be enhanced by the introduction of charged residues resulting in an altered overall protein 
charge.
85; 86
 In addition, our results match previous studies showing that single VH domains that are by 
themselves resistant to aggregation generally possess a greater negative net charge than their 
aggregation-prone counterparts.
86-88
 This correlation has, however, never been reported for full-
lengths IgGs so far. A similar connection between pI values and aggregation susceptibility has been 
presumed for single-domain camelid VHH antibodies. Although possessing partially lower 
conformational stabilities compared to their human VH counterparts, these molecules mainly unfold 
reversibly and resist aggregation.
42; 89
 Following a similar reasoning, a human VH domain prone to 
aggregation could be converted into an aggregation-resistant variant by introducing negatively 
charged residues within or near the CDR1 loop.
88
 However, in the same study it was shown that other 
negatively charged mutations in the most solvent-exposed residues outside of the CDRs were 
incapable of suppressing the parent VH's aggregation propensity. Therefore, the authors concluded 
that the simple difference in the net charge of this domain antibody might not be responsible for the 
improvements of the aggregation propensities. Instead, the specific locations of the mutations seemed 
to be of great importance. Our results, however, indicate that an N-terminal placement of negatively 
charged residues might be sufficient to increase aggregation resistance. This strategy circumvents the 
concern that the introduction of charged residues into the CDR regions may abolish the antibody-
antigen recognition directly or indirectly by altering the loop conformation.
88
 
Generally, it appears that the N-terminal location is particularly suitable for the addition of charges, as 
it has diminished the aggregation of a molecule as large as an IgG. Compared to the previously 
mentioned study by Perchiacca and colleagues
88
, the strategy resulting from our results should be 
more easily applicable to a large variety of molecules, as the charged EAEA extension can readily be 
attached to any molecule by simple cloning. In addition, there is no risk that these new residues might 
disturb the structure of the IgG as they are not inserted within the domains. Importantly, the present 
study could confirm that the various amino-terminal extensions did not affect the binding of the IgG 
variants to their antigen. As depicted in Supplementary Data Fig. S3.2.3, these interactions were 
analyzed for several mammalian constructs and the determined affinities were unaltered within 
experimental error. 
 
Conclusions 
Taken together, our results indicate that the production of full-length IgG in the yeast Pichia pastoris - 
being attractive for large scale preparations due to its convenient handling - is possible and results in 
molecules with the desired antigen-binding and thermal stability. However, obtaining correctly 
processed IgGs requires the direct fusion of a signal sequence to the heavy chain. When using the 
commonly utilized α-factor pre-pro secretion system, the secreted antibodies will contain the EAEA 
extension at both N-termini. Removing this extension from the coding sequence can easily be 
performed for the light chain, but will generate heterogeneous processing for the heavy chain. Most 
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surprisingly, antibodies produced in Pichia pastoris proved to be more resistant to aggregation than 
their counterparts with identical primary sequences produced in mammalian cells. This was shown to 
be caused by the mannose-rich glycosylation and the residual EAEA extensions. While the former 
effect appears to be general, the latter is most pronounced when this tetrapeptide addition can 
significantly increase the net negative charge of the antibody. Furthermore, these results show that the 
addition of a mere four amino acids to a protein of several hundred residues can have a dramatic 
impact on its biophysical characteristics. In a broader view, these findings could have important 
implications for the common approach of adding tags to a protein of interest, as it is generally 
assumed that few additional amino acids will not have major effects on the molecule and its properties. 
 
 
Material and Methods 
 
Cell Culture 
 
Materials and cultivation of mammalian and Pichia cells 
All media and supplements for mammalian expression were purchased either from Sigma-Aldrich 
(MO, USA), Invitrogen (CA, USA) or Amimed (BioConcept, Switzerland). The antibiotics that were 
used, Zeocin
TM
 and Hygromycin B, were bought from Invitrogen or PAA (Austria), respectively. All 
solutions used were sterilized by filtration through 0.22 µm filters (Millipore, MA, USA). Stably 
transformed human embryonic kidney (HEK) 293 cells were maintained in Dulbecco's Modified Eagle 
Medium (DMEM, Sigma-Aldrich; high glucose: 4.5 g/l) supplemented with 10% v/v heat-inactivated 
Fetal Bovine Serum (FBS, Amimed) in a humidified incubator under 5% carbon dioxide at 37°C. 
Expression of IgGs was carried out in DMEM supplemented with 5% v/v FBS (instead of the more 
commonly used 10%). For secretion of IgGs, derivatives of the vector pcDNA5 (Invitrogen) containing 
constitutively active CMV promoters upstream of the endogenous IgG signal sequences were used. 
For all work with Pichia pastoris, the strain SMD1163 (his4 pep4 prb1; Invitrogen) was used. All media 
and supplements for this work were purchased either from Sigma-Aldrich or Invitrogen. All work was 
performed in a sterile laminar flow bench, and yeast growth was generally performed at 30°C. 
Selection of clones stably expressing the IgGs was based on Zeocin
TM
 resistance. For secretion of 
IgGs, derivatives of the pGAPZαB vector (Invitrogen) containing the constitutively active P. pastoris 
GAP promoter followed by the α-factor pre-pro (αMFpp) region were used. Yeast extract-peptone-
dextrose (YPD) medium containing 20 g/l peptone, 10 g/l yeast extract and 20 g/l D-glucose (plus 20 
g/l agar for YPD-agar) was used for routine growth and subculturing of Pichia cells. Zeocin
TM
 was 
added to a final concentration of 100 µg/ml. IgG expression was performed in the phosphate-buffered 
medium BMGY (20 g/l peptone, 10 g/l yeast extract, 100 mM potassium phosphate pH 6.0, 1.34% 
yeast nitrogen base (YNB) without amino acids, 1% w/v glycerol, 400 µg/l biotin) in the absence of 
antibiotic. 
 
Construction of Expression Plasmids 
Unless stated otherwise, all molecular biology methods were performed according to standard 
protocols.
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 All enzymes used for cloning were purchased from New England Biolabs (MA, USA) or 
Fermentas (Germany). In general, cloning and propagation of all plasmids was carried out in 
Escherichia coli DH5α (Life Technologies, CA, USA), grown at 37°C in low salt LB Broth (10 g/l Bacto-
tryptone, 5 g/l yeast extract, 5 g/l NaCl, pH 7.5) containing 25 µg/ml Zeocin
TM
 for the Pichia plasmids 
or in 2YT broth (16 g/l Bacto-tryptone, 10 g/l yeast extract, 5 g/l NaCl, pH 7.5) containing 100 µg/ml 
Ampicillin (AppliChem, Germany) for mammalian vectors. 
Construction of initial expression plasmids are described in detail in Chapter 3.1. In summary, the 
vectors used for the creation of stable cell lines contained the genes for the light and heavy chain as 
complete individual expression cassettes, i.e. both genes had their own constitutively active promoter 
as well as their own downstream polyadenylation sequence. The attachment of additional appendices 
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to the N-termini of mammalian heavy and light chains was achieved by overhanging primers and PCR. 
The upstream regions of the heavy or light chain coding sequences were amplified with forward 
primers annealing upstream of the CMV promoter region and reverse primers introducing the new N-
terminal appendices. The following forward primers were used for the heavy (H) or light (L) chain: 
HEK_H_for (5′ GCG TTT CTG GGT GAG CAA AAA CAG GAA GGC 3′) and HEK_L_for (5′ GGC ACT 
GTC CTC TCA TGC GTT GGG TCC 3′). The reverse primers were HEK_H-E_rev (5′ GCC AGC CAA 
TTG CAC CTG AGC TTC AGC CTC GGA CAG GAC CCA TCT GGG AGC TGC CAC CAG CAG G 
3′), HEK_H-A_rev (5′ GCC AGC CAA TTG CAC CTG TTG AAT TCC TGC GGA CAG GAC CCA TCT 
GGG AGC TGC CAC CAG CAG G 3′), HEK_L-E_rev (5′ GCAT GATATC AGC TTC AGC CTC AGC 
CCA GGA TCC TGT GCC CTG AGT GAG G 3′), HEK_L-A_rev (5′ GCAT GATATC TTG AAT TCC 
TGC AGC CCA GGA TCC TGT GCC CTG AGT GAG G 3′) and HEK_L-EA_rev (5′ GCAT GATATC 
TTG AAT TCC TGC AGC TTC AGC CTC AGC CCA GGA TCC TGT GCC CTG AGT GAG G 3′). 
Regions coding for the new appendices are underlined while restriction sites used (MfeI or EcoRV for 
the heavy or light chain, respectively) are printed in italics.  
 
For each heavy or light chain fragment, a standard PCR using Phusion high-fidelity DNA polymerase 
(Finnzymes, acquired by Thermo Scientific) was carried out with a final concentration of 0.5 µM for 
each forward and reverse primer in the presence of 3% v/v DMSO. The PCR parameters were as 
follows: pre-denaturation at 98°C for 30 s, followed by 27 cycles of denaturation at 98°C for 10 s, 
annealing and extension at 72°C for 50 s, followed by a final incubation for 5 min at 72°C. The 
resulting PCR products were purified using a PCR clean-up kit (Macherey-Nagel, Germany) and 
digested with BglII and MfeI for the heavy chain or AflII and EcoRV for the light chain, respectively. 
Finally, these inserts were ligated into the identically treated and dephosphorylated initial expression 
vectors, yielding the final plasmids subsequently sequenced using standard techniques. 
The removal of the EAEA tetrapeptide from the initial yeast heavy chain construct was performed by 
assembly PCR in three steps: (i) Amplification of both the region upstream of the intersection of the 
αMFpp with the gene encoding either the heavy or light chain as well as of the region downstream of 
it, both lacking the sequence encoding the EAEA tetrapeptide, (ii) assembly of fragments by an 
overlapping PCR method and (iii) amplification of full-length products. The upstream region was 
amplified using the oligonucleotides PP_out_H_for (5′ GGA AGG AGT TAG ACA ACC TGA AGT CTA 
GGT CCC 3′) and the reverse PP_H_rev (5′ C CAA TTG CAC CTG TCT TTT CTC GAG AGA TAC 
CCC TTC TTC TTT AGC 3′) while the downstream fragment was amplified by using PP_out_H_rev (5′ 
CCG GAG ACA GGG AGA GGC TCT TCT GC 3′) and PP_H_for (5′ CT CTC GAG AAA AGA CAG 
GTG CAA TTG GTA CAG TCT GGT CCG GG 3′). For the deletion of the EAEA tetrapeptide from the 
light chain construct, the primers were adjusted to the following: PP_out_L_for (5′ CGT GGA GGT 
GCA TAA TGC CAA GAC AAA GCC GC 3′), PP_L_rev (5′ GGT CAG TTC GAT ATC TCT TTT CTC 
GAG AGA TAC CCC TTC TTC TTT AGC 3′), PP_out_L_rev (5′ CTA GGA CGG TTA ACT TCG TGC 
CGC CGC C 3′) as well as PP_L_for (5′ CT CTC GAG AAA AGA GAT ATC GAA CTG ACC CAG 
CCG CCT TCA GTG 3′). Regions complementary to the mature N-terminus of the heavy or light chain 
are underlined, while those annealing to the remaining pro-region of the αMFpp are printed in italics.  
The different fragments were generated by PCR using the respective forward and reverse 
oligonucleotides on the initial expression plasmid. The PCR was performed as follows: 30 s at 98°C; 
followed by 25 cycles of 10 s at 98°C and 50 s 72°C; followed by a 5 min final extension cycle at 72°C. 
The PCR products were purified using the same PCR purification kit as above and served as 
templates in the subsequent overlapping PCR. In this second PCR reaction, the outer primers (e.g. 
PP_out_H_for and PP_out_H_rev for the heavy chain; 0.5 µM each) were added to 15 ng of each 
purified PCR product. Twenty cycles of amplification (denaturation at 98°C for 10 s, annealing and 
extension at 72°C for 55 s) were performed, resulting in full-length fragments that were MluI/BstEII or 
HpaI/SacII digested (for the heavy and light chain, respectively) and finally inserted in the 
appropriately cut initial vector. 
The deletion of the complete pro-region in the H-pro-del construct was performed in almost the same 
manner, albeit using different primers in the first PCR. PP_H-pro-del_for (5′ CC TCC GCA TTA GCT 
CAG GTG CAA TTG GTA CAG TCT GGT CCG G 3′) as well as PP_H-pro-del_rev (5′ C CAA TTG 
CAC CTG AGC TAA TGC GGA GGA TGC TGC GAA TAA AAC AGC 3′) were used. The 
oligonucleotides for the pro-region deletion of the light chain construct were PP_L-pro-del_for (5′ CC 
TCC GCA TTA GCT GAT ATC GAA CTG ACC CAG CCG CCT TCA GTG 3′) and PP_L-pro-del_rev 
(5′ GGT CAG TTC GAT ATC AGC TAA TGC GGA GGA TGC TGC GAA TAA AAC AGC 3′). As in the 
primers above, regions complementary to the mature N-terminus of the heavy chain are underlined 
while, this time, those parts annealing to the remaining pre-region of the αMFpp are printed in italics.  
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Design of glycan knockout mutants T299A 
To analyze the influence of the glycan moiety attached to Asn 297 in the CH2 domain of the heavy 
chains, the glycan knockout construct T299A was designed. The ACG, coding for the threonine in the 
glycosylation motif Asn297-Ser298-Thr299, was mutated to the alanine encoding GCG using the 
QuikChange
®
 site-directed mutagenesis kit from Stratagene (acquired by Agilent, USA) according to 
the manufacturer’s instructions. Mutagenesis was performed with the following primers encoding the 
mutated triplet: IgG_deglyc_for (5′ G GAG CAG TAC AAC AGC GCG TAC CGG GTG GTC 3′) and the 
complementary reverse primer IgG_deglyc_rev (5′ GAC CAC CCG GTA CGC GCT GTT GTA CTG 
CTC C 3′). After selection and sequencing, a correct clone was digested by EcoNI, cleaving twice in 
the human γ1 constant region within the CH1 and the CH3 domain, and the resulting fragment was 
inserted in the original vector cut with the same enzyme. After the selection of a construct with the 
correct orientation of the insert, the final vectors were re-sequenced and prepared for transformation. 
 
Creation of stable cell lines 
Flp-In HEK293 cell lines (Invitrogen), stably expressing the IgG of interest and secreting it into the 
culture medium, were generated according to the instructions of the Flp-In system manual. For this 
purpose, the expression cassettes for both the heavy and light chain genes were cloned into the 
pcDNA5/FRT vector and finally inserted at a specific location in the genome by the Flp recombinase 
within the cell. After selection, ten single clones of each construct were tested for expression of the 
desired IgG by Western blot analysis of the supernatant. More than 90% of the analyzed clones were 
positive for the desired IgG.  
For the Pichia constructs, the corresponding plasmids containing both genes for the light and heavy 
chain under the control of constitutively active GAP promoters within one plasmid were linearized by 
BglII and integrated into the yeast genome upon transformation of competent P. pastoris. Finally, 
several colonies per construct were re-plated on fresh YPD-agar plates and subsequently analyzed for 
IgG expression by Western blot. 
 
Large scale expression of IgG 
For large scale expression of mammalian IgGs, 3 x 10
7
 cells stably expressing the respective IgG 
were seeded in 500 cm
2
 plates (Nunc), containing 65 ml of regular medium (DMEM, 10% FBS). At 
confluency (approximately 3 days after seeding), this medium was removed and replaced by 50 ml 
expression media, containing only 5% FBS. The supernatant containing the secreted IgGs was 
harvested 3-4 days later and renewed three times for additional rounds of expression. Detached cells 
were removed from the harvested supernatant by centrifugation (10 min; 9,000g; 4°C) and filtration 
through a 0.22 µm filter (Millipore). The filtered supernatant was adjusted to binding conditions by the 
addition of half the volume of 200 mM sodium phosphate pH 8.0 and 150 mM NaCl, refiltered and 
stored at 4°C until IgG purification by Protein A affinity chromatography. 
Large scale expression in the yeast system was performed using a three-step procedure using two 
different, consecutive pre-cultures. First, 5 ml YPD medium was inoculated with a single Pichia colony 
and grown overnight. The next day, the second pre-culture of 100 ml YPD media was inoculated with 
2 ml of the small scale overnight culture in a 300 ml Erlenmeyer flask. After 24 h at 30°C and 250 rpm, 
the final expression culture (1 l BMGY medium in 5 l Erlenmeyer flasks) was inoculated with the 
second pre-culture at an optical density (OD600) of 1. For this inoculation, the appropriate amount of 
cells from the pre-culture was pelleted by centrifugation (10 min; 5,000g; 4°C) and resuspended in the 
expression media. After incubation for 48-60 h at 30°C and 250 rpm, the expression culture was 
centrifuged (15 min; 5,000g; 4°C) and the supernatant was adjusted to the conditions required for IgG 
purification. Since the BMGY medium already contained potassium phosphate buffer at a 100 mM 
concentration, no sodium phosphate but only NaCl was added to the supernatant. The pH was 
adjusted to 8.0 by the addition of NaOH. Afterwards, the supernatant containing the IgGs was filtered 
through a 0.22 µm filter and loaded onto the Protein A column. 
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Biophysical and biochemical analysis 
 
Purification of IgGs 
Antibodies were purified from culture supernatants by Protein A affinity chromatography. For this 
purpose, the supernatants - adjusted to pH 8.0 and the appropriate [Na
+
] (see above) - were loaded 
onto HiTrap Protein A columns (GE Healthcare, USA) at 4°C with a flow rate of 1 ml/min. 
Chromatography was performed using an ÄKTA PrimePlus chromatography system (GE Healthcare) 
at 4°C. After loading, the column was washed with 100 mM sodium phosphate buffer pH 8.0 
containing 150 mM NaCl. Elution of IgG was accomplished by using 0.1 M glycine pH 2.7, followed by 
immediate neutralization of each fraction to pH 7.5 using 1 M Tris, pH 8.0. The concentrations of the 
sample fractions were determined by UV-spectroscopy at 280 nm with a NanoDrop ND-1000 
spectrophotometer (Thermo Scientific), assuming a mass extinction coefficient of 13.7 for a 10 mg/ml 
solution of IgG. The samples with the highest protein concentration were pooled and dialyzed twice 
against PBS (Sigma-Aldrich; 10 mM Na2HPO4, 1.8 mM KH2PO4, 2.7 mM KCl, 137 mM NaCl, pH 7.1) 
at 4°C. After dialysis, the samples were filtered through 0.22 µm filters (Millipore) and stored at 4°C. 
 
SDS-PAGE and Western blotting 
Sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) was performed using Tris-
glycine 7.5% or 12% gels for non-reduced or reduced samples, respectively. Gels and samples were 
prepared according to standard protocols
91
 and 1.5 µg of IgG antibody was loaded per lane. Non-
reduced samples were only mixed with loading buffer, while for reduced samples DTT was added to a 
final concentration of 16 mM followed by incubation for 5 min at 95°C. As molecular mass marker the 
PageRuler prestained protein ladder (Fermentas) was used. 
For the specific detection of the IgGs, the proteins were transferred to a polyvinylidene difluoride 
(PVDF) membrane (Millipore) after their separation by SDS-PAGE. The blotting was performed 
following the semi-dry method within a Trans-Blot SD cell (BioRad, CA, USA) for 60 minutes at 11 V, 
using a Tris-glycine buffer (20 mM Tris, 150 mM glycine, 10% methanol). After blocking the membrane 
in 5% MPBST (5% w/v skimmed milk dissolved in PBST (PBS with 0.05% Tween 20) for at least 1 h, 
the membrane was incubated for another hour in 2.5% MPBST containing detection antibodies 
conjugated to alkaline phosphatase. For detection of the heavy chain, a goat anti-human Fc-specific 
antibody (Sigma-Aldrich, #A 9544; 1:4,000 dilution) was used, for the light chain a goat anti-human 
lambda-light chain-specific antibody (Sigma-Aldrich, #A 2904; 1:1,500 dilution). The polyclonal rabbit 
αMFpp antiserum was a kind gift of Dr. Randy Schekman (UC Berkeley) and used in a 1:1,000 
dilution, followed by a secondary anti-rabbit IgG specific antibody conjugated to alkaline phosphatase 
(Sigma-Aldrich, #A 3687; 1:20,000 dilution). Antibodies were detected by the addition of NBT-BCIP 
solution (nitro-blue tetrazolium chloride with 5-bromo-4-chloro-3'-indolyphosphate p-toluidine salt; 
Sigma-Aldrich) in 100 mM Tris pH 9.5, 5 mM MgCl2, 100 mM NaCl; the development was terminated 
when the first bands became clearly visible by washing the membrane in ultra high pure water (UHP).  
 
Isoelectric focusing (IEF) 
Determination of the isoelectric point of the constructs was carried out in IEF Ready Gels (pH 3–10; 
Bio-Rad, CA, USA) according to the manufacturer's instructions on a Mini-PROTEAN II vertical cell 
system (Bio-Rad), using increasing voltages (100 V for 1 h, 250 V for 1 h, and 500 V for 30 min). Next 
to the samples, IEF standards, pI range 4.45 to 9.6 (Bio-Rad), were co-electrophoresed. The cathode 
and anode buffers were 20 mM lysine/20 mM arginine or 7 mM phosphoric acid, respectively. 
Following electrophoresis, the proteins were visualized by Coomassie Blue - Crocein Scarlet staining 
(0.04% w:v Coomassie R-250 and 0.05% w:v Crocein Scarlet 3B in 27% isopropanol / 10 % acetic 
acid) for 45 min and destaining (40% methanol / 10% acetic acid). 
 
N-terminal sequence analysis 
Sequence analysis was performed after incubating 50 µg purified IgGs with 0.3 mU of Pfu 
pyroglutamate aminopeptidase (TaKaRa Biomedicals, Japan) as described previously
92
 to remove 
blocking pyroglutamate residues. Reduced antibodies were separated using SDS-PAGE and 
transferred to PVDF membranes using Tris-glycine buffer as described above. After transfer, the 
membrane was stained with freshly prepared Coomassie stain (0.1% Coomassie Blue R-250, 40% 
methanol, 1% acetic acid) for 30 s, followed by destaining with 50% methanol until protein bands were 
clearly visible. Protein bands corresponding to the expected MW of the heavy and light chain, 
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respectively, were excised and submitted for N-terminal sequencing analysis. The first 5-8 amino acids 
of purified IgG from Pichia pastoris were sequenced at the Functional Genomic Center Zurich using an 
Applied Biosystems Procise 492 cLC protein sequencer. 
 
Analysis of IgG expression levels by enzyme linked immunosorbent assay (ELISA) 
To analyze the influence of N-terminal variations on the IgG expression and secretion levels, the same 
number of HEK293 cells stably expressing the corresponding constructs was seeded in 12-well plates. 
Upon reaching confluency, the medium was removed and replaced by 1 ml expression media, 
containing 5% FBS. 24 h later, the supernatant was analyzed for its IgG content by ELISA. For the 
Pichia-produced IgGs, OD-normalized aliquots were taken after 24 h expression for ELISA analysis. 
For the ELISA, a capture antibody recognizing the human IgG heavy chain (Jackson 
ImmunoResearch, PA, USA; #209-005-098) was immobilized on MaxiSorb plates (Nunc) overnight at 
4°C. After 1 h blocking in 5% skimmed milk in PBST, 100 µl of P. pastoris- or HEK-derived 
supernatant (diluted in a range of 1:25 to 1:100 in fresh BMGY or DMEM media) was incubated for 1 h 
at room temperature. The expressed IgG molecules were detected by incubating with an anti-human 
lambda-light chain specific antibody conjugated to alkaline phosphatase (Sigma-Aldrich, #A 2904; 
1:2,000 dilution) for 1 h and subsequent addition of p-nitrophenyl phosphate (Sigma-Aldrich). 
Absorbance at 405 nm was measured using a Perkin Elmer HTS 7000 Plus plate reader for up to 1 h.  
 
Circular dichroism spectroscopy 
Circular dichroism (CD) measurements were performed on a Jasco J-810 Spectropolarimeter (Jasco, 
Japan) equipped with a computer-controlled water bath (refrigerated circulator FS18, Julabo, 
Germany), using a 0.5 mm cylindrical thermocuvette. CD spectra were recorded from 200 to 250 nm 
with a data pitch of 0.5 nm, a scan speed of 20 nm/min, a response time of 4 s, and a bandwidth of 2 
nm. Measurements were performed at 25 °C and each spectrum was recorded three times and 
averaged. The CD signal was corrected by buffer subtraction and converted to mean residue ellipticity 
(MRE, θ) using the concentration of the sample determined spectrophotometrically at 280 nm. Heat 
denaturation curves were obtained by measuring the CD signal at 208 nm at temperatures increasing 
from 25°C to 90°C (heating rate 1°C/min; response time 4 s; bandwidth 2 nm). Data were collected 
and processed as described above. CD spectra and denaturation curves of the purified IgGs were 
measured in PBS (Sigma-Aldrich, pH 7.1) at a protein concentration of 5 µM. 
 
Fluorescence spectroscopy  
This method essentially was used to record the red shift of the emission maximum λmax upon heat-
induced unfolding of the large IgG proteins with numerous Trp residues. As water penetrates the 
unfolding IgG structure, the polarity in the vicinity of the Trp residues changes towards a more 
hydrophilic environment, thus causing an increase of λmax, recorded as a loss in the F330/F350 ratio 
upon unfolding. Fluorescence spectra were measured with a Jobin-Yvon Fluoromax-4 
spectrofluorimeter (Horiba Scientific, NJ, USA) equipped with a Peltier-controlled cuvette holder. The 
temperature was controlled by an LFI3751 5A digital temperature control instrument (Wavelength 
Electronics Inc, MT, USA). Upon excitation at 295 nm, Trp emission spectra were recorded from 300 
to 400 nm (Δλ = 1 nm, scan rate 1 nm/s) in 0.5°C steps from 25°C to 90°C. The sample cuvette was 
equilibrated for 2 min at each temperature to ensure that the desired temperature was reached within 
the cell. Protein concentrations were 1 µM in every case, and all measurements were performed in 
PBS (pH 7.1). The intensity of the emission spectrum at 330 nm (F330) and 350 nm (F350) was 
determined at each temperature, the ratio F330/F350 calculated and subsequently plotted as a function 
of temperature.  
 
Guanidine hydrochloride-induced equilibrium unfolding 
Guanidine hydrochloride (GdnHCl)-induced denaturation measurements were carried out with 
protein/GdnHCl mixtures containing a final protein concentration of 1 µM and denaturant 
concentrations ranging from 0 to 4 M (99.5% purity, Fluka MO, USA). These mixtures were prepared 
from a 6 M GdnHCl stock solution (in PBS, pH adjusted to 7.1) and equilibrated overnight at 25°C. 
Each final concentration of GdnHCl was determined by measuring the refractive index. The intrinsic 
fluorescence emission spectra were then recorded from 300 to 400 nm with an excitation wavelength 
of 295 nm. Slit widths of 2 nm were used for both excitation and emission. Individual GdnHCl blanks 
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were recorded and automatically subtracted from the data. The emission ratio F330/F350 was calculated 
and plotted as a function of GdnHCl concentration. 
 
Aggregation assay (light scattering at 500 nm) 
The temperature of aggregation was determined by light scattering using a Jobin-Yvon Fluoromax-4 
Spectrofluorimeter (Horiba Scientific). Excitation and emission wavelengths were set to 500 nm (slit 
width 2 nm each, integration time 1 s). Protein concentrations were 2 µM for HEK-produced IgGs and 
4 µM for antibodies produced in Pichia pastoris. A heating rate of 1°C/min was applied starting from 
25°C up to 90°C; the intensities were measured every 1°C. Each data point depicted in the plots is an 
average of five measured intensity values. The time period necessary to collect this set of five data 
points was about ~10 s, therefore only a negligible intensity change occurred due to the concomitant 
rise in temperature (about 0.1°C). All measurements were performed in triplicates in PBS (pH 7.1) and 
averaged values are given. 
 
Deglycosylation by PNGase F treatment 
The aggregation behavior was analyzed after enzymatic removal of the glycan moiety from Thr299. 
For this purpose, 80 µl of 2 µM purified IgGs were incubated with 50 U PNGase F (New England 
Biolabs, MA, USA) at 37°C for 3 h in PBS (in the absence of any detergents, in contrast to the 
instructions of the manufacturer). Afterwards, PNGase F-treated proteins were compared to their 
glycosylated counterparts by reducing SDS-PAGE for confirmation of complete deglycosylation. Then, 
these samples were analyzed by the aggregation assay as described before. 
 
Size-exclusion chromatography (SEC)  
SEC experiments were performed using a Superdex 200 PC 3.2/30 column (GE Healthcare). The runs 
were performed in PBS buffer (Sigma-Aldrich, pH 7.1) at a flow rate of 0.06 ml/min at 25°C on an 
ÄKTA Micro system (GE Healthcare). Samples of 50 µl containing 6.7 µM IgG were injected and 
protein elution was monitored at 280 nm. Cytochrome c (12.4 kDa), albumin (66 kDa) and β-amylase 
(200 kDa) were used as standards to calibrate the column. 
 
Static multi-angle light scattering 
The temperature-induced increase of aggregation was analyzed by SEC multi-angle light scattering 
(MALS). Purified IgGs were incubated in PBS (pH 7.1) at protein concentrations of 3 µM at 4°C, 37°C 
or 50°C for five days. Afterwards, SEC was carried out on an LC 1100 Series HPLC System (Agilent) 
using a Superdex 200 10/300 GL column (GE Healthcare) with a flow rate of 0.5 ml/min. MALS 
measurements were performed using a miniDAWN MALS instrument (Wyatt Technology, CA, USA) to 
determine the Rayleigh ratio. Three discrete photodetectors are spaced around the flow cell and 
enabled simultaneous measurements at 45°, 90° and 135°. An Optilab REX Refractometer (Wyatt 
Technology) was inline with the MALS detector. All measurements were carried out at 23°C. 
Chromatographic data were collected and processed using the ASTRA software (Version 5.3.4.14; 
Wyatt Technology). Bovine serum albumin (Sigma-Aldrich; 1 mg/ml) was used for the alignment and 
normalization of various detectors’ signals relative to the 90° detector signal. 
 
Electrospray ionization - mass spectrometry  
Mass spectrometry (MS) analyses were undertaken by the Functional Genomic Center Zurich. IgG 
samples were reduced with DTT (50 mM final concentration), desalted using a C4 ZipTip (Millipore) 
and measured in 50% acetonitrile / 0.2% formic acid (pH 2). The m/z data were deconvoluted into MS-
data using the MaxEnt1 software (Waters/Micromass, MA, USA). 
 
Differential scanning calorimetry  
Differential scanning calorimetry (DSC) measurements were performed using a VP-Capillary DSC 
system (Microcal Inc., acquired by GE Healthcare). The antibody concentrations were adjusted to 0.5 
mg/ml prior to the measurement. The corresponding buffer was used as a reference. The samples 
were heated from 8°C to 90°C at a rate of 1°C/min after an initial 15 min of equilibration at 8°C. A 
filtering period of 16 s was used and data were analyzed using Origin 7.0 software (OriginLab1 
corporation, MA, USA). Thermograms were corrected by subtraction of buffer-only scans and the 
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corrected thermograms were normalized to the molar concentration of the protein. The final excess 
heat capacity thermogram was obtained by interpolating a cubic baseline in the transition region. The 
midpoint of a thermal transition temperature (Tm) was obtained by analyzing the data using Origin 7 
software provided with the instrument. As all measured transitions are irreversible, all the experimental 
values reported in this study for melting temperatures have to be regarded as ʺapparentʺ values. 
 
Differential scanning fluorimetry  
Differential scanning fluorimetry (DSF) was performed using the Rotor-Gene Q real-time PCR cycler 
(QIAGEN) and fluorescence data were collected using the instrument's HRM channel settings (λex 460 
nm; λem 510 nm). The SYPRO Orange dye (Molecular Probes) was supplied in DMSO and diluted 
500-fold from the supplied stock solution into the appropriate buffers just prior to being added to the 
protein solutions. The samples with a final protein concentration of 3.5 µM in a 20 µl reaction mixture 
were subjected to a temperature ramp from 30°C to 90°C at a heating rate of 1°C/min and at 0.5°C 
increments with an equilibration time of 30 sec at each temperature prior to measurement. The Tm 
was determined as the temperature corresponding to the maximum value of the first derivative of the 
fluorescence changes, calculated by the software. When multiple unfolding transitions are observed, 
only the Tm value of the first transition can be accurately determined, as the transitions at higher 
temperatures overlap. Prior to the DSF analysis, several IgGs were analyzed by fluorescence 
spectroscopy in the presence and absence of SYPRO Orange. In agreement with the literature, the 
dye (at 1:200 to 1:500-fold dilutions of the original reagent) did not induce any changes in the thermal 
stability determined by the intrinsic fluorescence acquired during heating.  
 
Microscale thermophoresis measurements 
Binding affinities of purified IgGs to their antigen myoglobin (Sigma-Aldrich) were measured using 
microscale thermophoresis (MST, NanoTemper, Germany) as described previously.
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 Myoglobin was 
fluorescently labeled according to the manufacturer’s instructions with a reactive NT-647 dye using N-
hydroxysuccinimide (NHS) ester-chemistry which reacts with primary amines to form dye-protein 
conjugates. For each analyzed construct, a titration series with constant antigen concentration (20 µM) 
and varying IgG concentrations between 10
-11
 and 10
-6
 M was prepared in PBS. The mixed samples 
were equilibrated for 1 h at room temperature and approximately 4 µl of each sample was loaded in 
the capillary. An infrared laser diode within the Monolith NT.115 instrument (NanoTemper, Germany) 
was used to increase the temperature by 4 K in the beam center. Throughout the measurement, the 
fluorescence inside the capillary was recorded by a CCD-camera and the normalized fluorescence 
was afterwards plotted against the IgG concentrations. The KD values were subsequently obtained 
from fitting the binding curves using Prism 5 (GraphPad, CA, USA). 
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Supplementary Material for Chapter 3.2 
 
 
Charge engineering of Kex2 cleavage site 
Comparing the results of the maturation of the various Pichia constructs, it became obvious that while 
the omission of the EAEA tetrapeptide did not cause any problems in the processing of the light chain 
(as seen in Fig. 3.2.3b bottom panel and from the sequencing results in Fig. 3.2.3c), it led to severe 
heterogeneity for the heavy chain H*. As the global fold of the variable domains of the light and the 
heavy chain including the arrangement and accessibility of the N-terminal stretch is very similar, the 
cause of this inefficient processing must lie elsewhere. The most obvious parameter is the primary 
sequence of the POI following the Kex2 cleavage site. Therefore, the sequences of the light and the 
heavy chain were compared with each other as well as with the ʺwrongʺ species derived from the 
alternative cleavage site (Fig. 3.2.3c). Comparing their amino-terminal residues, a clear difference in 
the charge status between the N-terminal amino-acids of the light (member of the human Vλ3 family) 
and heavy chains (a human VH6 family member) were found (N-terminal sequences: QVQLV vs. 
DIELT). The natural human Vλ3 sequences generally start with the sequence SYELT, while most 
human kappa light chains have acidic residues at their N-termini.
1
 However, the consensus sequence 
of the human Vλ3 family had been engineered in the HuCAL library and thus also in our case to start 
with DIELT for cloning reasons.
2
 Interestingly, acidic amino acids are present in some VH families as 
well at these positions, e.g. in VH3 and VH5.
3
  
The overview depicted in Supplementary Data Fig. S3.2.2a showed that both the natural Kex2 site, 
the native N-terminus of the light chain as well as the alternative site within the heavy chain’s pro-
region exhibit acidic residues directly following the cleavage site. This suggests that the Kex2 
endopeptidase seems to require negative charged residues downstream of its cutting site for efficient 
cleavage. This preference for acidic amino acids was also found by Bader and colleagues in their 
analysis of various Kex2 cleavage sites.
4
 In a three-dimensional model of this enzyme, its S1’ and S3’ 
pockets are characterized by positive charges – thus allowing optimal charge-charge interactions with 
acidic amino acids in position P1' and P3'. 
 As the charge of the Kex2 substrates seems to be of great importance, the composition of the heavy 
chain was engineered, changing the non-charged glutamines (Q) in position P1' and P3' of the heavy 
chain to their charged counterparts glutamic acids (E), either individual or both at the same time. The 
resulting QE, EQ and EE variants were subsequently compared to the original QQ construct and 
analyzed for the distribution of the three species. None of these constructs led to a homogenously 
processed fraction but all contained molecules still having the full pro-region attached (Supplementary 
Data Fig. S3.2.2b). Nonetheless, the distribution of the three species could be improved by the 
introduction of negative charges: compared to the QQ variant the fraction of the ʺmatureʺ species for 
the EE construct was doubled, while the percentage of the other two species (panels (c) and (d) of 
Supplementary Data Fig. S3.2.2) was consequently reduced.  
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Taken together, these data indicate that the cleavage efficiency of Kex2 is clearly influenced by the 
charge distribution at its substrate-binding site. Although engineering of the residues in the P1' and P3' 
position towards charged amino acids influenced the processing of the resulting IgG construct, it did 
not lead to homologous, correctly processed heavy chains. Therefore, Kex2 cleavage efficiency not 
only depends on the charge distribution upstream of its cleavage site, but also on other characteristics 
of the POI. However, we cannot yet pinpoint what these features are exactly.
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Fig. S3.2.1. Influence of glycosylation on IgG stability. (a) Comparison of the DSF signal of HEK-
produced native IgG with that of its unglycosylated counterpart (T299A glycan knock-out). The transition of 
the CH2 unfolding is the dominant signal detected. (b) DSC signals recorded for the same constructs as in 
(a). (c) DSF analysis of Pichia-produced IgG constructs. (d) Comparison of DSF signals recorded for HEK- 
and Pichia-produced IgGs in their glycosylated and un-glycosylated state. (e) Thermal denaturation curves 
of the constructs seen in (d) measured by intrinsic tryptophan fluorescence. The curves were derived from 
the intensity ratio of the emission spectrum at 330 nm and 350 nm upon excitation at 295 nm, normalized 
to the plateaus of fully folded and fully denatured proteins. This value is plotted as a function of 
temperature. 
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Fig. S3.2.2. Charge engineering of Pichia-produced IgG H* / L construct. (a) Comparison of the 
mature N-terminal amino acid sequences of different yeast heavy chain variants analyzed. The uppermost 
sequence is the one primarily found for the H* construct, derived from an alternative cleavage within the 
pro-region and carrying two negatively charged amino acids at its N-terminus (red color). To test charge 
influence on cleavage efficiency the residues at the first and third position of the mature heavy chain N-
terminus were mutated from glutamine (Q) to glutamic acid (E) in individual combinations or combined in 
the EE variant. (b) Western blot analysis of IgG H* / L charge variants after incubation in the absence or 
presence of PNGase F. Shown are the blots detected with antibodies specific to the heavy chain (α-H) and 
to the α-factor pre-pro-region (α-αMFpp). (c) Comparative reducing SDS-PAGE analysis of yeast IgG H* / 
L QQ and EE variants after incubation in the absence or presence of PNGase F, stained with Coomassie 
Blue. (d) Comparison of distribution of IgG H* / L forms for the QQ and EE variants, based on the relative 
signal intensities found in Edman sequencing. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. S3.2.3. Binding affinity of IgG obtained 
from mammalian expression. Direct interaction 
studies between purified IgGs and their 
fluorescently labeled cognate antigen myoglobin 
(monomer) analyzed using microscale 
thermophoresis technology. Normalized 
fluorescence [‰] is plotted against the IgG 
concentration titrated from 0.03 nM to 1,000 nM. 
The fitted KD values lie within the experimental 
error range and indicate that the binding is fully 
retained for (a) IgG H / L, (b) IgG H-E / L and (c) 
IgG H-E / L-E. 
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Fig. S3.2.4. Biophysical characterization of 
Pichia-produced IgG constructs. (a) Thermal 
denaturation curves measured by intrinsic tryptophan 
fluorescence. The curves were derived from the 
intensity ratio of the emission spectrum at 330 nm 
and 350 nm upon excitation at 295 nm, normalized to 
the plateaus of fully folded and fully denatured 
proteins. This value is plotted as a function of 
temperature, comparing different Pichia IgG variants. 
(b) DSC of the Pichia-produced H / L, H-E / L and H-
E / L-E constructs. Depicted as ʺH / Lʺ construct is 
the H-pro-del variant. (c) Guanidine hydrochloride 
(GdnHCl)-induced denaturation of IgGs expressed in 
Pichia pastoris. The denaturation was followed by 
plotting the F330/F350 ratio normalized to the plateaus 
of fully folded and fully denatured proteins as a 
function of GdnHCl concentration. 
 
 
Fig. S3.2.5. Aggregation behavior of different IgGs obtained from mammalian expression. (a) 
Thermal denaturation curves. The denaturation was followed by CD, plotting the signals at 208 nm as a 
function of temperature. A comparison between different mammalian IgG variants is shown and the values 
are reported as MRE. (b) High tension (HT) voltage signal corresponding to the curves shown in (a) 
recorded by the photomultiplier connected to the CD spectrometer. The values were normalized by setting 
the initial and the highest values of the curves to 0 and 1, respectively.  (c) Aggregation of IgG constructs 
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measured by light scattering at 500 nm. Emission was recorded at the same wavelength as excitation. (d) 
Zoom at the aggregation temperatures of selected constructs. In addition to some of the constructs already 
shown in (c), also the signals derived from IgGs carrying the control peptide AGIQ on the heavy chain (H-A 
format) are presented. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. S3.2.6. Aggregation behavior of different 
Pichia-produced IgGs. (a) Thermal denaturation 
curves measured by CD. The signals at 208 nm are 
plotted as a function of temperature. A comparison of 
different Pichia-produced IgG variants is shown and 
the values are reported as MRE. Depicted as ʺH / Lʺ 
construct is the H-pro-del variant. (b) Photomultiplier 
high tension (HT) current signal corresponding to the 
curves shown in (a) recorded by the photomultiplier 
connected to the CD spectrometer. The values were 
normalized by setting the initial and the highest 
values of the curves as 0 and 1, respectively. (c) 
Aggregation of IgG constructs measured by light 
scattering at 500 nm.  
 
 
 
 
 
 
 
Fig. S3.2.7. Isoelectric Focusing of HEK and 
Pichia produced IgGs Non-reduced IgGs were 
separated based on their isoelectric point (pI) after 
incubation in the absence or presence of PNGase F. 
A pI standard is shown in the left lane, with the 
corresponding pI values denoted next to it. Based on 
the primary sequences, the pI's were calculated to be 
6.1 for the H-E / L-E and 6.7 for the H / L constructs, 
respectively. Upon deglycosylation, the asparagine to 
which the glycan was attached is converted to 
aspartic acid, resulting in an additional negative 
charge to the protein, which consequently focuses at 
a slightly lower pI value. 
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4. General Discussion and Outlook 
The main objective of this thesis was to investigate engineering approaches for improving the 
biophysical properties of full-length IgG antibodies, mainly focusing on stability and aggregation-
related aspects. Similar analyses have already been performed in the past - however, those studies 
were mainly restricted to smaller antibody fragments like scFv or Fab produced in prokaryotic systems 
due to various reasons. The first and foremost was that the initial analyses had to be able to untangle 
effects in the domain itself and on interactions with other domains. In addition, it had to be ensured 
that the effects could be observed at all - a task that becomes progressively more difficult with more 
domains. Thus, this question would have been unanswerable with a full-length IgG initially. Now, 
having the data for single domains and scFv fragments at our disposal, the question can be posed 
whether similar effects are seen in IgGs - the antibody format mainly used for therapeutical antibodies 
nowadays. 
 
It could be shown that enhanced stabilities both with respect to thermal and denaturant-induced 
unfolding can be achieved by rational engineering for various antibody formats and independent of the 
expression system. The presented data thus clearly indicate the transferability of improvements 
implemented in smaller antibody fragments onto full-lengths IgGs - a finding having important 
consequences: since the variable domains of IgGs and their features can be modified in smaller 
fragments, the required experimental set-ups can be simplified with respect to the employed format 
and the use of a prokaryotic system. Importantly, the findings presented here not only allow to 
retrospectively improve existing binders, but above all might also have important implications for future 
library designs. So far, based on the stability of the individual domains determined in isolation and 
within scFv fragments, it could be assumed that high-quality libraries for the selection of antibodies 
should only contain molecules possessing the most stable VH and VL domains, namely VH3 and Vκ3, 
respectively. The underlying rationale is that most applications prefer or even require the resulting 
antibodies to be stable and to be obtained as soluble proteins in high yields. However, these libraries 
would have the great disadvantage of being limited to only one framework combination, thereby 
reducing the binding diversity of its members significantly. As known from several analyses, the 
framework residues located either at the hapten binding interface or the outer loop greatly contribute 
to both affinity and diversity, but are rather variable among the different VH families. Therefore, it is not 
advisable to limit the members of the initial library to a few or even one framework only. So far, 
selected binders possessing a framework combination different from the best one might have suffered 
from suboptimal biophysical properties, like reduced stability or enhanced aggregation susceptibility. 
Consequently, it would be best for future library designs to create structurally diverse libraries of stable 
frameworks after optimizing the used consensus antibody frameworks in the first place. Since the 
study presented here restricted itself to members of the least stable VH6 family, it might be of interest 
to perform similar engineering experiments with members of the other even-numbered VH domains 
known for their less favorable biophysical properties. Although based on the sequence similarities 
presumably analogous results are to be expected for domains belonging to the VH2 and VH4 family, it 
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would be beneficial to have advanced consensus sequences available for these families as well. The 
study presented in this thesis should be of great help at this as it contributes to the understanding of 
the design of such consensus sequences and highlights promising procedures to improve them. 
Interestingly, the described mutations not only influenced the biophysical properties of the engineered 
full-length IgG but also had an impact on their structural integrity and homogeneity. It would be of great 
significance if IgGs with increased homogeneity had benefits over their heterologous counterparts, 
especially in the context of clinical applications with their potential side-effects. If few amino acid 
exchanges could enhance the efficiency and safety of antibody drugs this would not only present 
crucial benefits for the pharmaceutical industry (having better products that potentially require less 
laborious downstream processing) but, more importantly, for the patients as well. Of particular interest 
is furthermore the presented finding that the increased homogeneity was not only restricted to the VH 
domain but even affected the structural integrity of the adjacent CH1 domain with its intrachain 
disulfide bond. It is generally assumed that each of the IgG domains acts as an independent unit, 
especially being autonomous regarding its folding. However, it has already been demonstrated that 
adjacent domains can influence their neighbors by longitudinal interactions.
1
 While this intramolecular 
signaling has been the subject of controversial debates, the presented data clearly indicate that one 
domain might not only influence the stability but also the structure of another domain. To finally reveal 
the underlying mode of interaction, molecular details of the domain structures would be of enormous 
advantage. Therefore, crystal structures of both the WT and M variants should be prepared and 
analyzed with respect to differences in the VH-VL-interface or in the domain structures itself. Since 
antibodies have been successfully studied by X-ray crystallography for several decades,
2; 3
 this should 
be feasible and be performed – especially, as the conclusions of such investigations might be of great 
value for the future design of antibodies and for their various applications. 
 
Another main aspect of this thesis was the comparison of different eukaryotic expression systems, 
namely HEK293 cells and Pichia pastoris. In recent years, this yeast system has enjoyed an 
increasing popularity and has proven to be a very useful platform for the production of various 
proteins. The outlined results clearly indicate that Pichia is also well suited for the expression of full-
lengths IgG molecules at a large scale. Using the constitutively active GAP promoter and the proposed 
sequence designs, it is possible to continuously produce genuine antibodies without any remaining 
residues from the sequences used for secretion of the molecules. This should - combined with 
glycoengineered Pichia strains as described below - be quite helpful to further widen the application 
range of this expression system. Alternatively, the production of IgGs with reduced aggregation 
propensities can now easily be performed by intentionally using the α-factor pre-pro sequence, 
resulting in EAEA-tetrapeptides still being present at the respective N-termini after enzymatic 
cleavage. 
The usage of the Pichia system revealed another surprising feature. The presented results clearly 
indicate that the Pichia glycan moiety - despite slightly destabilizing the CH2 domain - has the 
surprising effect of protecting IgGs against aggregation. All analyzed glycosylated Pichia-produced 
IgGs showed a higher resistance to aggregation compared to their counterparts expressed in 
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mammalian cells. Constructs with additional sequences remaining from the α-factor pre-pro sequence 
even did not exhibit any aggregation at all under the conditions tested. Since the impact of the glycans 
seems not to be based on their contribution to the protein's overall charge (as shown by IEF), this 
phenomenon seems to be independent of the protein's isoelectric point and thus probably should be 
transferable to other molecules as well. Therefore, it would be of great interest to elucidate which 
modules of the Pichia glycan are accountable for this characteristic feature and to also examine the 
glycan's impact on proteins other than IgGs. Recently, glycoengineered Pichia strains have been 
developed and meanwhile successfully applied to the production of monoclonal antibodies.
4-7
 In this 
method based on the GlycoSwitch technology, already existing expression strains are gradually 
modified by the disruption of an endogenous glycosyltransferase gene followed by the stepwise 
introduction of heterologous glycosylation enzymes. Each of these engineering steps equips the 
Pichia endoplasmic reticulum and Golgi system with additional glycosidase or glycosyltransferase 
activities, resulting in individual strains expressing proteins with different intermediate glycoforms. 
Eventually, all steps combined cause the engineered strain to produce human-like (Gal)2(GlcNAc)2 
(Man)3(GlcNAc)2 N-glycans. To shed light on the question which components of the original Pichia 
glycan are responsible for its aggregation-preventing properties, IgG antibodies possessing 
intermediate glycoforms should be produced and subsequently analyzed for their aggregation 
susceptibilities. The finding might even lead to a better understanding of the aggregation mechanisms 
of antibodies in general and may present further engineering methods to successfully tackle this 
problem. The resulting insight could potentially even facilitate additional applications of aggregation-
resistant antibodies in the future. 
 
As already mentioned, also the EAEA-tetrapeptides left behind from the α-factor pre-pro sequence 
had a dramatic positive impact on the aggregation propensities of Pichia-produced IgGs, indicating 
that this susceptibility can be engineered by modifying the charge distributions at certain locations. 
Although the presence of these amino-terminal extensions might not always be desirable or could 
even potentially create new immunogenic epitopes in human therapy, these appendices may still be of 
great advantage in various other applications. For example, these four amino acids should not exhibit 
any drawback in in vitro usage of modified antibodies in the respective set-ups - like the detection of 
different proteins on ELISA or immunoblotting - since unaltered affinities were shown in this work. As a 
major advantage, the strategy of attaching the charged EAEA-peptides to the N-terminus of HEK-
produced IgGs is easily applicable to a large variety of molecules, because it can readily be performed 
by simple cloning means. Thus, it could also be applied retrospectively to already existing binders 
without any difficulty. Importantly, this approach may supersede the elsewhere outlined idea of 
introducing charged residues into the CDR regions.
8
 Since that method may abolish the antibody-
antigen recognition directly or indirectly by altering the loop conformation, it cannot be considered a 
generally applicable strategy. In further studies it should be investigated whether the introduction of 
additional charges at other locations within the IgG molecule (like, for example, at the C-terminus or in 
the hinge region of the molecule) would have a similar effect as the N-terminal EAEA-peptide. In these 
studies, care should be taken to also analyze other properties of the resulting molecules like thermal 
stability and expression yields. 
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Furthermore, it is rather unlikely that the described EAEA-tetrapeptide already constitutes the ultimate 
appendix to antibody molecules with respect to reduced aggregation propensities. As it could be 
shown that the addition of various peptides to the N-termini only marginally influenced the expression 
level of IgGs expressed in mammalian cells, peptides other than EAEA should be analyzed for their 
feasibility and influence. Therefore, obtaining more insight into the exact mode of action as well as 
detailed knowledge derived from crystal structures would be of great benefit. Alternatively, small 
peptide libraries may be attached to the antibody and screened for their impact onto the aggregation 
susceptibility if appropriate selection methods can be developed and implemented.  
 
As summarized so far, this study analyzed the impact of various amino acid alterations on the 
biophysical characteristics of different antibodies. The results might help to enhance the properties of 
already existing antibodies and to initially improve library members, allowing the selection of more 
stable binders or molecules that can act under harsh conditions such as the presence of denaturants. 
It would further be of great interest to use the knowledge obtained and the broad range of available 
IgG variants - stability engineered mutants, truncated variants as well as glycan-knockouts - to gain 
additional insight into kinetic aspects of their stability and to determine how this feature is influenced 
by various factors. In most studies, standard analyses of thermal stabilities are oversimplified as they 
are performed by equilibrium thermodynamics. While this strategy might be justified in some cases, it 
may not be the most adequate procedure for antibodies due to their multidomain structure and the 
irreversible nature of their thermally-induced denaturation. Therefore, it would be more accurate to use 
a comprehensive approach and to conduct a set of thermal-denaturation experiments of constructs 
with various combinations of domains at different scan rates and varying protein concentrations. As a 
drawback, such an extensive study requires large amounts of purified proteins that themselves 
demand appropriate mammalian expression facilities. The method of choice for the necessary 
biophysical analyses is Differential Scanning Calorimetry (DSC) since it not only enables the 
determination of thermodynamic features but also indirectly of kinetic parameters that are necessary 
for characterizing the overall stability of antibodies. As shown in this thesis, an important advantage of 
DSC is its ability to distinguish different transitions in multidomain proteins such as IgGs that are often 
overlapping in e.g. spectroscopic methods. Recent improvements in high-throughput DSC and in 
mathematical models facilitate the determination of the role of factors on protein stability such as 
concentration and storage conditions. It would be a major benefit to find correlations (if they exist at 
all) between thermodynamic and kinetic stabilities of individual domains and within the whole protein. 
Eventually, kinetic analysis of thermal denaturation of IgGs will provide proper parameters for the 
determination of important characteristics like their half-life (shelf-life) as a function of storage 
temperature. In addition, the influence of various additives or osmolytes on the stabilization of IgGs 
could be investigated by this set-up. These small molecules, ranging from sugars over polyols to 
amino acids and their derivatives, have been shown to counteract various stress conditions of 
proteins
9; 10
 and thus are used for the development of optimal storage conditions.
11
 Incorporating these 
aspects in our analyses, it should be possible to get a deeper insight into the exact mechanism by 
which this stabilization occurs and to compare the effects of various osmolytes. The resulting 
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conclusions will be of great importance for improving our understanding of antibody stability and even 
may pinpoint new hotspots of future engineering approaches. 
 
Taken together, the analyses presented in this thesis have dealt with various aspects of antibodies 
and with some of the challenges that still derogate the successful widening of their application range. 
With the help of the outlined modifications and the acquired insight, antibody engineering should be 
significantly pushed forward and may result in an advanced and improved IgG antibody generation, 
thereby perpetuating the success story of these molecules in the 21
st
 century. 
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5. Appendix 
 
 
5.1 Abbreviations 
 
αMFpp   α-factor pre-pro sequence 
ADCC   Antibody-dependent cellular cytotoxicity 
CD     Circular dichroism 
CDC   Complement-dependent cytotoxicity 
CDR    Complementarity determining region  
CHO    Chinese hamster ovary cells  
CIEX    Cation exchange chromatography  
CMV    Cytomegalovirus  
DMEM    Dulbecco's modified Eagle medium  
DSC   Differential scanning calorimetry  
DSF    Differential scanning fluorimetry  
DTT    Dithiothreitol  
EC    Escherichia coli 
ELISA    Enzyme-linked immunosorbent assay  
Fab    Fragment antigen binding 
Fc    Fragment crystallizable 
FcγR    Fc gamma receptors  
FBS    Fetal bovine serum  
GdnHCl    Guanidine hydrochloride  
H     Heavy chain of an antibody  
HEK   Human embryonic kidney cells  
HPLC    High-performance liquid chromatography  
HuCAL   Human Combinatorial Antibody Library 
HT    High tension voltage  
IEF    Isoelectric focusing  
IPTG   Isopropyl-β-D-thiogalactopyranoside 
IgG    Immunoglobulin G  
ITF    Intrinsic tryptophane fluorescence  
L    Light chain of an antibody  
M    Mutant 
mAb   Monoclonal antibodies 
MALS   Static multi-angle light scattering  
MHC   Major histocompatibility complex  
MRE   Mean residue ellipticity  
MS    Mass spectrometry  
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MST   Microscale thermophoresis  
PBS    Phosphate buffered saline  
pI    Isoelectric point  
POI    Protein of interest  
PP    Pichia pastoris  
scFv   Single-chain variable fragment of an antibody 
SEC   Size-exclusion chromatography  
SDS-PAGE   Sodium dodecyl sulfate-polyacrylamide gel electrophoresis  
VH    Variable domain of the heavy chain of an antibody 
VL     Variable domain of the light chain of an antibody 
WT    Wild type 
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pcDNA5/FRT/-MfeI/2C2 WT
8478 bp
CL
Vkappa leader
Hygro(R) (no ATG)
Amp(R)
VH-leader
CH1-CH2-CH3
bla promoter
VL
VH
SV40 pA
BGH pA
hGH_polyA CMV promoter
CMV promoter
pUC origin
FRT
5.2 Plasmid / Vector overviews 
 
For the expression of full-length IgG or Fab molecules, different vectors were used depending on the 
expression system. Here, representative vectors are shown for the IgG 2C2 WT and Fab 2C2 WT 
variants. Vectors encoding the M variants or the 6B3 constructs were constructed in an analogous 
manner. In general, the variable VH and VL domains, differing between the various antibodies, are 
shown in blue. The corresponding promoters used for the expression of the heavy and light chain are 
depicted in green while the origins of replication utilized for plasmid maintenance in E. coli are 
presented in red. As the Fab fragments cannot be purified from the supernatant via Protein A affinity 
chromatography, their Fd fragment, consisting of VH and CH1, possesses both an additional myc-tag 
(EQKLISEEDL) and a hexa his-tag at its C-terminus.  
 
 
Mammalian vectors: 
 
For the establishment of stable HEK293 cell lines expressing the various antibody formats, derivatives 
of the pcDNA5 vector (Invitrogen, Fig. 5.1) were used. Two complete expression cassettes for the 
heavy and light chain, respectively, were combined in a single vector containing constitutively active 
CMV promoters upstream of the endogenous IgG signal sequences. 
 
(a)           (b) 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 5.1: Vector maps of pcDNA5/FRT-derivatives for the expression of (a) IgG and (b) Fab 
fragments in stable HEK293 cells. Vkappa leader, VL, CL: sequence coding for variable and constant 
domain of the light chain; VH leader, VH, CH1, CH1-CH2-CH3: sequence coding for variable and constant 
domain(s) of the heavy chain; myc-tag: sequence coding for the c-myc tag; 6xHis: sequence coding for the 
hexa his-tag; CMV promotor: constitutively active promoter for the expression of heavy and light chain; 
Hygro(R): gene coding for hygromycin B resistance (hygromycin B phosphotransferase); Amp(R): gene 
coding for ampicillin resistance (β-lactamase); bla promoter: β-lactamase promoter; pUC origin: origin of 
replication for maintenance in E. coli; FRT: FLP recombinase target, used for integration into the HEK 
genome; BGH pA: poly-adenylation site (bovine growth hormone poly-A), used for the light chain; 
hGH_polyA: poly-adenylation site (human growth hormone poly-A), used for heavy chain construct; SV40 
pA: polyadenylation site (simian virus 40 poly-A), used for hygromycin B phosphotransferase. 
 
pcDNA5/FRT/-MfeI/Fab 2C2 WT
7878 bp
myc-tag
6xHis
CL
Vkappa leader
Amp(R)
Hygro(R) (no ATG)
CH1
bla promoter
VL
VH
hGH_polyA
BGH pA
SV40 pA
CMV promoter
CMV promoter
pUC origin
FRT
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pGAPZaB_IgG2C2 WT_kappa
6312 bp
CH1-CH2-CH3
alpha-factor signal peptide
VL
alpha-factor signal peptide
pTEF1
pEM7
Zeocin
VL
VH
GAP promoter
GAP promoter
pUC ori
AOX1 TT
AOX1 TT
BglII (2)
Pichia vectors:  
 
Expression of IgG or Fab fragments in Pichia pastoris was achieved after integration of derivatives of 
the pGAPZαB vectors (Fig. 5.2) into the yeast genome. As for HEK expression, the genes for the 
heavy and light chain were combined within one single vector, containing these genes as independent 
expression cassettes with their own promoter, their own alpha factor pre-pro sequence as well as their 
own terminator sequences. 
 
 
(a)      (b) 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 5.2: Vector maps of pGAPZαB derivatives for the (a) IgG and (b) Fab expression in Pichia 
pastoris. VL, CL: variable and constant domain of the light chain; VH, CH1, CH1-CH2-CH3: variable and 
constant domain(s) of the heavy chain; alpha-factor signal peptide: pre-pro sequence of the alpha factor 
for secretion; myc-tag: sequence coding for the c-myc tag; 6xHis: sequence coding for the hexa his-tag; 
AOX1TT: termination sequence for light and heavy chain, respectively; GAP-promoter: GAP promoter; 
pTEF1: S. cerevisiae promoter for Zeocin™ selection in yeast; pEM7 : bacterial promoter for Zeocin™ 
selection in E. coli; pUC ori: origin of replication for maintenance in E. coli; Zeocin: Zeocin resistance gene; 
BglII: BglII restriction site for linearization of the final vector. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
pGAPZaB_Fab_2C2 WT-kappa
5633 bp
alpha-factor signal peptide
alpha-factor signal peptide
pTEF1
pEM7
Zeocin
CL
CH1
VL
myc-tag
6xHis
VH
GAP-promotor
GAP-promotor
pUC ori
AOX1 TT
AOX1 TT
BglII (2)
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pMx7_IgG_2C2 WT_kappa
5682 bp
CL
cat
lacI
st II
pho A
CH1-CH2-CH3
VL
VH
ColEI ori
functional ssori
lac p/o
Vectors for prokaryotic expression: 
 
Prokaryotic assembly of IgG or Fab fragments was performed in the periplasm of E. coli SB536. 
Therefore, the IgG or Fab genes were arranged as a bicistronic unit, equipping each chain with its own 
signal sequence. The vectors used for the expression of the antibody constructs in this thesis were 
based on either pMx7 (for the IgG expression) or pMx9 (for the Fab production), respectively 
(MorphoSys, Fig. 5.3), differing in the signal sequences used for the corresponding light chain. 
 
 
(a)      (b) 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 5.3: Vector maps of pMx7 or pMx9 used for prokaryotic antibody expression. VL, CL: gene 
coding for the light chain; VH, CH1, CH1-CH2-CH3: gene coding for the heavy chain; myc-tag: sequence 
coding for the c-myc tag; 6xHis: sequence coding for the hexa his-tag; functional ssori: functional ssDNA-
Polymerase origin; ompA: OmpA signal sequence for periplasmic transport of the light chain; stII: STII 
signal sequence for periplasmic transport of the light chain; phoA: PhoA signal sequence for periplasmic 
transport of the heavy chain; lac p/o: IPTG-inducible lac promoter/operator; cat: chloramphenicol 
acetyltransferase (chloramphenicol resistance gene) ; lacI : lac repressor gene, active in the absence of 
IPTG; ColE1 ori: origin of replication. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
pMx9_Fab_2C2 WT_kappa
5073 bp
6xHis
myc-tag
CL
pho A
ompA
cat
lacI
CH1
VL
VH
ColEI ori
functional ssori
lac p/o
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5.3 Protein Sequences 
 
The following sequences are derived from the vectors shown above and represent the translated, but 
yet unprocessed, proteins. Thus, signal sequences and C-terminal Lys residues subsequently cleaved 
off are indicated. Apart from the prokaryotic constructs - that are expressed in a bicistronic unit - the 
individual heavy and light chain sequences are displayed, respectively. In general, the six distinct point 
mutations (Q5V, S16G, T58I, V72D, S76G and S90Y) discriminating WT and M constructs are 
highlighted either in red for the WT or in blue for the M. Secretion signals are each identified by gray 
highlights while spacer peptides used in the Pichia system are shown in light gray. Truncated C-
terminal lysines are placed into brackets. For the Fab fragments, the additional myc- and hexa-his-
tags are emphasized by dark green highlights. The residue 299 that is mutated to alanine in the glycan 
knock-out T299A variants is italicized and underlined in the HEK and PP IgG constructs. 
 
 
Mammalian (HEK) constructs: 
 
HEK IgG 2C2 WT 
MKHLWFFLLL VAAPRWVLSQ VQLQQSGPGL VKPSQTLSLT CAISGDSVSS NSAAWNWIRQ SPGRGLEWLG 
RTYYRSKWYN DYAVSVKSRI TINPDTSKNQ FSLQLNSVTP EDTAVYYCAR QRGHYGKGYK GFNSGFFDFW 
GQGTLVTVSS ASTKGPSVFP LAPSSKSTSG GTAALGCLVK DYFPEPVTVS WNSGALTSGV HTFPAVLQSS 
GLYSLSSVVT VPSSSLGTQT YICNVNHKPS NTKVDKRVEP KSCDKTHTCP PCPAPELLGG PSVFLFPPKP 
KDTLMISRTP EVTCVVVDVS HEDPEVKFNW YVDGVEVHNA KTKPREEQYN STYRVVSVLT VLHQDWLNGK 
EYKCKVSNKA LPAPIEKTIS KAKGQPREPQ VYTLPPSREE MTKNQVSLTC LVKGFYPSDI AVEWESNGQP 
ENNYKTTPPV LDSDGSFFLY SKLTVDKSRW QQGNVFSCSV MHEALHNHYT QKSLSLSPG(K) 
 
HEK IgG 2C2 M 
MKHLWFFLLL VAAPRWVLSQ VQLVQSGPGL VKPGQTLSLT CAISGDSVSS NSAAWNWIRQ SPGRGLEWLG 
RIYYRSKWYN DYADSVKGRI TINPDTSKNQ FYLQLNSVTP EDTAVYYCAR QRGHYGKGYK GFNSGFFDFW 
GQGTLVTVSS ASTKGPSVFP LAPSSKSTSG GTAALGCLVK DYFPEPVTVS WNSGALTSGV HTFPAVLQSS 
GLYSLSSVVT VPSSSLGTQT YICNVNHKPS NTKVDKRVEP KSCDKTHTCP PCPAPELLGG PSVFLFPPKP 
KDTLMISRTP EVTCVVVDVS HEDPEVKFNW YVDGVEVHNA KTKPREEQYN STYRVVSVLT VLHQDWLNGK 
EYKCKVSNKA LPAPIEKTIS KAKGQPREPQ VYTLPPSREE MTKNQVSLTC LVKGFYPSDI AVEWESNGQP 
ENNYKTTPPV LDSDGSFFLY SKLTVDKSRW QQGNVFSCSV MHEALHNHYT QKSLSLSPG(K) 
 
HEK Fab 2C2 WT 
MKHLWFFLLL VAAPRWVLSQ VQLQQSGPGL VKPSQTLSLT CAISGDSVSS NSAAWNWIRQ SPGRGLEWLG 
RTYYRSKWYN DYAVSVKSRI TINPDTSKNQ FSLQLNSVTP EDTAVYYCAR QRGHYGKGYK GFNSGFFDFW 
GQGTLVTVSS ASTKGPSVFP LAPSSKSTSG GTAALGCLVK DYFPEPVTVS WNSGALTSGV HTFPAVLQSS 
GLYSLSSVVT VPSSSLGTQT YICNVNHKPS NTKVDKRVEP KSCDKTHLEQ KLISEEDLNS AVDHHHHHH 
 
HEK Fab 2C2 M 
MKHLWFFLLL VAAPRWVLSQ VQLVQSGPGL VKPGQTLSLT CAISGDSVSS NSAAWNWIRQ SPGRGLEWLG 
RIYYRSKWYN DYADSVKGRI TINPDTSKNQ FYLQLNSVTP EDTAVYYCAR QRGHYGKGYK GFNSGFFDFW 
GQGTLVTVSS ASTKGPSVFP LAPSSKSTSG GTAALGCLVK DYFPEPVTVS WNSGALTSGV HTFPAVLQSS 
GLYSLSSVVT VPSSSLGTQT YICNVNHKPS NTKVDKRVEP KSCDKTHLEQ KLISEEDLNS AVDHHHHHH 
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HEK IgG 2C2 kappa 
MVLQTQVFIS LLLWISGAYG DIVLTQSPAT LSLSPGERAT LSCRASQSVS SSYLAWYQQK PGQAPRLLIY 
GASSRATGVP ARFSGSGSGT DFTLTISSLE PEDFATYYCQ QYYNIPTFGQ GTKVEIKRTV AAPSVFIFPP 
SDEQLKSGTA SVVCLLNNFY PREAKVQWKV DNALQSGNSQ ESVTEQDSKD STYSLSSTLT LSKADYEKHK 
VYACEVTHQG LSSPVTKSFN RGEC 
 
 
 
HEK IgG 6B3 WT 
MKHLWFFLLL VAAPRWVLSQ VQLQQSGPGL VKPSQTLSLT CAISGDSVSS NSAAWNWIRQ SPGRGLEWLG 
RTYYRSKWYN DYAVSVKSRI TINPDTSKNQ FSLQLNSVTP EDTAVYYCAR SYFISFFSFD YWGQGTLVTV 
SSASTKGPSV FPLAPSSKST SGGTAALGCL VKDYFPEPVT VSWNSGALTS GVHTFPAVLQ SSGLYSLSSV 
VTVPSSSLGT QTYICNVNHK PSNTKVDKRV EPKSCDKTHT CPPCPAPELL GGPSVFLFPP KPKDTLMISR 
TPEVTCVVVD VSHEDPEVKF NWYVDGVEVH NAKTKPREEQ YNSTYRVVSV LTVLHQDWLN GKEYKCKVSN 
KALPAPIEKT ISKAKGQPRE PQVYTLPPSR EEMTKNQVSL TCLVKGFYPS DIAVEWESNG QPENNYKTTP 
PVLDSDGSFF LYSKLTVDKS RWQQGNVFSC SVMHEALHNH YTQKSLSLSP G(K) 
 
HEK IgG 6B3 M 
MKHLWFFLLL VAAPRWVLSQ VQLVQSGPGL VKPGQTLSLT CAISGDSVSS NSAAWNWIRQ SPGRGLEWLG 
RIYYRSKWYN DYADSVKGRI TINPDTSKNQ FYLQLNSVTP EDTAVYYCAR SYFISFFSFD YWGQGTLVTV 
SSASTKGPSV FPLAPSSKST SGGTAALGCL VKDYFPEPVT VSWNSGALTS GVHTFPAVLQ SSGLYSLSSV 
VTVPSSSLGT QTYICNVNHK PSNTKVDKRV EPKSCDKTHT CPPCPAPELL GGPSVFLFPP KPKDTLMISR 
TPEVTCVVVD VSHEDPEVKF NWYVDGVEVH NAKTKPREEQ YNSTYRVVSV LTVLHQDWLN GKEYKCKVSN 
KALPAPIEKT ISKAKGQPRE PQVYTLPPSR EEMTKNQVSL TCLVKGFYPS DIAVEWESNG QPENNYKTTP 
PVLDSDGSFF LYSKLTVDKS RWQQGNVFSC SVMHEALHNH YTQKSLSLSP G(K) 
 
HEK Fab 6B3 WT 
MKHLWFFLLL VAAPRWVLSQ VQLQQSGPGL VKPSQTLSLT CAISGDSVSS NSAAWNWIRQ SPGRGLEWLG 
RTYYRSKWYN DYAVSVKSRI TINPDTSKNQ FSLQLNSVTP EDTAVYYCAR SYFISFFSFD YWGQGTLVTV 
SSASTKGPSV FPLAPSSKST SGGTAALGCL VKDYFPEPVT VSWNSGALTS GVHTFPAVLQ SSGLYSLSSV 
VTVPSSSLGT QTYICNVNHK PSNTKVDKRV EPKSCDKTHL EQKLISEEDL NSAVDHHHHH H 
 
HEK Fab 6B3 M 
MKHLWFFLLL VAAPRWVLSQ VQLVQSGPGL VKPGQTLSLT CAISGDSVSS NSAAWNWIRQ SPGRGLEWLG 
RIYYRSKWYN DYADSVKGRI TINPDTSKNQ FYLQLNSVTP EDTAVYYCAR SYFISFFSFD YWGQGTLVTV 
SSASTKGPSV FPLAPSSKST SGGTAALGCL VKDYFPEPVT VSWNSGALTS GVHTFPAVLQ SSGLYSLSSV 
VTVPSSSLGT QTYICNVNHK PSNTKVDKRV EPKSCDKTHL EQKLISEEDL NSAVDHHHHH H 
 
HEK IgG 6B3 lambda 
MAWALLLLTL LTQGTGSWAD IELTQPPSVS VAPGQTARIS CSGDALGDKY ASWYQQKPGQ APVLVIYDDS 
DRPSGIPERF SGSNSGNTAT LTISGTQAED EADYYCQSYD SGFSTVFGGG TKLTVLGQPK AAPSVTLFPP 
SSEELQANKA TLVCLISDFY PGAVTVAWKG DSSPVKAGVE TTTPSKQSNN KYAASSYLSL TPEQWKSHRS 
YSCQVTHEGS TVEKTVAPTE CS 
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Pichia (PP) constructs: 
 
PP IgG 2C2 WT 
MRFPSIFTAV LFAASSALAA PVNTTTEDET AQIPAEAVIG YSDLEGDFDV AVLPFSNSTN NGLLFINTTI 
ASIAAKEEGV SLEKREAEAA GIQQVQLQQS GPGLVKPSQT LSLTCAISGD SVSSNSAAWN WIRQSPGRGL 
EWLGRTYYRS KWYNDYAVSV KSRITINPDT SKNQFSLQLN SVTPEDTAVY YCARQRGHYG KGYKGFNSGF 
FDFWGQGTLV TVSSASTKGP SVFPLAPSSK STSGGTAALG CLVKDYFPEP VTVSWNSGAL TSGVHTFPAV 
LQSSGLYSLS SVVTVPSSSL GTQTYICNVN HKPSNTKVDK RVEPKSCDKT HTCPPCPAPE LLGGPSVFLF 
PPKPKDTLMI SRTPEVTCVV VDVSHEDPEV KFNWYVDGVE VHNAKTKPRE EQYNSTYRVV SVLTVLHQDW 
LNGKEYKCKV SNKALPAPIE KTISKAKGQP REPQVYTLPP SREEMTKNQV SLTCLVKGFY PSDIAVEWES 
NGQPENNYKT TPPVLDSDGS FFLYSKLTVD KSRWQQGNVF SCSVMHEALH NHYTQKSLSL SPGK 
 
PP IgG 2C2 M 
MRFPSIFTAV LFAASSALAA PVNTTTEDET AQIPAEAVIG YSDLEGDFDV AVLPFSNSTN NGLLFINTTI 
ASIAAKEEGV SLEKREAEAA GIQQVQLVQS GPGLVKPGQT LSLTCAISGD SVSSNSAAWN WIRQSPGRGL 
EWLGRIYYRS KWYNDYADSV KGRITINPDT SKNQFYLQLN SVTPEDTAVY YCARQRGHYG KGYKGFNSGF 
FDFWGQGTLV TVSSASTKGP SVFPLAPSSK STSGGTAALG CLVKDYFPEP VTVSWNSGAL TSGVHTFPAV 
LQSSGLYSLS SVVTVPSSSL GTQTYICNVN HKPSNTKVDK RVEPKSCDKT HTCPPCPAPE LLGGPSVFLF 
PPKPKDTLMI SRTPEVTCVV VDVSHEDPEV KFNWYVDGVE VHNAKTKPRE EQYNSTYRVV SVLTVLHQDW 
LNGKEYKCKV SNKALPAPIE KTISKAKGQP REPQVYTLPP SREEMTKNQV SLTCLVKGFY PSDIAVEWES 
NGQPENNYKT TPPVLDSDGS FFLYSKLTVD KSRWQQGNVF SCSVMHEALH NHYTQKSLSL SPGK 
 
PP Fab 2C2 WT 
MRFPSIFTAV LFAASSALAA PVNTTTEDET AQIPAEAVIG YSDLEGDFDV AVLPFSNSTN NGLLFINTTI 
ASIAAKEEGV SLEKREAEAA GIQQVQLQQS GPGLVKPSQT LSLTCAISGD SVSSNSAAWN WIRQSPGRGL 
EWLGRTYYRS KWYNDYAVSV KSRITINPDT SKNQFSLQLN SVTPEDTAVY YCARQRGHYG KGYKGFNSGF 
FDFWGQGTLV TVSSASTKGP SVFPLAPSSK STSGGTAALG CLVKDYFPEP VTVSWNSGAL TSGVHTFPAV 
LQSSGLYSLS SVVTVPSSSL GTQTYICNVN HKPSNTKVDK RVEPKSCDKT HLEQKLISEE DLNSAVDHHH HHH 
 
PP Fab 2C2 WT 
MRFPSIFTAV LFAASSALAA PVNTTTEDET AQIPAEAVIG YSDLEGDFDV AVLPFSNSTN NGLLFINTTI 
ASIAAKEEGV SLEKREAEAA GIQQVQLVQS GPGLVKPGQT LSLTCAISGD SVSSNSAAWN WIRQSPGRGL 
EWLGRIYYRS KWYNDYADSV KGRITINPDT SKNQFYLQLN SVTPEDTAVY YCARQRGHYG KGYKGFNSGF 
FDFWGQGTLV TVSSASTKGP SVFPLAPSSK STSGGTAALG CLVKDYFPEP VTVSWNSGAL TSGVHTFPAV 
LQSSGLYSLS SVVTVPSSSL GTQTYICNVN HKPSNTKVDK RVEPKSCDKT HLEQKLISEE DLNSAVDHHH HHH 
 
PP IgG 2C2 kappa 
MRFPSIFTAV LFAASSALAA PVNTTTEDET AQIPAEAVIG YSDLEGDFDV AVLPFSNSTN NGLLFINTTI 
ASIAAKEEGV SLEKREAEAA GIQDIVLTQS PATLSLSPGE RATLSCRASQ SVSSSYLAWY QQKPGQAPRL 
LIYGASSRAT GVPARFSGSG SGTDFTLTIS SLEPEDFATY YCQQYYNIPT FGQGTKVEIK RTVAAPSVFI 
FPPSDEQLKS GTASVVCLLN NFYPREAKVQ WKVDNALQSG NSQESVTEQD SKDSTYSLSS TLTLSKADYE 
KHKVYACEVT HQGLSSPVTK SFNRGEC 
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PP IgG 6B3 WT 
MRFPSIFTAV LFAASSALAA PVNTTTEDET AQIPAEAVIG YSDLEGDFDV AVLPFSNSTN NGLLFINTTI 
ASIAAKEEGV SLEKREAEAA GIQQVQLQQS GPGLVKPSQT LSLTCAISGD SVSSNSAAWN WIRQSPGRGL 
EWLGRTYYRS KWYNDYAVSV KSRITINPDT SKNQFSLQLN SVTPEDTAVY YCARSYFISF FSFDYWGQGT 
LVTVSSASTK GPSVFPLAPS SKSTSGGTAA LGCLVKDYFP EPVTVSWNSG ALTSGVHTFP AVLQSSGLYS 
LSSVVTVPSS SLGTQTYICN VNHKPSNTKV DKRVEPKSCD KTHTCPPCPA PELLGGPSVF LFPPKPKDTL 
MISRTPEVTC VVVDVSHEDP EVKFNWYVDG VEVHNAKTKP REEQYNSTYR VVSVLTVLHQ DWLNGKEYKC 
KVSNKALPAP IEKTISKAKG QPREPQVYTL PPSREEMTKN QVSLTCLVKG FYPSDIAVEW ESNGQPENNY 
KTTPPVLDSD GSFFLYSKLT VDKSRWQQGN VFSCSVMHEA LHNHYTQKSL SLSPGK 
 
PP IgG 6B3 M 
MRFPSIFTAV LFAASSALAA PVNTTTEDET AQIPAEAVIG YSDLEGDFDV AVLPFSNSTN NGLLFINTTI 
ASIAAKEEGV SLEKREAEAA GIQQVQLVQS GPGLVKPGQT LSLTCAISGD SVSSNSAAWN WIRQSPGRGL 
EWLGRIYYRS KWYNDYADSV KGRITINPDT SKNQFYLQLN SVTPEDTAVY YCARSYFISF FSFDYWGQGT 
LVTVSSASTK GPSVFPLAPS SKSTSGGTAA LGCLVKDYFP EPVTVSWNSG ALTSGVHTFP AVLQSSGLYS 
LSSVVTVPSS SLGTQTYICN VNHKPSNTKV DKRVEPKSCD KTHTCPPCPA PELLGGPSVF LFPPKPKDTL 
MISRTPEVTC VVVDVSHEDP EVKFNWYVDG VEVHNAKTKP REEQYNSTYR VVSVLTVLHQ DWLNGKEYKC 
KVSNKALPAP IEKTISKAKG QPREPQVYTL PPSREEMTKN QVSLTCLVKG FYPSDIAVEW ESNGQPENNY 
KTTPPVLDSD GSFFLYSKLT VDKSRWQQGN VFSCSVMHEA LHNHYTQKSL SLSPGK 
 
PP Fab 6B3 WT 
MRFPSIFTAV LFAASSALAA PVNTTTEDET AQIPAEAVIG YSDLEGDFDV AVLPFSNSTN NGLLFINTTI 
ASIAAKEEGV SLEKREAEAA GIQQVQLQQS GPGLVKPSQT LSLTCAISGD SVSSNSAAWN WIRQSPGRGL 
EWLGRTYYRS KWYNDYAVSV KSRITINPDT SKNQFSLQLN SVTPEDTAVY YCARSYFISF FSFDYWGQGT 
LVTVSSASTK GPSVFPLAPS SKSTSGGTAA LGCLVKDYFP EPVTVSWNSG ALTSGVHTFP AVLQSSGLYS 
LSSVVTVPSS SLGTQTYICN VNHKPSNTKV DKRVEPKSCD KTHLEQKLIS EEDLNSAVDH HHHHH 
 
PP Fab 6B3 M 
MRFPSIFTAV LFAASSALAA PVNTTTEDET AQIPAEAVIG YSDLEGDFDV AVLPFSNSTN NGLLFINTTI 
ASIAAKEEGV SLEKREAEAA GIQQVQLVQS GPGLVKPGQT LSLTCAISGD SVSSNSAAWN WIRQSPGRGL 
EWLGRIYYRS KWYNDYADSV KGRITINPDT SKNQFYLQLN SVTPEDTAVY YCARSYFISF FSFDYWGQGT 
LVTVSSASTK GPSVFPLAPS SKSTSGGTAA LGCLVKDYFP EPVTVSWNSG ALTSGVHTFP AVLQSSGLYS 
LSSVVTVPSS SLGTQTYICN VNHKPSNTKV DKRVEPKSCD KTHLEQKLIS EEDLNSAVDH HHHHH 
 
PP IgG 6B3 lambda 
MRFPSIFTAV LFAASSALAA PVNTTTEDET AQIPAEAVIG YSDLEGDFDV AVLPFSNSTN NGLLFINTTI 
ASIAAKEEGV SLEKREAEAA GIQDIELTQP PSVSVAPGQT ARISCSGDAL GDKYASWYQQ KPGQAPVLVI 
YDDSDRPSGI PERFSGSNSG NTATLTISGT QAEDEADYYC QSYDSGFSTV FGGGTKLTVL GQPKAAPSVT 
LFPPSSEELQ ANKATLVCLI SDFYPGAVTV AWKGDSSPVK AGVETTTPSK QSNNKYAASS YLSLTPEQWK 
SHRSYSCQVT HEGSTVEKTV APTECS 
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Prokaryotic constructs (E. coli; EC): 
 
EC IgG 2C2 WT/kappa 
MKKNIAFLLA SMFVFSIATN AYADIVLTQS PATLSLSPGE RATLSCRASQ SVSSSYLAWY QQKPGQAPRL 
LIYGASSRAT GVPARFSGSG SGTDFTLTIS SLEPEDFATY YCQQYYNIPT FGQGTKVEIK RTVAAPSVFI 
FPPSDEQLKS GTASVVCLLN NFYPREAKVQ WKVDNALQSG NSQESVTEQD SKDSTYSLSS TLTLSKADYE 
KHKVYACEVT HQGLSSPVTK SFNRGEC**A CVGENKMKQS TIALALLPLL FTPVTKAQVQ LQQSGPGLVK 
PSQTLSLTCA ISGDSVSSNS AAWNWIRQSP GRGLEWLGRT YYRSKWYNDY AVSVKSRITI NPDTSKNQFS 
LQLNSVTPED TAVYYCARQR GHYGKGYKGF NSGFFDFWGQ GTLVTVSSAS TKGPSVFPLA PSSKSTSGGT 
AALGCLVKDY FPEPVTVSWN SGALTSGVHT FPAVLQSSGL YSLSSVVTVP SSSLGTQTYI CNVNHKPSNT 
KVDKRVEPKS CDKTHTCPPC PAPELLGGPS VFLFPPKPKD TLMISRTPEV TCVVVDVSHE DPEVKFNWYV 
DGVEVHNAKT KPREEQYNST YRVVSVLTVL HQDWLNGKEY KCKVSNKALP APIEKTISKA KGQPREPQVY 
TLPPSREEMT KNQVSLTCLV KGFYPSDIAV EWESNGQPEN NYKTTPPVLD SDGSFFLYSK LTVDKSRWQQ 
GNVFSCSVMH EALHNHYTQK SLSLSPGK 
 
EC IgG 2C2 M/kappa 
MKKNIAFLLA SMFVFSIATN AYADIVLTQS PATLSLSPGE RATLSCRASQ SVSSSYLAWY QQKPGQAPRL 
LIYGASSRAT GVPARFSGSG SGTDFTLTIS SLEPEDFATY YCQQYYNIPT FGQGTKVEIK RTVAAPSVFI 
FPPSDEQLKS GTASVVCLLN NFYPREAKVQ WKVDNALQSG NSQESVTEQD SKDSTYSLSS TLTLSKADYE 
KHKVYACEVT HQGLSSPVTK SFNRGEC**A CVGENKMKQS TIALALLPLL FTPVTKAQVQ LVQSGPGLVK 
PGQTLSLTCA ISGDSVSSNS AAWNWIRQSP GRGLEWLGRI YYRSKWYNDY ADSVKGRITI NPDTSKNQFY 
LQLNSVTPED TAVYYCARQR GHYGKGYKGF NSGFFDFWGQ GTLVTVSSAS TKGPSVFPLA PSSKSTSGGT 
AALGCLVKDY FPEPVTVSWN SGALTSGVHT FPAVLQSSGL YSLSSVVTVP SSSLGTQTYI CNVNHKPSNT 
KVDKRVEPKS CDKTHTCPPC PAPELLGGPS VFLFPPKPKD TLMISRTPEV TCVVVDVSHE DPEVKFNWYV 
DGVEVHNAKT KPREEQYNST YRVVSVLTVL HQDWLNGKEY KCKVSNKALP APIEKTISKA KGQPREPQVY 
TLPPSREEMT KNQVSLTCLV KGFYPSDIAV EWESNGQPEN NYKTTPPVLD SDGSFFLYSK LTVDKSRWQQ 
GNVFSCSVMH EALHNHYTQK SLSLSPGK 
 
EC Fab 2C2 WT/kappa 
MKKTAIAIAV ALAGFATVAQ ADIVLTQSPA TLSLSPGERA TLSCRASQSV SSSYLAWYQQ KPGQAPRLLI 
YGASSRATGV PARFSGSGSG TDFTLTISSL EPEDFATYYC QQYYNIPTFG QGTKVEIKRT VAAPSVFIFP 
PSDEQLKSGT ASVVCLLNNF YPREAKVQWK VDNALQSGNS QESVTEQDSK DSTYSLSSTL TLSKADYEKH 
KVYACEVTHQ GLSSPVTKSF NRGEC**ACV GENKMKQSTI ALALLPLLFT PVTKAQVQLQ QSGPGLVKPS 
QTLSLTCAIS GDSVSSNSAA WNWIRQSPGR GLEWLGRTYY RSKWYNDYAV SVKSRITINP DTSKNQFSLQ 
LNSVTPEDTA VYYCARQRGH YGKGYKGFNS GFFDFWGQGT LVTVSSASTK GPSVFPLAPS SKSTSGGTAA 
LGCLVKDYFP EPVTVSWNSG ALTSGVHTFP AVLQSSGLYS LSSVVTVPSS SLGTQTYICN VNHKPSNTKV 
DKRVEPKSCD KTHLEQKLIS EEDLNSAVDH HHHHH 
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EC Fab 2C2 M/kappa 
MKKTAIAIAV ALAGFATVAQ ADIVLTQSPA TLSLSPGERA TLSCRASQSV SSSYLAWYQQ KPGQAPRLLI 
YGASSRATGV PARFSGSGSG TDFTLTISSL EPEDFATYYC QQYYNIPTFG QGTKVEIKRT VAAPSVFIFP 
PSDEQLKSGT ASVVCLLNNF YPREAKVQWK VDNALQSGNS QESVTEQDSK DSTYSLSSTL TLSKADYEKH 
KVYACEVTHQ GLSSPVTKSF NRGEC**ACV GENKMKQSTI ALALLPLLFT PVTKAQVQLV QSGPGLVKPG 
QTLSLTCAIS GDSVSSNSAA WNWIRQSPGR GLEWLGRIYY RSKWYNDYAD SVKGRITINP DTSKNQFYLQ 
LNSVTPEDTA VYYCARQRGH YGKGYKGFNS GFFDFWGQGT LVTVSSASTK GPSVFPLAPS SKSTSGGTAA 
LGCLVKDYFP EPVTVSWNSG ALTSGVHTFP AVLQSSGLYS LSSVVTVPSS SLGTQTYICN VNHKPSNTKV 
DKRVEPKSCD KTHLEQKLIS EEDLNSAVDH HHHHH 
 
 
 
 
 
EC IgG 6B3 WT/lambda 
MKKNIAFLLA SMFVFSIATN AYADIELTQP PSVSVAPGQT ARISCSGDAL GDKYASWYQQ KPGQAPVLVI 
YDDSDRPSGI PERFSGSNSG NTATLTISGT QAEDEADYYC QSYDSGFSTV FGGGTKLTVL GQPKAAPSVT 
LFPPSSEELQ ANKATLVCLI SDFYPGAVTV AWKGDSSPVK AGVETTTPSK QSNNKYAASS YLSLTPEQWK 
SHRSYSCQVT HEGSTVEKTV APTECS**AC VGENKMKQST IALALLPLLF TPVTKAQVQL QQSGPGLVKP 
SQTLSLTCAI SGDSVSSNSA AWNWIRQSPG RGLEWLGRTY YRSKWYNDYA VSVKSRITIN PDTSKNQFSL 
QLNSVTPEDT AVYYCARSYF ISFFSFDYWG QGTLVTVSSA STKGPSVFPL APSSKSTSGG TAALGCLVKD 
YFPEPVTVSW NSGALTSGVH TFPAVLQSSG LYSLSSVVTV PSSSLGTQTY ICNVNHKPSN TKVDKRVEPK 
SCDKTHTCPP CPAPELLGGP SVFLFPPKPK DTLMISRTPE VTCVVVDVSH EDPEVKFNWY VDGVEVHNAK 
TKPREEQYNS TYRVVSVLTV LHQDWLNGKE YKCKVSNKAL PAPIEKTISK AKGQPREPQV YTLPPSREEM 
TKNQVSLTCL VKGFYPSDIA VEWESNGQPE NNYKTTPPVL DSDGSFFLYS KLTVDKSRWQ QGNVFSCSVM 
HEALHNHYTQ KSLSLSPGK 
 
EC IgG 6B3 M/lambda 
MKKNIAFLLA SMFVFSIATN AYADIELTQP PSVSVAPGQT ARISCSGDAL GDKYASWYQQ KPGQAPVLVI 
YDDSDRPSGI PERFSGSNSG NTATLTISGT QAEDEADYYC QSYDSGFSTV FGGGTKLTVL GQPKAAPSVT 
LFPPSSEELQ ANKATLVCLI SDFYPGAVTV AWKGDSSPVK AGVETTTPSK QSNNKYAASS YLSLTPEQWK 
SHRSYSCQVT HEGSTVEKTV APTECS**AC VGENKMKQST IALALLPLLF TPVTKAQVQL VQSGPGLVKP 
GQTLSLTCAI SGDSVSSNSA AWNWIRQSPG RGLEWLGRIY YRSKWYNDYA DSVKGRITIN PDTSKNQFYL 
QLNSVTPEDT AVYYCARSYF ISFFSFDYWG QGTLVTVSSA STKGPSVFPL APSSKSTSGG TAALGCLVKD 
YFPEPVTVSW NSGALTSGVH TFPAVLQSSG LYSLSSVVTV PSSSLGTQTY ICNVNHKPSN TKVDKRVEPK 
SCDKTHTCPP CPAPELLGGP SVFLFPPKPK DTLMISRTPE VTCVVVDVSH EDPEVKFNWY VDGVEVHNAK 
TKPREEQYNS TYRVVSVLTV LHQDWLNGKE YKCKVSNKAL PAPIEKTISK AKGQPREPQV YTLPPSREEM 
TKNQVSLTCL VKGFYPSDIA VEWESNGQPE NNYKTTPPVL DSDGSFFLYS KLTVDKSRWQ QGNVFSCSVM 
HEALHNHYTQ KSLSLSPGK 
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EC Fab 6B3 WT/lambda 
MKKTAIAIAV ALAGFATVAQ ADIELTQPPS VSVAPGQTAR ISCSGDALGD KYASWYQQKP GQAPVLVIYD 
DSDRPSGIPE RFSGSNSGNT ATLTISGTQA EDEADYYCQS YDSGFSTVFG GGTKLTVLGQ PKAAPSVTLF 
PPSSEELQAN KATLVCLISD FYPGAVTVAW KGDSSPVKAG VETTTPSKQS NNKYAASSYL SLTPEQWKSH 
RSYSCQVTHE GSTVEKTVAP TECS**ACVG ENKMKQSTIA LALLPLLFTP VTKAQVQLQQ SGPGLVKPSQ 
TLSLTCAISG DSVSSNSAAW NWIRQSPGRG LEWLGRTYYR SKWYNDYAVS VKSRITINPD TSKNQFSLQL 
NSVTPEDTAV YYCARSYFIS FFSFDYWGQG TLVTVSSAST KGPSVFPLAP SSKSTSGGTA ALGCLVKDYF 
PEPVTVSWNS GALTSGVHTF PAVLQSSGLY SLSSVVTVPS SSLGTQTYIC NVNHKPSNTK VDKRVEPKSC 
DKTHLEQKLI SEEDLNSAVD HHHHHH 
 
EC Fab 6B3 M/lambda 
MKKTAIAIAV ALAGFATVAQ ADIELTQPPS VSVAPGQTAR ISCSGDALGD KYASWYQQKP GQAPVLVIYD 
DSDRPSGIPE RFSGSNSGNT ATLTISGTQA EDEADYYCQS YDSGFSTVFG GGTKLTVLGQ PKAAPSVTLF 
PPSSEELQAN KATLVCLISD FYPGAVTVAW KGDSSPVKAG VETTTPSKQS NNKYAASSYL SLTPEQWKSH 
RSYSCQVTHE GSTVEKTVAP TECS**ACVG ENKMKQSTIA LALLPLLFTP VTKAQVQLVQ SGPGLVKPGQ 
TLSLTCAISG DSVSSNSAAW NWIRQSPGRG LEWLGRIYYR SKWYNDYADS VKGRITINPD TSKNQFYLQL 
NSVTPEDTAV YYCARSYFIS FFSFDYWGQG TLVTVSSAST KGPSVFPLAP SSKSTSGGTA ALGCLVKDYF 
PEPVTVSWNS GALTSGVHTF PAVLQSSGLY SLSSVVTVPS SSLGTQTYIC NVNHKPSNTK VDKRVEPKSC 
DKTHLEQKLI SEEDLNSAVD HHHHHH 
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5.4 Conferences, Posters and Oral presentations 
 
Pichia 2012: oral and poster presentation 
ʺImproving the biophysical properties of full-length IgGs by using P. pastoris as expression hostʺ 
February 29
th
 - March 3
rd
, 2012 in Alpbach / Austria 
 
3
rd
 PEGS Europe - Protein and Antibody Engineering Summit: oral presentation 
ʺFolding and Aggregation of IgGs - Influence of Mutations & Expression Systemsʺ 
October 11
th
 - 13
th
, 2011 in Hannover / Germany 
 
BioProcessing, Biologics & Biotherapeutics: oral presentation 
ʺFolding and Aggregation of IgGs - Influence of Mutations & Expression Systemsʺ 
July 20
th
 - 21
st
, 2011 in Edinburgh / Scotland  
 
4
th
 Halle Conference - Recombinant Protein Production: oral presentation 
ʺFolding and Aggregation of IgGs - Influence of Mutations & Expression Systemsʺ 
February 24
th
 - 26
th
, 2011 in Halle / Germany 
 
IBC's 21
st
 Annual Antibody Engineering & Antibody Therapeutics: poster presentation 
ʺFolding and Aggregation in the IgG Format: Influence of Mutations and the Expression Systemʺ 
December 5
th
 - 9
th
, 2010 in San Diego / USA 
 
VIII European Symposium of the Protein Society: poster presentation 
ʺStability engineering of antibody variable domains improves their biophysical properties in the 
context of IgGs produced in eukaryotic cellsʺ 
June 14
th
 - 18
th
, 2009 in Zurich / Switzerland  
 
7
th
 International Conference on Recombinant Antibodies 
June 23
rd
 - 27
th
, 2008 in Dublin / Ireland 
 
Antibody Europe: The Next Generation of Antibodies 
November 7
th
 - 8
th
, 2007 in Vienna / Austria 
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